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ABBRIVIATIONS 
  
FSH    Follicle stimulating hormone  
DNA   Deoxyribonucleic acid 
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HIV    Human immunodeficiency virus  
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PDT    Photodynamic therapeutics  
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rt    Room temperature 
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SAR    Structure activity relationship 
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1.1 INTRODUCTION 
   
Thiazolidinones which belong to an important group of heterocyclic compounds 
have been widely explored for their applications in the field of medicine. Thiazolidinones, 
with a carbonyl group at position 2 in structure (1) and position 4 or 5 in structure (2, 3) 
have been subjected of widespread study in the recent past. Numerous examples have 
appeared in the literatures which underscore their chemistry and use.1-9  
NH
S
O
NHS
O
N
H
S
O
NH
S
O
(CH2)5-COOH
1 2 3 4
1
2
3
4
5
1
2
3
45
1
2
3
4
5
1
23
4 5
 
 
 Among the 4-thiazolidinone derivatives (2), substituents at the 2, 3 and 5 positions 
may be varied, but the greatest different in structure and properties is exerted by the 
groups attached to carbon atom at the 2-position and to nitrogen atom at the 3-position. 
The cyclic structure was assigned after recognition of mercaptoacetic acid as a primary 
product of hydrolysis of 3-phenyl-2-phenylimino-4-thiazolidinones.10 A well known 
antibiotic, actithiazic acid (4), isolated from a species of streptomyces showed specific in 
vitro activity against M. tuberculosis belongs to this class of agents.11-12  
 
1.2 Synthetic methods for thiazolidinones 
 In General, the thiazolidinone motif can be prepared by one pot reaction of 
aldehyde, primary amine and mercaptoacetic acid.13-22 several methods for the preparation 
of 4-thiazolidinone are narrated in literature described as follows.  
1.  Hongyu Zhou et al.23 have synthesized a library of microwave-assisted 2-aryl-
substituted 4-thiazolidinone and 4-thiazinanone derivatives (Figure 1). 
CHOR1
O
S
O
OC8F17 H2N R2
HSCH2COOH
3:4:5=1:2:3,
DCC/THF/rt
R1
O
S
O
OC8F17
S
N
R2 O
Figure 1  
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2.  Ravindra K. Rawal et al.24 have reported a series of compounds bearing 
isothiourea or thiourea functional group and have shown high anti-HIV-1 activity. 
Furthermore, a series of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones was also reported by 
this group (Figure 2).  
S
N
NH2
CHO
R
SHCH2COOH
Toluene, Reflux S
N
N S
O
RFigure 2
 
 
3.  Tumul Srivastava et al.25 have synthesized some new 4-thiazolidinones assembled 
by DCC mediated three-component reaction of amines, aldehyde and mercaptoacetic acid 
(Figure 3). 
R-NH2 C
H
O
R' HSCH2COOH
DCC /THF N
S
R
R'
O
Figure 3
 
 
4.   Zhong-Zheng Zhou et al.26 have prepared a one-pot liquid-phase combinatorial 
synthesis of 2-(4-oxo-4H-1-benzopyran-3-yl)-4-thiazolidinones bearing diverse 
substituents at the 3-position under microwave irradiation using 3-formyl chromone, 
primary amine, and mercaptoacetic acid as reactants (Figure 4). 
O
O
H
O
NH2
R
Na2SO4, PTSA
O
O S
N
O
R
Figure 4
MW
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5.  Christopher J. Hobbs et al.27 have synthesized some new N-type (Cav2.2) calcium 
channel blockers derived from the ‘hit’ structures 2-(3-bromo-4-fluorophenyl)-3-(2-
pyridin-2-ylethyl)thiazolidin-4-one and its 2-[4-(4-bromophenyl)pyridin-3-yl]-3-isobutyl 
analogues (Figure 5). 
N
OH Br
HSCH2COOH
isobutylamine ,  
C6H6, 70 oC
N
BrSN
O
Figure 5
 
 
6.   Adele Bolognese et al.28 have described mechanistic and synthetic aspects of the 
formation of thiazolidine-4-one by the reaction of imines and mercaptoacetic acid under 
microwave and conventional heating (Figure 6). 
N
R1
R2
HSCH2COOH
N
S O
R2R1
dry benzene
Figure 6
 
 
7.   Joan Fraga-Dubreuil et al29  have reported the efficient combination of task 
specific ionic liquid and microwave dielectric heating applied to one-pot three component 
synthesis of a small library of 4-thiazolidinones (Figure 7). 
O O
O
N
R1
O O
O
HSCH2COOH N
S
O
R1
Figure 7
 
 
 12
8. Bioactive venlafaxine analogs such as 2,3-disubstituted-1,3-thiazolidinones 
(Figure 8) have  been synthesized and reported as antimicrobial agent by C. V. Kavitha 
and coworkers.30 
H3CO
NH2
HO
R-CHO
DCC, THF
HSCH2COOH H3CO
N
OH
S
O
RFigure 8  
 
9.   Denis R. St. Laurent et al.31 have synthesized 4-thiazolidinone derivatives by the 
cyclization of unsymmetrical thiourea. H. S. Joshi and co-workers32 has synthesized 
thiazolidinones bearing benzo[b]thiophene nucleus from N-arylaminothoxomethyl 
derivatives with chloroacetic acid in ethanol (Figure 9). 
S
Cl
O
N
Cl-CH2COOH
NaoAc
S
Cl
O
HN
NH
S
R
S
O
N
R
Figure 9
 
 
10.   M. Shrinivas et al.33 have reported some new thiazolidinones from isoxazolyl 
thiourea by treatment with chloroacetic acid and fused anhydrous sodium acetate in 
ethanol (Figure 10). 
O
N
HN
S
NH
R
ClCH2COOH
CH3COONa
O
N
N
S
N
O
R
Figure 10  
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1.3 Mechanism 
The reaction mechanisms of the formation of 4-thiazolidinones are well studied 
by34 It was shown that the construction of 4-thiazolidinones proceeds by the attacks of the 
mercaptoacetic acid upon the C=S group, the tautomerism takes place with removal of 
water and subsequent cyclization (Figure 11). 
R1 NH2
R2
R3
O Step-1
-H2O
R1 N C
R3
R2
SH
R5
R4
O
OH
Step-2
R1 HN C
R2
S
R3
R4
R5
HO
O
Step-3
-H2O
N
S
O
R4
R5
R3
R2
R1
Figure 11
 
 
1.4 Biological activity of 4-thiazolidinones 
 As mentioned above, the 4-thiazolidinone derivatives possessed diverse biological 
activities such as anticonvulsant activity, Hypnotic activity, antitubercular activity, 
anthelmintic activity, cardiovascular effects, antibacterial activity, anticancer activity, 
antihistaminic activity (H1-antagonist), antifungal activity, antiviral activity, Anti-
inflammatory activity (COX-inhibitors), Follicle stimulating hormone (FSH) receptor 
agonist activities which are described briefly as follows. 
 
1.4.1 Anticonvulsant activity 
The anticonvulsant activity of several series of 2-(arylimino)/(arylhydrazono)-3-
aryl/(alkylaryl)/furfuryl/2-pyrimidyl/cycloalkyl/(substitutedamino)/(3-(N-morpholi-n-4-
yl-propyl)-4-thiazolidinones (Figure 12) has been studied against pentylenetetrazol 
induced seizures 35-38 in albino mice of either sex ata dose of 100 mg/kg. Most of the 
compounds were found to exhibit protection against pentylenetetrazol-induced seizures, 
 14
and the degree of protection ranged up to 80%. However, no definite structure-activity 
relationship could be observed regarding the anticonvulsant activity possessed by 
thiazolidinones. 
H3CO
H3CO
N
S
N
O
(E)-3-(3,4-dimethoxybenzyl)-2-
(phenylimino)thiazolidin-4-one
NS
O
N
Cl
(Z)-3-(4-chlorophenethyl)-2-
(phenylimino)thiazolidin-4-one
Figure 12  
 
1.4.2 Hypnotic activity 
 Several 3-(3-(N-morpholin-4-yl-propyl)-2-(arylimino)-4-thiazolidinones39 and 2-
(arylimino)-3-(pyrimidin-2-yl)-4-thiazolidinones40 were also evaluated for their ability to 
potentiate pentobarbital-induced hypnosis in mice at a dose of 100 mg/kg (Figure 13). 
All thiazolidinones were found to potentiate pentobarbital sleeping time. The increase in 
the duration of sleep ranged from 10+ 3 min in untreated control to 98.6+ 10 min in mice 
pretreated with substituted thiazolidinones. 
NO
N
SO
N
3-(3-(N-Morpholin-4-yl)-propyl)-
2-phenylimino-4-thiazolidinone
N S
N
O
N
N
2-Phenylimino-3-9pyrimidin-2-yl)-
4-thiazolidinone
Figure 13  
 
1.4.3 Antitubercular activity 
The 4-thiazolidinones also found to be effective against the multi-drug resistant 
tuberculosis, coupled with the increasing overlap of AIDS and tuberculosis pandemics 
has brought tuberculosis to the forefront as a major worldwide health concern.41   
 15
N
S
O
CH2COOCH3
H
RN
R
R= H, CH3, C6H5 or C6H5CH2
Figure 14   
 A few derivatives were found to inhibit the growth of human tubercle bacilli, 
H37Rv strain, in a concentration of 12.5 mg/mL (Figure 15).41 Several other derivatives 
of thiazolidinones have also been found to inhibit the growth of Mycobacterium 
tuberculosis H37Rv strain (Figure 15).42-44 In an attempt to find new inhibitors of the 
enzymes in the essential rhamnose biosynthetic pathway, a virtual library of 2,3,5 
trisubstituted-4-thiazolidinones was created (Figure 15). These compounds were 
developed as diphosphate surrogates and inhibitors of MurB that bind at the nucleotide 
sugar site. It was found that the 4-thiazolidinone scaffold mimicked the diphosphate and 
specificity was generated through the different R-groups placed around the ring. These 
compounds were then docked into the active site cavity of 60 hydroxyl; dTDP-6-deoxy-
D-xylo-4-hexulose 3,5-epimerase (RmlC) from Mycobacterium tuberculosis. Those, 30 
(32%) have >50% inhibitory activity (at 20 mM) in the coupled rhamnose synthetic assay. 
This work proposed a hypothesis that the thiazolidinone scaffold can act as a diphosphate 
mimetic.45 The effects of thiazolidinone derivatives on other Mycobacterium strains had 
also been found.46-48 
S
N O
O
O2N
OH
O
S
N
O
O
O
3-ethyl-5-((5-nitrofuran-2-
yl)methyl)thiazolidin-4-one
ethyl 2-(2-(2-hydroxy-3-methoxyphenyl)-5-methyl
-4-oxothiazolidin-3-yl)-3-methylbutanoate
Figure 15  
 
1.4.4 Anthelmintic activity 
3-Methyl-5-[(4-nitrophenyl)azo]rhodanin, nitrodan (Figure 16), was reported as a 
potent anthelmintic compound.49-51  which was effective when administered in feed 
against Hymenolepsis nana and Syphacia obvelata infections in mice, Asceridia galli 
 16
infections in chickens, and Toxocera canis, Ancylostoma caninum, and Uncinaria 
stenocephala infections in dogs, pigs and horses. 2-Imino-3-(2-acetamidophenyl)-4-
thiazolidinone derivatives have been found to be effective in vitro against horse 
Strongyloids at concentration of 10-3–10-6 M.52 Various 2-thiono-3-substituted-5-[(2-
methyl-4-nitrophenyl)azo]-4-thiazolidinones and 2-thiono-3-methyl-5-[(2,4-
dinitrophenyl)azo]-4-thiazolidinone as potent anthelmintic agents, which were not only 
effective alone but also showed activity with other parasiticides.53-54  
N
N
S
N
S
O
O2N
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 1.4.5 Cardiovascular effects 
  Cardiovascular effects of a series of 2-cyclopentyl/(cyclohexylimino)- 3-aryl-4-
thiazolidinone-5-ylacetic acids (Figure 17) on adult cats of either sex were reported.55  
All substituted 4-thiazolidinones induced hypotension of varying degree. The duration of 
hypertensive activity observed with most of these compounds was less than 15 min. 
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Figure 17  
Suzuki et al. examined the effects of CP-060S (3-{3-[(Benzo[1,3]dioxol-4-
yloxymethyl)-methyl-amino]-propyl}-2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-4-  
thiazolidinone) (Figure 17) on cardiac function and myocardial oxygen consumption 
(MVO2) in anesthetized dogs.56 CP-060S (10-300 mg/kg IV) decreased heart rate, 
increased aortic flow and decreased mean blood pressure in a dose-dependent manner. 
The PR (pulse rate) interval was significantly prolonged by administration of CP-060S 
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(300 mg/kg IV). It increased coronary blood flow in a dose-dependent manner (10-300 
mg/kg IV). Its effect on cardiac function and MVO2 were qualitatively similar to those of 
diltiazem, a typical Ca-channel blocker.  
 
1.4.6 Antibacterial activity  
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Figure 18  
Several 2-[(dichlorophenyl)imino]-4-thiazolidinones and 2-(arylhydrazino)-4-
thiazolidinones and their corresponding 5-arylidine derivatives were tested against 
Staphylococcus aureus (Figure 18). The antibacterial activity of 5-arylidine derivatives 
of both 2-[(dichlorophenyl)imino]/2-(arylhydrazino)-4-thiazolidinones was found greater 
than that of the parent compound.57 The screening data of more than 50 thiazole and 
thiazolidinone derivatives against some common bacteria revealed that the 
thiazolidinones were more active than the thiazoles.58 An enhancement in the activity was 
observed with mercurated thiazolidinone derivatives as compared to nonmercurated 
derivatives. Novel 2,3-disubstituted-1,3-thiazolidin-4-one derivatives which are 
venlafaxine analogs were tested against Bacillus subtilis and Escherichia coli, and found 
to exhibit potent inhibitory activity compared to that of standard drugs at the tested 
concentrations. From the results obtained, it was concluded that the presence of two 
fluorine atoms at 2nd and 6th positions in 2-(2,6-difluorophenyl)-3-[2-(1-hydroxy-
cyclohexyl)-2-(4-methoxy-phenyl)-ethyl]-4  thiazolidinone might be the reason for the 
significant inhibitory activity.59               Different derivatives of N-[3,4-disubstituted-1,3-
thiazol-2(3H)-ylidene]-2-(pyrazin-2-yloxy)acetohydrazide and N-[(2)-3-(4-
alkyl/arylsubstituted)-4-oxo-1,3-thiazolidin-2-ylidene]-2-(pyrazin-2-yloxy)-
acetohydrazide compounds when evaluated for antibacterial activity against the Gram-
positive (Staphylococcus aureus and Bacillus subtilis) and Gram-negative (Escherichia 
coli and Staphylococcus typhi) strains of bacteria, showed good antibacterial activity. The 
structure activity relationship revealed that thiazolidine ring is essential for antibacterial 
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activity.60 Bondock et al. reported some new 4-thiazolidinones synthesized from 1-chloro-
3,4-dihydronaphthalene-2-carboxaldehyde for their antimicrobial activity.61 Thirteen 
compounds were screened in vitro for their antimicrobial activities against three strains of 
bacteria Bacillus subtilis, Bacillus megaterium and Escherichia coli by the agar diffusion 
technique.62  A 1 mg/mL solution in dimethylformamide was used. The bacteria were 
maintained on nutrient agar and Czapek’s-Dox agar media, respectively. Vicini et al. and 
other workers also examined some 4-thiazolidinone derivatives for their antimicrobial 
activity.63 
 
1.4.7 Anticancer activity 
A series of 2-aryl-4-oxo-thiazolidin-3-yl amides and derivatives were synthesized 
and evaluated for their ability to inhibit the growth of prostate cancer cells (Figure 19). 
The antiproliferative effects of synthesized compounds were examined in five human 
prostate cancer cell lines (DU-145, PC-3, LNCaP, PPC-1, and TSU), and in RH7777 cells 
(negative controls). 
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Figure 19  
 From these studies, few potent compounds were detected, which were effective in 
killing prostate cancer cells with improved selectivity compared to serine amide 
phosphates (SAPs).64 Cyclooxygenase (COX) is a well-known enzyme that catalyzes the 
conversion of arachidonic acid to prostaglandins (PGs) in the cells. However, PGs are 
also important in cancer pathogenesis. Study reported COX-2 inhibitors as potential drugs 
aimed at the prevention and treatment of cancer, especially colorectal cancer. Some 
representative 2-phenylimino-4-thiazolidinones have been investigated as potent 
inhibitors of the growth of human colon carcinoma cell lines with a different COX-2 
expression. The antiproliferative in vitro screening was performed on five cell lines of 
human colon cancers, such as DLD-1,65  HCT-116,66 HT-29,67  HCT-8,68  and H-630,69  
 19
obtained from the American Type Culture Collection (Manassas, VA); among them, HT-
29 cell line expresses high COX-2 levels.70-72 Derivative 5-(3-trifluoromethyl 
benzylidene)-2,4-thiazolidinedione which does not interact with COX enzymes, inhibited 
the growth of HT- 29 cells. This compound displayed activity on all cell lines, mainly on 
the DLD-1.73 
 
1.4.8 Antihistaminic activity (H1-antagonist) 
Thiazolidinone are also known to show their action on histamine receptors. The 
geometrical similarity between 2-aryl-3-[3-(N,N-dimethylamino)propyl]-1,3-thiazolidin-
4-ones (Figure 20) and different histamine (H1) antagonists such as bamipine, 
clemastine, cyproheptadine, triprolidine, promethazine, chlorpheniramine, and 
carbinoxamine 74-75 prompted Diurno et al. to evaluate these compounds for 
antihistaminic activity.76  Singh et al. have investigated the antihistaminic (H1-antagonist) 
activity of 2,3-disubstituted thiazolidin-4-ones and concluded that the hydrophobic 
substitution at the 4-position of the phenyl ring and cumulative negative polar effects of 
all the substituents in the phenyl group are advantageous for antihistaminic activity.77-78 
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 In another study, Diurno et al. synthesized, characterized and evaluated a series of 
2-(substituted-phenyl)-3-[3-(N,N-dimethylamino)-propyl]-1,3-thiazolidin-4-ones for their 
capacity to inhibit the contraction induced by histamine on guinea pig ileum.79 2-(3-
Carbamoyl-phenyl)-3-[3-(N,N-dimethylamino)-propyl]-1,3-thiazolidin-4-one and 
derivatives as free bases were converted into the corresponding hydrochlorides for the 
pharmacological assays (Figure 20). The H1-antihistaminic activity of the synthesized 
compounds was evaluated in vitro by measuring their ability to inhibit the histamine-
induced contractions of isolated guinea pig ileum.80 Results showed that whenever the 
phenyl moiety of the 4-thiazolidinones interacts with a complementary area of the H1-
receptor, the p interaction was enhanced by hydrophobic substituents increasing the 
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HOMO energy and is affected by the size of the 4-alkyl substituents. These studies have 
highlighted the importance of overall hydrophobicity of the compounds in deciding the 
antihistaminic activity.81-82 
 
1.4.9 Antifungal activity 
Rao et al. have reported high fungal activity of some mercurated derivatives of 4-
thiazolidinones against Aspergillus niger at a dilution of 1:10,000. Various 2-(40-
arylthiazolyl-20-imino)- 3-aryl-4-thiazolidinones have been found to be sufficiently 
active against Aspergillus niger and Alternaria tenius at a dilution of 1:10,000.83  
Matolcsy et al. have found very high antifungal activity associated with the derivatives of 
2-thiono-4-thiazolidinones against Alternaria tenius and Botrytis allii. Several 2-[(o-
methylphenyl) imino]-3-aryl-4-thiazolidinones and their 5-phenylazo derivatives have 
been found to be very good fungicidal agents against Helminthosporium euphorbiae.84 3-
ethyl-5-methyl-2-[(4-chlorobenzthiazol-2-yl)imino]-4-thiazolidinone and 3-ethyl-5-
methyl-2-[(5-chlorobenzo- thiazol-2-yl)imino]-4-thiazolidinone were found to exhibit 
100% inhibition of spore germination of Alternaria tenius at concentration of 1:1000, 
1:5000 and 1:10,000.85  
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 Katti et al. synthesized 8-(2-amino-3-phenyl-propionyl)-4-dodecyl-1-thia-4-aza-
spiro [4.5] decan-3-one(Figure 21) and derivatives and evaluated against two strains of 
Candida albicans and one strain of Cryptococcus neoformans in terms of (MIC) in 50 
mg/mL, following the Serial Double Dilution reference method86 and found to possess 
moderate to good activity against the three fungal strains(Figure 21).87  Recently Dandia 
et al. screened few microwave synthesized spiro[3H-indole-3,2′-thiazolidine]-3′(1,2,4-
triazol-3-yl)-2,4′(1H)-dione for their antifungal activity against three pathogenic fungi, 
namely Rhizoctonia solani, causing root of okra, Fusarium oxysporum, causing wilt of 
mustard and Colletotrichum capsici, causing leaf spot and it was found that all 
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compounds show good activity against these pathogens, indicating that the incorporation 
of triazole ring enhances the antifungal activity of compounds (Figure 21).88  Baynate 
and Thiram, recommended as standard fungicides as seed dressers to control this disease, 
also have a –N–C–S linkage, similar to the synthesized compounds, which is responsible 
for their antifungal activity.  
 
1.4.10 Antiviral activity 
Recently, there are several reports in the literature have been found regarding the 
anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones (Figure 22). Some derivatives 
proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentration 
with minimal cytotoxicity. They act by inhibiting reverse transcriptase enzyme, which 
plays an essential and multifunctional role in the replication of the human 
immunodeficiency virus (HIV). Barreca designed and synthesized 2,3-diaryl-1,3-
thiazolidin- 4-one derivatives as new NNRTIs.89      
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 Results showed that the compounds were highly potent anti- HIV agents, up to 10-
fold more active than the corresponding 1-arylsubstituted 1H, 3H-thiazolo[3,4-
a]benzimidazole derivative (TBZs) lead compounds, probably because conformational 
changes may allow the correct positioning of the new molecules for a facile attack at the 
active site residues. Mechanism of action of the compounds was attributed to the 
inhibition of HIV-1 RT. In addition, these compounds were minimally toxic to MT-4 
cells and their selectivity indices were remarkably high. In fact, 6-methylpyridin-2-yl 
derivatives, particularly compound 2-(2,6-dichlorophenyl)-3-(6-methyl-pyridin-2-yl)-4-
thiazolidinone (Figure 22), possessed the most promising selectivity index of 6470 and 
activity with EC50 value of 0.044 mM. In terms of SARs, anti-HIV activity was strongly 
enhanced by introducing a 2-pyridinyl substituent at the N-3 atom of the thiazolidinone 
ring and in particular by two chlorine atoms at 20 and 60 positions of the phenyl rings at 
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C-2. In another study, Katti et al. in collaboration with E. De Clercq and his group have 
reported that some novel 2,3-diaryl substituted 4-thiazolidinone derivatives containing N-
3-substituted furfuryl amine particularly, 2-(2,6-dichloro-phenyl)-3-furan-2-ylmethyl-4-
thiazolidinone, show promising HIV-RT inhibitory activity by determining their ability to 
inhibit the replication of HIV-1 (IIIB) in MT-4 cells with EC50 value of 0.204 mM .90 
 
1.4.11 Anti-inflammatory activity (COX-inhibitors) 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are an inhomogeneous family of 
pharmacologically active compounds used in the treatment of acute and chronic 
inflammation, pain, and fever. Although several mediators support the inflammatory 
processes, the main target of NSAIDs is cyclooxygenase (COX),91 the enzyme involved 
in the first step of the conversion of arachidonic acid to prostaglandins (PGs). The latter 
regulate important functions in the gastric, renal, and emetic systems and are known to 
mediate all inflammatory responses.92-93  The therapeutic effects are mainly due to the 
decrease of proinflammatory PGs produced by COX-2, whereas their unwanted side 
effects result from the inhibition of constitutive COX-1 isoform. 
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 Ottana et al. have investigated 3,3′-(1,2-ethanediyl)-bis[2-aryl-4-thiazolidinone] 
derivatives (Figure 23), which showed interesting stereoselective anti-
inflammatory/analgesic activities together with better gastrointestinal safety profile than 
known NSAIDs,94 suggesting that they might preferentially interact with inducible COX-
2 isoform. Synthesized 2-imino-4-thiazolidinones and 5-arylidene-2-imino-4-
thiazolidinones were tested for in vivo anti-inflammatory activity in models of acute 
inflammation such as carrageenan-induced paw edema and pleurisy assays in rats.95-96 All 
derivatives exhibited significant activity levels. In addition, the ability of such a new class 
of anti-inflammatory agents to inhibit COX isoform was assessed in murine 
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monocyte/macrophage J774 cell line assay.5-(4-Methoxyphenylidene)-2-phenylimino-3-
propyl-4-thiazolidinone, the most interesting compound, showed promising interaction 
for COX-2 selectivity at concentration of 1 and 10 mM with 35 and 55% inhibition, 
respectively. In another study, Kumar et al. synthesized some new anthranilicacid 
derivatives, 2-substituted-3-(4-bromo-2-carboxyphenyl)-5-methyl-4-thiazolidinones and 
evaluated them for anti-inflammatory activity against carrageen an-induced edema in 
albino rats. The most active member of the series, 3-(4-bromo-2-carboxyphenyl)-2-
(fluorophenyl)-5-methyl-4-thiazolidinon was compared (Figure 23) with phenylbutazone 
for its relative anti-inflammatory potency at three graded oral doses (25, 50 and 100 
mg/kg) and were found nearly equipotent, with ED50 =100.0 and 94.4 mg/kg, 
respectively.97  Ottana et al. described the anti-inflammatory activity of 5-arylidene-2-
imino-4-thiazolidinones.98 All derivatives exhibited significant activity in models of acute 
inflammation such as carrageenan-induced paw and pleurisy edema in rats. In particular, 
5-(3-methoxyphenylidene)-2-phenylimino-3-propyl-4-thiazolidinone displayed high 
levels of carrageenan-induced paw edema inhibition, comparable to those of 
indomethacin. In addition, the ability of such a new class of anti-inflammatory agents to 
inhibit COX isoforms was assessed in murine monocyte/macrophage J774 cell line assay. 
5-(4-methoxyphenylidene)-2-phenylimino-3-propyl-4-thiazolidinone, the most interesting 
compound in such an experiment, was docked in the known active site of COX-2 protein 
and showed that its 4-methoxyarylidene moiety can easily occupy the COX-2 secondary 
pocket considered as the critical interaction for COX-2 selectivity. 
 
1.4.12 Follicle stimulating hormone (FSH) receptor agonist activity 
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 Maclean et al. reported the FSH agonist activity of an encoded 4-thiazolidinone 
library.99 Among the hits discovered in these studies was compound 2-chloro-4-[5-{[2-
(3H-inden-1-yl)-ethylcarbamoyl]-methyl}-2-(4-methoxy-phenyl)-4-oxothiazolidin-3-yl]-
benzamide (Figure 24), which possessed moderate activity as an agonist of FSH, by 
virtue of its ability to stimulate a reporter cell line expressing the FSH receptor.100  FSH is 
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a 31-kDa heterodimeric glycoprotein, and the discovery of a small molecule FSH agonist 
was an unprecedented achievement.101  An orally active compound of this class could be a 
useful addition to the portfolio of drugs available for the alleviation of female infertility.  
 
1.5 Aim of current work 
 As described above, the thiazolidinone and its derivatives are an important class 
of heterocyclic compounds because of their broad spectrum of biological activities, such 
as COX-1 inhibition, 2 anti-inflammatory, 102 antiproliferative, 73, 103 antihistaminic,5  and 
anti-HIV activities.104-105 
The search for new synthetic analgesics has led to the preparation of diphenyl-
propylamine derivatives. A comprehensive survey of this work has been given. Lindner106 
and Kochsiek, et al.,107 reported on a new therapeutic action of one member of this group. 
The novel 3,3-diphenylpropylamine (Figure 25), is a coronary dilator of prolonged 
action. Moreover, 3,3-diphenylpropylamine is a key intermediate of lercanidipine drug108 
(Figure 26).   
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In view of the above observations, the synthesis of novel 2-aryl-3-(3,3-
diphenylpropyl)thiazolidin-4-ones derivatives has been developed starting from 3,3-
diphenylpropylamine and various substituted aromatic aldehyde with the aim of 
investigating their biological activities. 
 
1.6 Chemistry 
  The synthetic strategies adopted to obtain the target compounds are depicted in 
Schemes 1. The key intermediate 3 was prepared in an moderate yield in two 
consequence steps by condensing 3,3diphenylpropylamine (1) with various benzaldehyde 
(2) to afford Schiff’s base 3 , which was reacted with mercaptoacetic acid in toluene. 
Thus, refluxing 3 in toluene in the presence of catalytic amount of AcOH furnished 2-
aryl-3-(3,3-diphenylpropyl)thiazolidin-4-ones. However, the yields were moderate. 
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 To find better reaction conditions, next we investigated the application of fuller’s 
earth in a two-step reaction sequence for preparation of 4-thiazolidinones. We found that 
the 4-thaizolidinones can be prepared in excellent yield by microwave-assisted fuller’s 
earth-catalyzed reaction of various benzaldehydes with amines and mercaptoaceticacid. 
The results are reported herein.  
 
1.7 Results and discussion 
The synthesis of substituted thiazolidin-4-ones 4a–r (Scheme 1) was performed 
using a microwave irradiation and conventional procedure. All the reactions were 
performed in closed vessels and the microwave program was composed of appropriate 
ramping and holding steps. Identification of the optimum profile power at 350W and time 
for the experiments is reported in Table 1. 
 We first performed conventional method in the reaction using 3,3diphenylpropyl 
amine 1 as a starting material for a three-component reaction. 3,3diphenylpropylamine 1 
was first reacted with appropriate aldehyde 2a-r in toluene at reflux temperature followed 
by reaction with mercaptoacetic acid in presence of catalytic amount of AcOH yielded 
compounds 4a–r in moderate yields (Table 1). 
 
Table 1: Yields of the thiazolidinones 4a–r by conventional and microwave-
irradiation method 
Conventional Method Microwave Method Entry   R1 
Time(hr) Yield (%)* Time(min) 
Yield 
(%)* 
4a H 25 50 3.4 92 
4b 4-OCH3 21 53 3.5 95 
4c 4-F 23 60 3.0 92 
4d 3-Cl 29 52 3.6 89 
4e 4-NO2 30 50 4.5 90 
4f 4-Cl 28 55 3.8 87 
4g 2-NO2 30 43 4.0 85 
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*Isolated yield 
 Preliminary experiments to examine the reaction time, the solvent, and irradiation 
power were performed using 3,3-diphenylpropylamine 1 (0.01 mol)  and appropriate 
aldehydes 2a-r (0.01 mol), mercaptoacetic acid (0.01 mol) and fuller’s earth (100 mg) 
catalyzed was  irradiated under microwave oven for 3 to 7.5 min at 350W as a model 
system to synthesize the compound 4a and 4b (Table 2). Various reaction times and 
irradiation power were tested using various solvent (Table 2). All comparative reactions 
were conducted under optimized conditions, and compound 4a and 4b was obtained 
under MW irradiation. The best yield of 4b (95%) was obtained by carrying out the 
reaction in DMF under MW irradiation (350 W) for 3.5 min. Compare to the other 
solvents including methanol (MeOH), acetonitrile (MeCN), and tetrahydrofuran (THF) 
(Table 2), the use of DMF resulted in a faster reaction with a higher yield, in contrast to a 
reaction in less polar THF. When the reaction was carried out with conventional heating 
(Table 1), it requires extended heating time (24-30 h), providing the product in a lower 
yield (30–60%). 
 
 
 
4h 3-NO2 25 46 3.9 85 
4i 2-Cl 27 48 3.6 88 
4j 3,5 di-fluoro 30 37 6.8 87 
4k 2-OH 26 35 7.2 85 
4l 3-OH 22 41 7.5 86 
4m 4-OH 20 45 6.8 89 
4n 2-Br 24 36 5.3 85 
4o 3-Br 25 43 6.0 88 
4p 4-Br 24 45 6.2 90 
4q 4-OH, 3-OCH3 28 38 7.4 87 
4r 
5- NO2, 4-OH, 3-
OCH3 
30 30 7.5 85 
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Table: 2 Reaction of 4a and 4b in various solvents using in microwave  
Irradiation 
Entry Solvent Mode of 
Activation
Time Power 
 
Yield 
(%)* 
4a DMF MW 3.4 min 350 W 92 
4a THF MW 5.0 min 350 W 55 
4a MeOH MW 5.5 min 350 W 61 
4a MeCN MW 7.0 min 350 W 60 
4b DMF MW 3.5 min 350 W 95 
4b THF MW 4.5 min 350 W 56 
4b MeOH MW 5.5 min 350 W 60 
4b MeCN MW 7.5 min 350 W 58 
*Isolated yield 
 These results confirm that the focused microwave irradiation is a very effective 
technique for accelerating thermal organic reactions. Thus, it has been found that reaction 
of substituted aldehyde (2a-r) derivatives (Scheme 1) with 3,3diphenylpropylamine in 
the presence of fuller’s earth followed by the cyclocondensation with mercaptoacetic acid 
gives the novel 2-aryl-3-(3,3-diphenylpropyl)thiazolidin-4-ones (4a-r), the corresponding 
thiazolidinones 4a–r was obtained in 85 to 95% yield. 
 The structures of 4a-r were established on the basis of their elemental analysis and 
spectral data (MS, IR, 1H NMR, and 13C NMR). For example, compound 4a showed 
molecular peak at m/z: 374[M + 1], 373[M+], which agrees with its molecular formula 
C24H23NOS. The structure of 2-phenyl-3-(3,3-diphenylpropyl)thiazolidin-4-one (4a) 
was assigned to the transient species 4a on the basis of 1H NMR resonances. The C2–H 
signal appears as a doublet at 5.49 δ long range coupled (d, 1H, J =1.76 Hz, SCHPh) with 
the higher field proton of the C5 geminal system at 3.79 δ (dd, 1H, J =1.92, 2.28 Hz, 
SCHα) and 3.82 δ (d, 1H, J = 7.84 Hz, SCHβ) in accordance with the cyclic structure 4a 
reported in Scheme 1. On the basis of this evidence, it seems reasonable to attribute the 
structure of a cyclic gem-diol to the transient species 4a, in which the two long-range 
coupled protons participate in a W-arrangement, an observation consistent with the 
literature.109-112 The 13C NMR displayed peaks at 41.27 (SCH2), 61.21 (NCHPh), 160.90 
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(PhC-F) and 170.25 (C=O), which account for all the carbon atoms in the molecule. In the 
IR spectra, bands in the 3064-3063 cm-1  and 1666-1662 cm-1 regions attributed to (C-H, 
Ar-H) and C=O stretching of the compounds 4a-r respectively. New C=O bands (1666-
1662 cm-1) in the IR spectra of thiazolidin-4-ones provided confirmatory evidence for 
ring closure.113-115 
 Comparison of the results for 18 compounds showed that microwave-assisted 
irradiation improved the yields by 20% to 60% compared to those obtained using 
conventional heating technique. Although the yield of compound 4j and 4r was moderate, 
it was still greater then that achieved under conventional heating, and was obtained in a 
reaction time of 3 to 7.5 min rather than 30 h (Table 1). 
 
1.8 Conclusion 
In summary, we have established a rapid and economical procedure for 
constructing novel 2-aryl-3-(3,3diphenylpropyl)thiazolidin-4-ones using fuller’s earth as a 
catalyst. Comparison of the proposed method with conventional syntheses of the same 
compound showed that the microwave-assisted syntheses were characterized by much 
shorter reaction times and higher product yields. The newly developed protocol is 
efficient for the rapid synthesis of 2-aryl-3-(3,3-diphenylpropyl)thiazolidin-4-ones via 
one-pot three-component strategy under microwave irradiation. 
1.9 Reaction scheme of   2-aryl-3-(3,3-diphenylpropyl)thiazolidin-4-ones 
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1.10  Experimental procedure 
Melting points were determined on an electro thermal apparatus using open 
capillaries and are uncorrected. Thin-layer chromatography was accomplished on 0.2-mm 
precoated plates of silica gel G60 F254 (Merck). Visualization was made with UV light 
(254 and 365nm) or with an iodine vapor. IR spectra were recorded on a FTIR-8400 
spectrophotometer using DRS prob. 1H NMR spectra were recorded on a Bruker 
AVANCE II (400 MHz) spectrometer in DMSO. Chemical shifts are expressed in δ ppm 
downfield from TMS as an internal standard. Mass spectra were determined using direct 
inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were 
evaporated with a BUCHI rotary evaporator.  
 
1.10.1 By conventional heating 
A mixture of 3,3-diphenylpropylamine (1, 0.01 mol)  and appropriate aldehydes 
(2a-r, 0.01 mol) in dry toluene (25 ml) was refluxed until no more water was collected in 
a Dean–Stark water separator. The reaction being monitored by TLC. To this crude 
mixture, mercaptoacetic acid (0.01 mol) was added dropwise and the reaction mixture 
was heated at reflux temperature for 10-15 h. The reaction mixture was cooled to room 
temperature and evaporated to dryness under vaccuo. The crude compound (4a-r) 
obtained was taken up in chloroform (200 mL). The organic layer was washed with 5% 
aq. citric acid (100 mL), followed by water (200 mL), 5% aqueous sodium hydrogen 
carbonate (100 mL) and brine (100 mL). The organic layer was dried over anhydrous 
sodium sulphate and the solvent was removed under reduced pressure. The crude product 
obtained was purified by column chromatography (SiO2) using hexane–ethyl acetate (8:2) 
as an eluent. The fraction containing main products were combined and evaporated to 
dryness under reduce pressure. The residue was crystallized from ethanol to give pure 
product 4a-r. 
 
1.10.2 By microwave heating 
  A well stirred mixture of 3,3-diphenylpropylamine (1, 0.01 mol) in 25 ml 
dimethylformamide, appropriate aldehyde (2a-r, 0.01 mol), mercaptoacetic acid (0.01 
mol) and fuller’s earth (100 mg) was irradiated under microwave oven for 3 to 7.5 min at 
350W. The reaction was monitored by TLC. After completion of reaction, the reaction 
mixture was taken up in chloroform and extracted with water. The organic layer was 
washed with 5% aqueous citric acid (100 mL), followed by water (200 mL), 5% aqueous 
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sodium hydrogen carbonate (100 mL) and brine (100 mL). And dried over anhydrous 
sodium sulphate. The solvent was removed under reduced pressure and the residue was 
purified by column chromatography (SiO2) using hexane–ethyl acetate (8:2) as an eluent. 
The fraction containing the main products were combined and evaporated to dryness 
under reduce pressure. The crude product thus obtained was crystallized from ethanol to 
afford the targeted 4-thiazolidinones (4a-r). 
  Similarly, other 2-aryl-3-(3,3-diphenylpropyl)thiazolidin-4-ones were prepared. 
 
2-phenyl-3-(3,3-diphenylpropyl)thiazolidin-4-one (4a). This compound was obtained 
as yellow solid in 92% yield. mp 114–116 °C; Anal. Calcd for C24H23NOS: C, 77.18; H, 
6.21; N, 3.75; Found: C, 77.03; H, 6.08; N, 3.60; m/z: 373[M+]; 1H NMR (400 MHz, 
CDCl3): δ ppm 2.15-2.30 (m, 2H, CH2), 2.69–2.76 (m, 1H, CH), 3.49–3.64 (m, 2H, CH2), 
3.74–3.83 (m, 2H, CH2), 5.49 (d, J=1.70 Hz, 1H, CH), 7.07–7.23 (m, 10H, Ar), 7.24 (s, 
2H, Ar), 7.34–7.36 (m, 3H, Ar), IR (KBr) (cm-1): 3060-3024, 1660, 1610, 1520, 1340, 
1268, 1225, 1150. 
 
2-(4-methoxyphenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4b). This compound 
was obtained as white solid in 95% yield. mp 135–134 °C; Anal. Calcd for C25H25NO2S: 
C, 74.41; H, 6.24; N, 3.47; Found: C, 74.25; H, 6.08; N, 3.32; m/z: 403[M+]; 1H NMR 
(400 MHz, CDCl3): δ ppm 2.09–2.26 (m, 2H, CH2), 2.68–2.76 (m, 1H, CH), 3.45–3.59 
(m, 2H,CH2), 3.72–3.81 (m, 2H, CH2), 3.82 (s, 3H, OCH3), 5.47 (d, J=1.40 Hz, 1H, CH), 
6.85  (d, J=8.72 Hz, 2H, Ar), 7.07 (m, 12H, Ar), IR (KBr) (cm-1): 3060-3028, 1666, 1608, 
1524, 1348, 1268, 1218, 1148. 
 
2-(4-fluorophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4c). This compound was 
obtained as off-white solid in 92% yield. mp 98–100°C; Anal. Calcd for C24H22FNOS: C, 
73.63; H, 5.66; N, 3.58; Found: C, 73.50; H, 5.52; N, 3.41;  m/z: 391[M+]; 1H NMR (400 
MHz, CDCl3): δ ppm 2.18–2.31 (m, 2H, CH2), 2.65–2.72 (m, 1H, CH), 3.52-3.63 (m, 2H, 
CH2), 3.74–3.84 (m, 2H, CH2), 5.47 (d, J=1.84 Hz, 1H, CH), 7.05–7.22 (m, 10H, Ar), 
7.23–7.33 (m, 4H, Ar), IR (KBr) (cm-1): 3063-3026, 1666, 1597, 1492, 1406, 1330, 1220, 
1197; 13C NMR (400 MHz, DMSO): 31.43, 31.98, 41.27, 48.15, 61.21, 115.55, 155.75, 
126.18, 128.43, 136.32, 144.28, 160.90. 
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2-(3-chlorophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4d). This compound was 
obtained as white solid in 89% yield. mp 119–121°C; Anal. Calcd for C24H22ClNOS: C,  
70.66; H, 5.44; N, 3.43; Found: C, 70.49; H, 5.28; N, 3.28; m/z: 407 [M+]; 1H NMR (400 
MHz, CDCl3): δ ppm 2.12–2.15 (m, 1H, CH), 2.22–2.26 (m, 1H, CH), 2.64–2.71 (m, 1H, 
CH), 3.48–3.55 (m, 1H, CH), 3.60–3.64 (m, 1H, CH), 3.72–3.83 (m, 2H, CH2),  5.47 (d, 
J=1.64 Hz, 1H, CH), 6.99–7.21 (m, 10H, Ar), 7.21–7.24 (m, 4H, Ar), IR (KBr) (cm-1): 
3064-3026, 1662, 1600, 1523, 1346, 1269, 1220, 1155. 
 
2-(4-nitrophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4e). This compound was 
obtained as yellow solid in 90% yield. mp 153–155°C; Anal. Calcd for C24H22N2O3S: C,  
68.88; H, 5.30; N, 6.69; Found: C, 68.70; H, 5.15; N, 6.57;  m/z: 418 [M+]; 1H NMR (400 
MHz, CDCl3): δ ppm 2.23–2.29 (m, 2H, CH2), 2.57–2.65 (m, 1H, CH), 3.61–3.68 (m, 2H, 
CH2), 3.75–3.84 (m, 2H, CH2), 5.53 (d, J=1.76 Hz, 1H, CH), 7.12–7.28 (m, 10H, Ar), 
7.31 (d, J=8.72 Hz, 2H, Ar), 8.17 (d, J=8.72 Hz, 2H, Ar), IR (KBr) (cm-1): 3073-3036, 
1667, 1587, 1482, 1416, 1340, 1230, 1187. 
 
2-(4-chlorophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4f). This compound was 
obtained as yellow solid in 87% yield. mp 128–130°C; Anal. Calcd for C24H22ClNOS: C,  
70.66; H, 5.44; N, 3.43; Found: C, 70.48; H, 5.30; N, 3.30; m/z: 407 [M+]; IR (KBr) (cm-
1): 3064-3036, 1668, 1610, 1525, 1340, 1267, 1225, 1158. 
 
2-(2-nitrophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4g).  This compound was 
obtained as yellow solid in 85% yield. mp 118–120°C; Anal. Calcd for C24H22N2O3S: C,  
68.88; H, 5.30; N, 6.69; Found: C, 68.71; H, 5.14; N, 6.55; m/z: 418 [M+]; IR (KBr) (cm-
1): 3066-3022, 1661, 1598, 1511, 1340, 1264, 1223, 1145. 
 
2-(3-nitrophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4h). This compound was 
obtained as yellow solid in 85% yield. mp 140–142°C; Anal. Calcd for C24H22N2O3S: C,  
68.88; H, 5.30; N, 6.69; Found: C, 68.69; H, 5.16; N, 6.56; m/z: 418 [M+];  IR (KBr) (cm-
1): 3068-3029, 1667, 1605, 1528, 1354, 1264, 1221, 1153. 
 
2-(2-chlorophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4i). This compound was 
obtained as off-white solid in 88% yield. mp 105–107°C; Anal. Calcd for C24H22ClNOS: 
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C,  70.66; H, 5.44; N, 3.43; Found: C, 70.44; H, 5.27; N, 3.24; m/z: 407 [M+]; IR (KBr) 
(cm-1): 3064-3026, 1660, 1615, 1528, 1340, 1260, 1230, 1145. 
 
2-(3,5-difluorophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4j). This compound 
was obtained as off-white solid in 87% yield. mp 104–106°C; Anal. Calcd for  
C24H21F2NOS: C, 70.39; H, 5.17; N, 3.42; Found: C, 70.23; H, 5.01; N, 3.28; m/z: 409 
[M+]; IR (KBr) (cm-1): 3064-3025, 1660, 1620, 1528, 1344, 1266, 1222, 1153. 
 
2-(2-hydroxyphenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4k). This compound 
was obtained as white solid in 85% yield. mp 108–110°C; Anal. Calcd for C24H23NO2S: 
C, 74.00; H, 5.95; N, 3.60; Found: C, 73.87; H, 5.80; N, 3.47; m/z: 389 [M+];  IR (KBr) 
(cm-1): 3070-3030, 1666, 1610, 1518, 1340, 1263, 1225, 1165. 
 
2-(3-hydroxyphenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4l). This compound 
was obtained as white solid in 86% yield. mp 126–128°C; Anal. Calcd for C24H23NO2S: 
C, 74.00; H, 5.95; N, 3.60; Found: C, 73.84; H, 5.83; N, 3.45;  m/z: 389 [M+]; IR (KBr) 
(cm-1): 3068-3036, 1669, 1610, 1533, 1356, 1259, 1230, 1145. 
 
2-(4-hydroxyphenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4m). This compound 
was obtained as white solid in 89% yield. mp 142–144°C; Anal. Calcd for C24H23NO2S: 
C, 74.00; H, 5.95; N, 3.60; Found: C, 73.85; H, 5.81; N, 3.46; m/z: 389 [M+];  IR (KBr) 
(cm-1): 3054-3016, 1652, 1690, 1513, 1336, 1259, 1210, 1145. 
 
2-(2-bromophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4n). This compound was 
obtained as brown solid in 85% yield. mp 58–60°C; Anal. Calcd for C24H22BrNOS: C, 
63.72; H, 4.90; N, 3.10; Found: C, 63.58; H, 4.73; N, 2.96; m/z: 453 [M+]; IR (KBr) (cm-
1): 3065-3024, 1660, 1612, 1518, 1345, 1276, 1212, 1145. 
 
2-(3-bromophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4o). This compound was 
obtained as brown solid in 88% yield. mp 78–80°C; Anal. Calcd for C24H22BrNOS: C, 
63.72; H, 4.90; N, 3.10; Found: C, 63.55; H, 4.77; N, 2.94; m/z: 453 [M+]; IR (KBr) (cm-
1): 3044-3016, 1672, 1630, 1533, 1336, 1279, 1230, 1135. 
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2-(4-bromophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4p). This compound was 
obtained as brown solid in 90% yield. mp 94–96°C; Anal. Calcd for C24H22BrNOS: C, 
63.72; H, 4.90; N, 3.10; Found: C, 63.59; H, 4.76; N, 3.00; m/z: 453 [M+]; IR (KBr) (cm-
1): 3054-3036, 1652, 1610, 1519, 1356, 1259, 1229, 1148. 
2-(4-hydroxy-3-methoxyphenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one (4q). This 
compound was obtained as pale yellow solid in 87% yield. mp 118–120°C; Anal. Calcd 
for C25H25NO3S: C, 71.57; H, 6.01; N, 3.34; Found: C, 71.43; H, 5.88; N, 3.20;  m/z: 419 
[M+]; IR (KBr) (cm-1): 3068-3021, 1658, 1598, 1515, 1336, 1258, 1218, 1140. 
 
2-(4-hydroxy-3-methoxy-5-nitrophenyl)-3-(3,3-diphenylpropyl)thiazolidin-4-one 
(4r). This compound was obtained as pale yellow solid in 85% yield. mp 124–126°C; 
Anal. Calcd for C25H24N2O5S: C, 64.64; H, 5.21; N, 6.03; Found: C, 64.50; H, 5.08; N, 
5.88; m/z: 464 [M+]; IR (KBr) (cm-1): 3070-3029, 1660, 1611, 1533, 1356, 1255, 1222, 
1161. 
 
1.11 spectral representation of synthesized compounds 
1.11.1 1H NMR spectrums compound of 4a 
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1.11.2 1H NMR spectrums of compound 4b 
 
1.11.3 1H NMR spectrums of compound 4c 
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1.11.4 1H NMR spectrums of compound 4d 
 
1.11.5 1H NMR spectrums of compound 4e 
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1.11.6 13C NMR spectrum of compound 4c 
 
1.11.7 Mass spectrum of compound 4a 
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1.11.8 Mass spectrum of compound 4b 
 
1.11.9 Mass spectrum of compound 4d 
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1.11.10 Mass spectrum of compound 4e 
 
1.11.11 IR spectra of compound 4c 
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1.11.12 IR spectra of compound 4i 
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Etidronic acid-catalyzed synthesis of novel Mannich base 
derivatives of 7-hydroxy-4-isopropyl-2H-chromen-2-one. 
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2.1. Introduction 
 
 The chemistry of coumarins 
Benzo-2-pyrones, commonly known as coumarins, are a fascinating group of 
compounds occurring widely in nature, both in free and combined states. Benzo-2-
pyrones and benzo-4-pyrones are known as coumarins and chromone respectively. They 
occur in plants of the families Orchideceae, Leguminaceae, Rutaceae, Umbellifereae and 
Labiateae. Most red and blue flower petals contain anthocyanine derivatives of the 
benzo-2-pyrones and benzo-4-pyrones are widely distributed. Coumarins form a distinct 
class of oxygen containing heterocycles that are widely distributed in nature.  
 
Coumarins, the parent substance of the benzo-α-pyrone group, was first isolated 
from Tonka beans in 1820.1 A number of naturally occurring and synthetic monomeric 
coumarin derivatives are used in drugs and dyes.2  
 
The fusion of a pyrone ring with a benzene nucleus gives rise to heterocyclic 
compounds known as benzopyrones, of which two distinct types are recognized as benzo-
α-pyrone, commonly called coumarins, and benzo-γ-pyrones, called chromones, the latter 
differing from the former only in the position of the carbonyl group in the heterocyclic 
ring.3 (Figure-1). 
 
O O O
O
Benzo-α-pyrone Benzo-γ-pyrone
Figure-1  
 
 
   48
 
OHO
OH O
OH
OH
OH
Alloxanthoxyletin
O
OOH
H3CO
OH
OCH3
CH3
Paepalantine
OHO
OH O
OH
OH
OH
Quercetin
O
OO
CH3H3C
CH3
O
O
Calanolide-A
O O
O
O
Me
O
CH3
CH3
Geiparvarin
Figure-2: Few naturally occurring coumarins  
The coumarins have diverse biological properties and various effects on the 
different cellular systems. Coumarins have important effects in plant biochemistry and 
physiology, acting as antioxidants, enzyme inhibitors and precursors of toxic substances. 
In addition, these compounds are involved in the actions of plant growth hormones and 
growth regulators, the control of respiration, photosynthesis, as well as defense against 
infection.  
The coumarins have also been recognized to possess anti-inflammatory, 
antioxidant, antiallergic, hepatoprotective, antithrombotic, antiviral and anticarcinogenic 
activities. The coumarins are extremely variable in structure, due to the various types of 
substitutions in their basic structure, which can influence in their biological activity.4 
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2.2 Synthetic methods for coumarin and Mannich coumarin 
Several various methods for the preparation of coumarin and Mannich coumarin 
are narrated in literature.5-18 
1.  Babak Karimi et al.19 have synthesized a highly efficient and water-tolerant 
sulfonic acid nanoreactor based on tunable ordered porous silica for the von Pechmann 
reaction (Figure 3). 
HO
R
EtO
OO
nanoreactor/catalyst
130 oC, Solvent-free
O O
R
Figure 3  
 
2.  Mauro Mazzei et al20 have reported some Mannich bases of 7-hydroxycoumarin 
and their simple derivatives were prepared and tested against viruses containing single-
stranded, positive-sense RNA genomes (ssRNA) (Figure 4). 
O O
R1
HO
R1= H, CH3
HNR2, HCHO
EtOH, reflux,3-5 h
O O
R1
HO
CH2
NR2
R2=Various secondary amine
Figure 4
 
 
3. Rodolfo Quevedo et al21 have synthesized new macrocyclic compounds having 
two benzoxazine subunits joined by two ethylene bridges have been prepared by Mannich 
condensation of the appropriate 4-hydroxyphenylethylamine with an excess of 
formaldehyde. This is a general method for synthesizing a new family of 
heterocyclophanes (Figure 5). 
R
NH2
HO
HCHO
O
NR
O
N R
R= COOC2H5, H
Figure 5
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4. Hui Mao et al22 have synthesized facile and diastereoselective synthesis of β-
acetamido ketones and keto esters via direct Mannich-type reaction (Figure 6). A 
Mannich type three-component reaction involving aldehydes, acetamide, and enolizable 
ketones or β-keto esters for the preparation of β-acetamido carbonyl compounds in the 
presence of TMSCl is described. This newly developed protocol is operationally 
convenient, widely applicable, and highly diastereoselective. 
CHO
CH3CONH2
OO
TMSCl
CH3CN , refluxR R
O
O
NHAc
R= Aryl  aldehydeFigure 6  
 
5. Rosaria Villano et al23 have synthesized a convenient approach to α-amino-β-
ketoester by vinylogous Mannich reaction of masked acetoacetate (Figure 7). SiCl4 
showed an efficient and selective catalyst for the vinylogous Mannich reaction of linear 
and cyclic synthetic equivalents of acetoacetate dianion, leading to α-amino-β-ketoesters 
in moderate to high yields and complete γ-selectivity; anti-diastereoselective was 
observed by using a γ -methyl-substituted cyclic silyloxydiene. 
R=Aryl aldehyde
PhNH2 , CH2Cl2
3 A0 MS, Sio2, 1 h/rt;
R-CH=N-C6H4
CH2Cl2
DIPEA, SiCl4
0.5 h/ -78 0C
N
COOMe
O
CHO
R
R
Figure 7
 
 
6. M. M. Garazd et al24 have synthesized modified coumarins with Mannich reaction 
of substituted 4-phenylcoumarine (Figure 8).   
O
Ph
OHO
H2NCHRCOOH
CH2O
O
Ph
OHO
NH
R
O
HO
Figure 8  
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7. Wen-Juan Hao et al25 have synthesized a new mild base-catalyzed Mannich   
reaction of heteroarylamines in water highly efficient stereoselective synthesis of β-
aminoketones under microwave heating (Figure 9). 
Ar
O N
X
NH2
X=CH, N
Ph
Ph
O
K2CO3, Water
130 oC MW
   Sealed N
X
N
H
PhO
Ph
Ar
Figure 9
 
 
8. Hua Yang et al26 have synthesized enantioselective Mannich reactions with the 
practical proline mimetic N-(p-dodecylphenyl-sulfonyl)-2-pyrrolidinecarboxamide 
(Figure 10). 
R'
O
R
N
P
"R
NH
O
N
H
O2
S
C12H2510-20 mol % cat
DCE, 2-Me-THF 1 M concentration H2O(1 equiv)
  4 oC to rt
R'
"R
HN
R
O
P
Figure 10  
 
9.    Shou-Ri Sheng et al27 have synthesized novel traceless liquid-phase synthesis of 
coumarin derivatives on poly (Ethylene Glycol) support (Figure 11). Coumarin 
derivatives were prepared by the von Pechmann reaction of PEG-bound acetoacetate 
reagent with phenols in the presence of TiCl in excellent yield and purity with a facile 
workup procedure. The polymer reagent could be recycled two to four times without 
diminishing the yield or purity. 
O
O O R
OH
TiCl4 /THF, rt
O O
CH3
R OH
Figure 11  
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2.3 Biological activities of coumarin derivatives 
 
2.3.1 Coumarins as cytotoxicity agents 
 Coumarins have attracted intense interest in recent years because of their diverse 
pharmacological properties. The cytotoxic coumarins represent an exploitable source of 
new anticancer agents, which might help addressing cytotoxicity and resistance 
phenomena. These natural compounds have served as valuable leads for further design 
and synthesis of more active analogues. Promising data have been reported for a series of 
different coumarins used as cytotoxic agents.28 
 A large number of structurally novel coumarin derivatives have ultimately been 
reported to show substantial cytotoxic and anti-HIV activity in vitro and in vivo.29 
Coumarins have shown cytotoxicity with derivatives containing o-dihydroxy substituents 
as reported by Kolodziej et. al.30. The chemical structure and biological activity study of 
the coumarins showed that the addition of a catecholic group to the basic structure 
induced increased cytotoxic activity in tumor cell lines.31 
Figure-12: Structures of cytotoxic coumarins30 
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6-Nitro-7-hydroxy 
coumarin 
 
O O
HO
HO
 
6,7-Dihydroxy 
coumarin (Esculetin) 
O OHO
OH
 
7,8-dihydroxycoumarin 
(Daphnetin) 
 
O O
O
OH
 
Coumarin-3-carboxylic 
acid 
 
  
   53
O O
CH3
HO
HO
 
4-Methyl-6,7-dihydroxy 
coumarin 
O OHO
CH3  
4-Methyl-7-hydroxy 
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Figure-12 
 
 The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A1 are 
known as potent inhibitors of gyrase.32 Their equilibrium dissociation constants are in the 
range of 10 nM, 33.e., their affinity for gyrase is considerably higher than that of modern 
fluoroquinolones. Novobiocin is licensed as an antibiotic for clinical use (Albamycin; 
Pharmacia-Upjohn) and is used for the treatment of infections with multi resistant gram-
positive bacteria, e.g. Staphylococcus aureus34 (Figure 13). 
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 Novobiocin is produced by Streptomyces spheroides (syn. S. caeruleus)35CIMB 
11891, Clorobiocin (Figure 14) is produced by S. roseochromogenes var. oscitans 
DS12.976 and coumermycin A1 (Figure 15) is produced by S. rishiriensis DSM 40489.36 
Obviously, these organisms must protect their gyrases from the inhibitory effect of 
aminocoumarin during antibiotic formation. 
O
O
N C
O
CH3
O
OHO
CH3
CH3OH
Cl
O
C
OH
H
N
H
H3C
O
Figure 14 : Chlorobiocin
OCH3
CH3
 
  
Thiara and Cundliffe37-39 have reported that the principal resistance mechanism of 
the novobiocin producer S. sphaeroides is the de novo synthesis of a coumarin-resistant 
gyrase B subunit, which replaces the sensitive GyrB subunit in the active 
(GyrA)2(GyrB)2 heterotetramer. Thus, this novobiocin producer contains two gyrB 
genes, a constitutively expressed gyrBS, encoding the coumarin-sensitive protein and the 
gyrBR gene, encoding the resistant protein and expressed in the presence of novobiocin. 
The promoter of gyrBR appears to be regulated by changes in the superhelical density of 
DNA.37 Mitchell et. al.34 supplied evidence that additional genes may contribute to 
novobiocin resistance. They used the novobiocin producer S. niveus, which has recently 
been identified as a subjective synonym for S. spheroids.32 
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2.3.2 Coumarin as potent anti-HIV compounds 
 Natural coumarins and their derivatives can display anti-HIV activity through 
different mechanisms, including blockade of viral entry, inhibition of reverse 
transcriptase and interference with viral integration.40,41Some phenyl coumarins and 
chalcones, as well as tannins and lignins, have been proposed as suppressors of LTR-
dependent transcription, but the mechanism of action has not been fully characterised.42 
(+)-Calanolide A, a natural dipyranocoumarin, currently undergoing anti-AIDS 
clinical trials,43 has also proven to be an effective antimycobacterial against drug-sensible 
and drug-resistant Mycobacterium tuberculosis strains (Figure 16). 
O
O
CH3H3C
OO
OHH3C
CH3
CH3
Figure 16: (+)-Calanolide A  
 
It has been reported that mesuol and isomesuol, (Figure 17) two 4-phenyl 
coumarins, isolated from the tree Marila pluricostata, suppress HIV-1 replication in 
Jurkat T cells.44 These coumarins do not affect the reverse transcription and intregration 
steps of the viral cycle and their antiviral effect is additive with that of azidothymidine 
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(AZT). In addition, mesuol inhibits TNFα-induced HIV-1-LTR transcriptional activity by 
targeting the nuclear factor-κB (NF-κB) pathway. While mesuol does not prevent either 
the binding of NF-κB to DNA or the phosphorylation and degradation of NF-κB 
inhibitory protein, IκBα, it inhibits the phosphorylation and the transcriptional activity of 
the NF-κB p65 subunit in TNFα-stimulated cells. These results highlight the potential of 
the NF-κB transcription factor as a target for anti-HIV-1 compounds such as 4-phenyl 
coumarins, which could serve as lead compounds for the development of additional 
therapeutic approaches against AIDS.  
O
H3C
HO
O
CH3
CH3
OHCH3
O OHO
OH
O
H3C CH3
CH3
H3C
O
Isomesuol Mesuol
Figure 17: Chemical structures of the 4-phenylcoumarins Isomesuol and Mesuol.  
 
2.3.3 Protease inhibitors 
Warfarin is believed to inhibit the vitamin K dependent conversion of 
prothrombin and serine protease activity of thrombin. A 100 μM dose of warfarin is 
inhibitory toward HIV aspartyl protease. In view of the four remarkable properties of 
warfarin, i.e., inhibition of serine protease, aspartyl protease, reverse transcriptase and 
integrase, all of which are essential for HIV replication, this drug deserves clinical testing 
in a larger population of HIV-positive individuals (Figure 18). 
Two large pharmaceutical companies, Parke-Davis, a division of Warner Lambert 
and Pharmacia & Upjohn confirmed that warfarin and related coumarin compounds were 
HIV protease inhibitors.45 Warfarin, the first non-peptide derived protease inhibitor, was 
proclaimed to be a modest PI (IC50 of 18 or 30 μM) and coumarin derivatives with better 
specificity were provided. Inhibitors of HIV-1 protease, the pyran-2-one group, 4 
hydroxyl group, and substitution at the 3-position are all necessary for activity.46  
   57
PD099560 is also identified as a non-peptide competitive HIV-1 protease inhibitor47 
(Figure 18). 
O
CH3
O
O
OH O
OH
O
O
Warfarin PD099560
Figure 18  
 
2.3.4 Integrase inhibitors 
 In addition to HIV RT and protease, HIV integrase is also a major 
chemotherapeutic target;48 integrase inhibitors mainly includes biscatechols and 
coumarins. Because catechols are cytotoxic, partly due to in situ oxidation to quinone 
species, coumarins have clinical advantages. A natural tetrameric coumarin showed high 
anti-integrase activity (IC50 = 0.8 µM for integration and 1.5 µM for 30-processing)49 
(Figure-19). 
Increasing the number of aryl rings on the central linker enhanced potency; the 
rigid stilbene analog50 is the most potent (integration 3.7 µM, 30-processing 5.5 µM) 
among the compounds synthesized (Figure-20). 7-Hydroxylation was beneficial in a 
wide range of dimeric 4,7-hydroxycoumarins and led to a simplified coumarin integrase 
inhibitor without greatly sacrificing the potency of the tetrameric compound.  
O O
O O
O
O O
O
OH OH
OH OH
Figure 19: A Natural tetrameric coumarin
O O
O O
OH OH
HO OH
Ph
Figure 20: Stilbene analog  
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2.3.5 Reverse trancriptase inhibitors 
 HIV-1 RT interacts with complementary oligodeoxynucleotide (ODN) primers at 
the 50-end of the tRNA binding site as well as at the 30-end of the primer. ODN 
derivatives can form specific, more stable complexes with complementary nucleic acids. 
When several chromone and coumarin structures were conjugated to the 50-end of ODNs 
affinity toward HIV-1 RT is increased, suggesting that these compounds may be 
functioning as primers. This action was confirmed when protection of RT by tRNA lys3 
decreased the complex formation between the enzyme and the conjugated ODN. The 
same ODNs conjugated to chromone or coumarin did change the polymerization rate: 
either inhibition or slight activation followed by inhibition depending on the 
concentration. When ‘‘chain terminator’’ 30ddT was added, the ligand-ODN complex 
was easily converted to a strong inhibitor (Figure 21).51 
O O
C2H5
O(CH2)3NH ODN
OO O(CH2)nNH ODN
n=5 or 3
Figure 21  
 
2.3.6 Coumarins as photodynamic therapeutics (PDT) agents 
 Furancoumarins, such as the psoralene and angelicin, are common constituents of 
many members of the Rutaceae and Apriaceae plant families. They are commonly UV 
phototoxic toward cells, bacteria, fungi, and viruses. Photomodified viral genomes can 
not be transcribed into RNA/DNA,52 thus, the furanocoumarins inhibit viral replication. 
Coriandrin, a furanoisocoumarin from coriander, is much more photoreactive than 
psoralen but does not cross-link with DNA nor photosensitize human skin.53 (a)  
Most of the dialkylaminoalkyl coumarin-4-acetates showed a local anesthetic 
activity53 (b) by infiltration approaching that of procaine. In contrast to procaine, they were 
also found to be topically active. For example, 3-(2-methylpiperidyl-1)-propyl 7-
methylcoumarin-4-acetate hydrochloride was equal in activity to procaine by infiltration 
(external canthus of the rabbit's eye) and about one-half as active as cocaine topically. Its 
toxicity was about onehalf that of cocaine. In general, the coumarin-4-acetic acid 
derivatives were much less toxic than the corresponding coumarin-3-carboxylic acid 
derivatives.  
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2.4 Aim of current work 
The Mannich reaction is a fundamentally important carbon–carbon bond forming 
reaction in organic synthesis, and it has been widely utilized in the syntheses of nitrogen-
containing drugs, natural products and biologically active compounds.54 
 Following our interest in benzopyrans, 55-57 this chapter devoted to exploring the 
activity of some Mannich bases of 7-hydroxy-4-isopropyl-2H-chromen-2-one and their 
simple derivatives in position 8 as secondary amine against Flaviviridae. It is well known 
that natural and synthetic coumarins have multiple biological activities.58 
O O
R
HO
Figure 22 R= Secondary amine
 
Mannich bases can be synthesized by Mannich reaction on nitrogen of secondary 
amine having hydrogen atom with pronounced activity using simplified methodology and 
easy work up and this inspired us to develop some new 7-hydroxy-4-isopropyl-2H-
chromen-2-one derivatives by Mannich reaction (Figure 22). Literature also revealed that 
secondary amines viz. morpholine, piperidine, pyrrolidine, piperazine derivatives.  
 
2.5 Chemistry 
The requisite 7-hydroxy-4-isopropyl-2H-chromen-2-one were prepared by 
Pechmann condensation of polyphenols and methylisobutyralacetate in the presence of 
trifluoroacetic acid (TFA).59-63 (Scheme 1).  The Mannich bases 4a-i were synthesized 
from 7-hydroxy-4-isopropyl-2H-chromen-2-one (3) with 40% form aldehyde and suitable 
secondary amines in absolute dioxane. The final products (5a-i) were treated with dry 
HCl to prepare their corresponding hydrochloride salts. 
To find better reaction conditions, next we investigated the application of 
etidronic acid in a one-pot multicomponent reaction sequence for preparation of Mannich 
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base. We found that the Mannich base can be prepared in excellent yield by microwave-
assisted etidronic acid catalyzed reaction of various secondary amines with formaldehyde 
and 7-hydroxy-4-isopropyl-2H-chromen-2-one. The results are reported herein. 
 
2.6 Results and discussion 
Etidronic acid [(1-hydroxyethylidene) bisphosphonic acid] (Figure 23) is one of 
the bisphosphonic acid derivative and also known as bisphosphonate having molecular 
formula C2H8O7P2. The two PO3 (phosphonate) groups covalently linked to carbon atom. 
PO
OH
OH
P
OH
O
OHCH3
OH
Figure 23
 
It is differ from polyphosphate ester and polyphosphoric acid. Various 
bisphosphonic acids are known.64-65 Etidronic acid is mild enough as compare to another 
strong acid such as polyphosphoric acid etc. moreover, the catalyst did not affect acid 
sensitive aldehydes.  
We first performed classical method in the reaction using 7-hydroxy-4-isopropyl- 
2H-chromen-2-one as a starting material for a three-component reaction. 7-hydroxy-4-
isopropyl- 2H-chromen-2-one was first reacted with formaldehyde in dioxane at reflux 
temperature followed by reaction with appropriate secondary amine to gave yielded 
compounds 4a–i in moderate yields (Table 1). 
 
Table 1: One-pot three-component synthesis of Mannich base derivatives of 7-
hydroxy-4-isopropyl-2H-chromen-2-one by conventional method 
Entry R Time / hr Yield % 
4a Morpholine 3.5 48 
4b Piperidine 3.5 49 
4c 4-methylpiperazin 3.0 52 
4d Piperazin 3.2 55 
4e 4-methylpiperidin 4.5 60 
4f 3-methylpiperidin 4.5 51 
4g Pyrrolidine 5.5 49 
4h Dimethylamine 3.5 53 
4i Diethylamine 3.5 51 
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Our recent interest has been in the development of new synthetic methods on 
using etidronic acid catalyst under microwave irradiation. In a typical reaction, the 7-
hydroxy-4-isopropyl-2H-chromen-2-one, formaldehyde, appropriate secondary amine and 
etidronic acid catalyzed was irradiated under microwave oven for a specified time period 
(Table 2). After completion of the reaction, extraction with organic solvent followed by 
aqueous work-up afforded pure Mannich base in 80-90 % yield. The etidronic acid is 
water-soluble and therefore goes into the aqueous layer. 
  
Table 2.  Etidronic acid catalyzed one-pot three-component synthesis of Mannich 
base derivatives of 7-hydroxy-4-isopropyl-2H-chromen-2-one by 
microwave irradiation method 
Entry R Time / min Yield % 
4a Morpholine 14 93 
4b Piperidine 15 91 
4c 4-methylpiperazin 10 94 
4d Piperazin 13 90 
4e 4-methylpiperidin 11 95 
4f 3-methylpiperidin 13 91 
4g Pyrrolidine 15 90 
4h Dimethylamine 12 91 
4i Diethylamine 14 90 
 
Results are summarized in Table 1 and Table 2. In all of the studied examples, 
the reaction proceeded smoothly; formaldehyde having either electron-withdrawing or 
electron-releasing substituents, including 7-hydroxy-4-isopropyl-2H-chromen-2-one, 
reacted efficiently to give very good to excellent yields of the desired Mannich base. As 
an example, the reaction between 7-hydroxy-4-isopropyl-2H-chromen-2-one, 
formaldehyde, and morpholine in the presence of etidronic acid gave the corresponding 
Mannich base 4a in 93% yield (Table 2, entry 1), also 4a gives extremely poor yields in 
the classical method, yielded 48% (Table 1, entry 1) 
 
According to the literature, the position ortho to the hydroxyl is most preferred for 
attack in a Mannich reaction for all phenolic derivatives. This is explained by the reaction 
mechanism, according to which a H-bond is formed first between the Mannich reagent 
and the substrate. This is followed by attack at the ortho position.66 The C-
aminomethylation reaction was performed by boiling 7-hydroxy-4-isopropyl-2H-
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chromen-2-one with substituted amine in absolute dioxane. The amino methyl group 
occupies the 8-position of the coumarin system.67  
 
The formation of Mannich bases (4a–i) was confirmed by recording 1H NMR, 13C 
NMR, and mass spectra. The IR spectrum of 4a–i displayed bands at 3686–3676 and 
1722–1708 cm–1 due to -OH and –C=O stretching frequencies, respectively. On the other 
hand, the absorption bands were observed in the region 1599– 1660 cm−1 for (C-N). The 
aromatic stretching bending vibrations were observed as a sharp medium to strong band 
at 3072-3070 cm−1 in compounds (4a–i). The PMR spectra of compounds (4a-i) also 
contain signals for a methylene at 4.1-4.2 ppm and signals characteristic peak for amine 
substituents. The hydroxyl protons of 7-OH resonate at weak field (9.97 ppm) because 
they are involved in an intramolecular H-bond with the N of the secondary amine group. 
The 13C NMR of compound 4a displayed peaks at 21.64 (2 × iPrCH3), 27.91 (iPrCH), 
57.14-51.55 (morpholine 8CH), 106.15 (pyron C-3), 112.69 (coumarin C-6), 124.65 
(coumarin C-5), and 162.95 (C=O), which account for all the carbon atoms in the 
molecule.  The PMR spectra of (5a-i) lack signals at 6.12 ppm for H-3 of the pyron 
system. Protons in the 5- and 6-positions resonate as doublets with 8 to 9 Hz at 7.6 and 
7.07 ppm, respectively (5a-i). The spectra of compounds (5a-i) also contain signals for a 
methylene at 4.40 ppm and signals characteristic for secondary amine substituents. The 
hydroxyl protons of 7-OH resonate at weak field (11.38 ppm) because they are involved 
in an intramolecular H-bond with the N of the secondary amine group. Structure 4a was 
supported by its mass (m/z 303), which agrees with its molecular formula C17H21NO4. 
Other prominent peaks appeared at m/z 286, 272, 256, 216, 188, 173 and 86. 
 
2.7 Conclusion  
 In conclusion, a convenient synthesis of Mannich base has been achieved through 
a one-pot multicomponent reaction involving a etidronic acid-catalyzed Mannich reaction 
of 7-hydroxy-4-isopropyl-2H-chromen-2-one, with moderate to good yield. We have 
reported a new simple, economical and environmental friendly multicomponent approach 
for the one-pot synthesis of heteroatom compounds with microwave irradiation. 
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2.8 Reaction scheme of 7-hydroxy-4-isopropyl-2H-chromen-2-one and (4a-i & 5a-i) 
O OHO
HNR , HCHO
O OHO
3 4a-i
OHHO
Trifloroacetic acid  
     0-5 oC , 24 hr
OHO OO
O
OScheme 1
0-5 oC
HCl gas
O OHO
5a-i
R= Aliphatic, Aromatic,
      Cyclic secondary amine
Scheme 2
Dioxane, Reflux for 3-5 hr
1 2 3
N
R
+N
R HCl--
Classical Method
O OHO
HNR , HCHO
O OHO
3 4a-i
MW, Dioxane, Etidronic acid
N
R
Catalytical MethodScheme 3
 
2.9 Experimental Procedure 
Melting points were determined on an electro thermal apparatus using open 
capillaries and are uncorrected. Thin-layer chromatography was accomplished on 0.2-mm 
precoated plates of silica gel G60 F254 (Merck). Visualization was made with UV light 
(254 and 365nm) or with an iodine vapor. IR spectra were recorded on a FTIR-8400 
spectrophotometer using DRS prob. 1H NMR spectra were recorded on a Bruker 
AVANCE II (400 MHz) spectrometer in DMSO. Chemical shifts are expressed in δ ppm 
downfield from TMS as an internal standard. Mass spectra were determined using direct 
inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were 
evaporated with a BUCHI rotary evaporator.  
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2.9.1 General synthesis of 7-hydroxy-4-isopropyl-2H-chromen-2-one 
 (See reference no. 59 to 63) 
 
2.9.2 General procedure for conventional synthesis of Mannich bases 4a-i 
  A solution or suspension of 7-hydroxy-4-isopropyl-2H-chromen-2-one (20 mmol) 
in absolute dioxane (20-25 ml) was treated with the appropriate amine (20 mmol) and 2.0 
ml of 40% formaldehyde were added. The resulting mixture was refluxed for 4–6 h. 
(completion of the reaction was determined by TLC). The solvent was removed under 
vaccuo when the reaction was completed. The solid or oil was crystallized from hexane-
diethyl ether (1:1) to give pure product. 
 
2.9.3 General procedure for microwave-assisted synthesis of Mannich 
bases 4a-i 
 A well stirred mixture of 7-hydroxy-4-isopropyl-2H-chromen-2-one (20 mmol) in 
absolute dioxane (20-25 ml), appropriate amine (20 mmol), 2.0 ml of 40% formaldehyde 
and etidronic acid (20 mg/20 mmol) was irradiated under microwave oven for 5 to 10 min 
at 300W. The reaction was monitored by TLC. After completion of reaction, the reaction 
mixture was taken up in chloroform and extracted with water. The organic layer was 
washed with 5% aq. hydrochloric acid (100 mL), followed by water (200 mL), and brine 
(100 mL). And dried over anhy.sodium sulphate. The solvent was removed under reduced 
pressure and the residue was purified by column chromatography (SiO2) using hexane–
ethyl acetate (8:2) as an eluent. The fraction containing the main products were combined 
and evaporated to dryness under reduce pressure. The crude product thus obtained was 
crystallized from hexane—diethyl ether (1:1) to afford the targeted Mannich base 
derivatives. 
 
 
2.9.4 General procedure for synthesis of Mannich bases hydrochloride salt 
5a-i 
As above prepare Mannich base 4a-i was dissolved in ethyl acetate (20 ml) and 
treated with 2.5M HCl in EA (7 ml) at 0 oC. The solid separated was filtered to give 5a-i 
 Similarly, other Mannich bases were prepared. 
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2.10 Spectral data of synthesized compounds (3, 4a-i and 5a-i) 
 
7-hydroxy-4-isopropyl-2H-chromen-2-one (3). Off-white solid, yield 90%, mp 118–
120°C; Anal. Calcd for C12H12O3: C, 70.57; H, 5.92; Found: C, 70.53; H, 5.90. m/z: 
204[M+]; 1H NMR (400 MHz, CDCl3): δ ppm 1.29-1.31 (d, J=6.76 Hz, 6H, 2CH3), 3.22–
3.27 (m, 1H, CH), 6.07 (s, 1H, H-3), 6.79–6..83 (m, 2H, CH), 7.51–7.53 (t, J=6.04 & 2.56 
Hz, 1H, CH), 9.97 (s, 1H, OH); IR (KBr), ν(cm-1): 3686, 2823, 1722, 1600, 1498, 1388.  
 
7-hydroxy-4-isopropyl-8-(morpholinomethyl)-2H-chromen-2-one (4a).  white solid, 
yield 88%, mp 208–210°C; Anal. Calcd for C17H21NO4: C, 67.31; H, 6.98; N, 4.62; 
Found: C, 67.30; H, 6.95; N, 4.58; m/z:303[M+]; 1H NMR (400 MHz, DMSO): δ ppm 
1.22-1.24 (d, J=6.8 Hz, 6H, 2CH3), 2.59 (s, 4H, morpholine-CH2 bridge), 3.14-3.21 (m, 
1H, CH), 3.66-3.71 (s, 4H, morpholine-CH2 bridge), 4.0 (s, 1H, CH2), 6.06 (s, 1H, H-3), 
6.70-6.72(d, J=8.84 Hz , 1H, H-6), 7.42-7.44(d, J=8.88 Hz , 1H, H-5);  IR (KBr), ν(cm-1): 
3688, 2823, 1722, 1610, 1496, 1385; 13C NMR (400 MHz, DMSO): 21.64, 27.91, 51.57, 
52.62, 57.14, 66.02, 79.16, 95.41, 106.15, 108.70, 110.42, 112.69, 152.99,160.86, 162.95   
 
7-hydroxy-4-isopropyl-8-((piperidin-1-yl)methyl)-2H-chromen-2-one (4b).  off-white 
solid, yield 85%, mp 215–218°C; Anal. Calcd for C18H23NO3: C, 71.73; H, 7.69; N, 4.65; 
Found: C, 71.70; H, 7.65; N, 4.62; m/z:301[M+]; 1H NMR (400 MHz, CDCl3): δ ppm 
1.22-1.24 (d, J=6.8 Hz, 6H, 2CH3), 1.96-1.37 (m, 6H, piperidine CH2), 2.85-2.27 (m, 4H, 
piperidine CH2), 3.13-3.20 (m, 1H, CH), 4.05 (s, 2H, CH2 bridge), 6.09 (s, 1H, H-3), 
6.68-6.70 (d, J=9.08 Hz 1H, H-6), 7.46 (d, 1H, H-5), 12.39 (s, 1H, OH); IR (KBr), ν(cm-
1): 3680, 2828, 1720, 1620, 1498, 1380.  
 
7-hydroxy-4-isopropyl-8-((4-methylpiperazin-1-yl)methyl)-2H-chromen-2-one (4c).  
off-white solid, yield 89%, mp 235–238°C; Anal. Calcd for C18H24N2O3: C, 68.33; H, 
7.65; N, 8.85; Found: C, 68.30; H, 7.68; N, 8.80; m/z:316[M+]; 1H NMR (400 MHz, 
CDCl3): δ ppm 1.18-1.22 (d, 6H, 2CH3), 3.11-3.20 (m, 1H, CH),  3.25 (s, 3H, –N–CH3), 
4.00–4.37 (m, 8H, –N–CH2), 4.99 (s, 2H, CH2 bridge), 6.68 (s, 1H, H-3), 7.30 (d, J = 9 
Hz 1H, H-6), 8.02 (d, J = 9 Hz, 1H, H-5); IR (KBr), ν(cm-1): 3686, 2958, 2823, 1722, 
1600, 1498, 1388.   
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7-hydroxy-4-isopropyl-8-((piperazin-1-yl)methyl)-2H-chromen-2-one (4d). white 
solid, yield 90%, mp 205–208°C; Anal. Calcd for C17H22N2O3: C, 67.53; H, 7.33; N, 9.26; 
Found: C, 67.46; H, 7.38; N, 9.20; m/z:302[M+]; 1H NMR (400 MHz, CDCl3): δ ppm 
1.22-1.23 (d, 6H, 2CH3), 2.69 (m, 1H, CH), 2.89-3.18 (m, 8H, –N–(CH2)4 ), 4.03 (s, 2H, 
CH2), 6.06-6.05 (d, J=5.2 Hz 1H, H-3), 6.68-6.70 (d, J=8.8 Hz 1H, H-6), 7.40-7.42 (d, 
J=9.2 Hz 1H, H-5), 12.39 (s, 1H, brs,exchangeable NH);  IR (KBr), ν(cm-1): 3690, 2825, 
1730, 1620, 1490, 1395.  
 
7-hydroxy-4-isopropyl-8-((4-methylpiperidin-1-yl)methyl)-2H-chromen-2-one (4e).  
White solid, yield 87%, mp 245–248°C; Anal. Calcd for C19H25NO3: C, 72.35; H, 7.99; N, 
4.44;  Found: C, 72.30;  H, 7.98; N, 4.40; m/z:315 [M+]; IR (KBr), ν(cm-1): 3692, 2968, 
2833, 1723, 1610, 1492, 1395.   
 
7-hydroxy-4-isopropyl-8-((3-methylpiperidin-1-yl)methyl)-2H-chromen-2-one  (4f).  
White solid, yield 84%, mp 231–232°C; Anal. Calcd for C19H25NO3: C, 72.35; H, 7.99; N, 
4.44; Found: C, 72.30; H, 7.99; N, 4.41; m/z:315 [M+]; IR (KBr), ν(cm-1): 3691, 2966, 
2830, 1720, 1615, 1496, 1399.   
 
7-hydroxy-4-isopropyl-8-((pyrrolidin-1-yl)methyl)-2H-chromen-2-one  (4g).  off-
white solid, yield 80%, mp 160-162°C; Anal. Calcd for C17H21NO3: C, 71.06; H, 7.37; N, 
4.87;  Found: C, 71.00; H, 7.37; N, 4.40. m/z:287 [M+]; IR (KBr), ν(cm-1): 3670, 2980, 
2850, 1730, 1625, 1476, 1369.   
 
8-((dimethylamino)methyl)-7-hydroxy-4-isopropyl-2H-chromen-2-one (4h). off-white 
solid, yield 74%, mp 192-195°C; Anal. Calcd for C15H19NO3: C, 68.94; H, 7.33; N, 5.36; 
Found: C, 68.90; H, 7.33; N, 5.30; m/z:261 [M+]; IR (KBr), ν(cm-1): 3680, 2978, 2866, 
1745, 1655, 1486, 1379.   
 
8-((diethylamino)methyl)-7-hydroxy-4-isopropyl-2H-chromen-2-one (4i). off-white 
solid, yield 70%, mp 172-175°C; Anal. Calcd for C17H21NO3: C, 71.06; H, 7.37; N, 4.87;  
Found: C, 71.00; H, 7.37; N, 4.40; m/z:287 [M+]; IR (KBr), ν(cm-1): 3690, 2970, 2860, 
1740, 1635, 1496, 1389.   
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7-hydroxy-4-isopropyl-8-(morpholinomethyl)-2H-chromen-2-onehydrochloride (5a). 
white solid, yield 95%;  Anal. Calcd for C17H22ClNO4: C, 60.09; H, 6.53; N, 4.12; Found: 
C, 60.00; H, 6.50; N, 4.10; 1H NMR (400 MHz, CDCl3): δ ppm 1.31-1.32 (d, J=6.8 Hz, 
6H, 2CH3), 3.22-3.31 (m, 5H, 1H & morpholine 4H), 3.98 (s, 4H, morpholine-CH2 
bridge),  4.40 (s, 2H, CH2), 6.12 (s, 1H, H-3), 7.05-7.07(d, J=8.84 Hz , 1H, H-6), 7.59-
7.64(d, J=8.88 Hz , 1H, H-5), 11.38 (s, 1H, brs,exchangeable, OH); IR (KBr), ν(cm-1): 
3688, 2823, 1722, 1610, 1496, 1385.  
 
7-hydroxy-4-isopropyl-8-((piperidin-1-yl)methyl)-2H-chromen-2-one-hydrochloride 
(5b). Off-white solid, yield 92%; Anal. Calcd for C18H24ClNO3: C, 63.99; H, 7.16; N, 
4.15; Found: C, 63.90; H, 7.13; N, 4.10;  1H NMR (400 MHz, CDCl3): δ ppm 1.32-1.34 
(d, J=6.8 Hz, 6H, 2CH3), 1.90-1.35 (m, 6H, piperidine CH2), 2.85-2.30 (m, 4H, 
piperidine CH2), 3.14-3.20 (m, 1H, CH), 4.90 (s, 2H, CH2 bridge), 6.15 (s, 1H, H-3), 
7.06-7.08 (d, J=9.08 Hz 1H, H-6), 7.66 (d, 1H, H-5), 12.39 (s, 1H, brs, exchangeable, 
OH); IR (KBr), ν(cm-1): 3680, 2828, 1720, 1620, 1498, 1380.  
 
7-hydroxy-4-isopropyl-8-((4-methylpiperazin-1-yl)methyl)-2H-chromen-2-one 
hydrochloride (5c).  white solid, yield 90%; Anal. Calcd for C18H24ClNO3: C, 61.27; H, 
7.14; N, 7.94; Found: C, 61.15; H, 7.02; N, 7.10; IR (KBr), ν(cm-1): 3686, 2958, 2823, 
1722, 1600, 1498, 1388.   
 
7-hydroxy-4-isopropyl-8-((piperazin-1-yl)methyl)-2H-chromen-2-one hydrochloride 
(5d). off-white solid, yield 92%; Anal. Calcd for C17H22ClN2O3: C, 60.44; H, 6.56; N, 
8.29; Found: C, 60.40; H, 7.48; N, 8.20; 1H NMR (400 MHz, CDCl3): δ ppm 1.18-1.23 
(d, 6H, 2CH3), 2.69 (m, 1H, CH), 2.89-3.20 (m, 8H, –N–(CH2)4 ), 4.88 (s, 2H, CH2), 6.82 
(d 1H, H-3), 7.68-7.70 (d, J=8.8 Hz 1H, H-6), 8.40-8.42 (d, J=9.2 Hz 1H, H-5); IR (KBr), 
ν(cm-1): 3690, 2825, 1730, 1620, 1490, 1395.  
 
7-hydroxy-4-isopropyl-8-((4-methylpiperidin-1-yl)methyl)-2H-chromen-2-one 
hydrochloride (5e).  Off-white solid, yield 95%; Anal. Calcd for C19H26ClNO3: C, 64.85; 
H, 7.45; N, 3.98;  Found: C, 64.75;  H, 7.35; N, 3.90; IR (KBr), ν(cm-1): 3692, 2968, 
2833, 1723, 1610, 1492, 1395.   
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7-hydroxy-4-isopropyl-8-((3-methylpiperidin-1-yl)methyl)-2H-chromen-2-one 
hydrochloride (5f).  white solid, yield 94%; Anal. Calcd for C19H26ClNO3: C, 64.85; H, 
7.45; N, 3.98;  Found: C, 64.75;  H, 7.35; N, 3.90; IR (KBr), ν(cm-1): 3691, 2966, 2830, 
1720, 1615, 1496, 1399.   
 
7-hydroxy-4-isopropyl-8-((pyrrolidin-1-yl)methyl)-2H-chromen-2-one hydrochloride  
(5g).  white solid, yield 92%; Anal. Calcd for C19H26ClNO3: C, 63.06; H, 6.85; N, 4.33;  
Found: C, 63.02;  H, 6.77; N, 4.24; IR (KBr), ν(cm-1): 3670, 2980, 2850, 1730, 1625, 
1476, 1369.  
 
8-((dimethylamino)methyl)-7-hydroxy-4-isopropyl-2H-chromen-2-onehydrochloride  
(5h). off-white solid, yield 94%; Anal. Calcd for C15H20ClNO3: C, 60.50; H, 6.77; N, 
4.70; Found: C, 60.40; H, 6.70; N, 7.60; IR (KBr), ν(cm-1): 3680, 2978, 2866, 1745, 1655, 
1486, 1379.   
 
8-((diethylamino)methyl)-7-hydroxy-4-isopropyl-2H-chromen-2-one hydrochloride 
(5i). off-white solid, yield 90%; Anal. Calcd for C17H24ClNO3: C, 62.67; H, 7.42; N, 4.30; 
Found: C, 62.60; H, 7.33; N, 4.24; IR (KBr), ν(cm-1): 3690, 2970, 2860, 1740, 1635, 
1496, 1389.   
2.11 Spectral representation of synthesized compounds 
2.11.1  1H NMR spectrums of 7-hydroxy-4-isopropyl-2H-chromen-2-one (3) 
 
OHO O
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2.11.2 1H NMR spectrums of 4a 
 
2.11.3 13C NMR spectrums of 4a 
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2.11.4 1H NMR spectrums of 5a 
 
2.11.5 Mass spectrums of 7-hydroxy-4-isopropyl-2H-chromen-2-one (3) 
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2.11.6 Mass spectrums of 4a 
 
2.11.7 Mass spectrums of 4c 
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2.11.8 IR spectrums of 4a 
 
2.11.9 IR spectrums of 4c 
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3.1 Introduction   
 
 Synthesis of pyrazole and its N-aryl analogues has been a subject of consistent 
interest because of the wide applications of such heterocycles in pharmaceutical as well 
as in agrochemical industry.1,2 Numerous compounds containing pyrazole moiety have 
been shown to exhibit antihyperglycemic, analgesic, anti-inflammatory, antipyretic, 
antibacterial, and sedative-hypnotic activity.2d-f The 1-phenylpyrazole motif is present in 
several drug candidates for treatment of various diseases such as cyclooxygenase-2 (Cox-
2) inhibitors, IL-1 synthesis inhibitors, and protein kinase inhibitors etc.3 Similarly a few 
of the 1,5-diarylpyrazole derivatives have been shown to exhibit non-nucleoside HIV-1 
reverse transcriptase inhibitory activities4 along with Cox-2 inhibitor.2g-h The 
corresponding 1,3,5-triaryl-4-alkylpyrazoles have been recently identified as efficient 
ligands for estrogen receptor, displaying high binding affinities and selective 
transcriptional efficacy for ERR subtype.5 Therefore continuous efforts have been 
devoted to the development of more general, efficient, and regioselective methods for the 
synthesis of this class of compounds. 
 Pyrazoles are well known five member heterocyclic compounds and several 
procedures for its synthesis have been extensively studied (Figure 1). Such studies have 
been stimulated by various promising applications, especially in the case of N-substituted 
pyrazole derivatives. In fact, certain N-substituted pyrazole are used as analgesic, anti-
inflammatory, antipyretic, agrochemicals whereas some others are being studied for their 
medicinal interest. The knowledge of such applications has pointed out that N-substituted 
pyrazole are important target to be prepared to our interest on synthesis and molecular 
structure determination of some types of pyrazole. The pyrazole ring system consists of a 
doubly unsaturated five member ring containing two adjacent nitrogen atoms. 
N
H
N
Figure 1  
The discovery of pyrazole derivatives as antipyretic agents dates back to 1884, when the 
German chemist Ludwig Knorr6 attempted to synthesize quinoline derivatives with 
antipyretic activity and accidentally obtained antipyrine (2,3-dimethyl-1-phenyl-3-
pyrazolin-5-one), which has analgesic, antipyretic and antirheumatic activity. 
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Aminopyrine, a more potent analogue was synthesized there after and these drugs were 
widely used in market as antipyretics. 
 
3.2 Synthetic methods for pyrazole 
Different methods are reported in literature for the preparation of pyrazole some 
are as under. 
1. S. Peruncheralathan et al.7 have synthesized highly efficient and regioselective 
synthesis of 1-aryl-3,4-substituted/annulated-5-(methylthio)-pyrazoles and 1-aryl-3-
(methylthio)-4,5-substituted/annulated pyrazoles has been reported via cyclocondensation 
of arylhydrazines with either α-oxoketene dithioacetals or α-oxodithioesters.(Figure 2) 
R1 O
R2
SMe
SMe
N
N
R1 R2
SMe
Ar
a
N
N
MeS R2
R1
Ar
b
SMe
S
R2
O R1
a, ArNHNH2 / t-BuOK/t-BuOH/ Δ ; b, ArNHNH2/EtOH / Δ
Figure 2  
 
2. Xuemei Wang et al.8 have synthesized the pyrazole analogs (Figure 3) were 
prepared from a common aryl isocyanides intermediate. Cyclization with the oxime or the 
BOC-protected hydrazones of ethyl bromopyruvate generated the pyrazole carboxy 
esters, respectively. 
C
N
H
Br
CO2Et
NH
a = Na2CO3, CH2Cl2, rt, 24 h,
b = TFA, 1 h,
HN N
HN
CO2Et
Figure 3  
 
3. Pranab K. Mahata et al9 have been synthesized 3-(dimethoxymethyl)-5-
(methylthio) pyrazole derivative (Figure 4) shown to be useful three carbon synthon for 
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efficient regiospecfic synthesis of a varity of five (pyrazole) with mask or unmask 
aldehyde functionality by cyclocondensation with bifunctional heteronucleophiles such as  
hydrazine. 
OMe
MeO
HC
O
SMe
SMe
N2H4•H2O / EtOH
Δ  / 2 h N
N
H
SMe
OMe
MeO
Figure 4  
 
4. Lidia De Luca et al.10 has been developed the synthesis of libraries of substituted 
pyrazole via in situ generation of polymer-bound enaminones (Figure 5). The synthetic 
protocol makes use of commercially available aniline cellulose, a low-cost and versatile 
biopolymer, under very mild conditions. This new support allowed us to carry out 
reactions in polar solvents under both conventional heating and MW irradiation without 
degradation of the polymer. The reaction between cellulose-bound enaminones and 
hydroxylamine or hydrazine to afford the target heterocycles in high yields directly in 
solution is the key step. The support can be conveniently recycled. 
R
O
H
N
N
O
Et
Et
NH2NHPh
NH2
N
N
H
N
O
Et
Et
iPrOH, 1 h, reflux
R
R= Me, iPr, PhCH2Figure 5  
 
5. Sabine Kuettel et al.11 have been synthesized 4-(3-phenylisoxazol-5-
yl)morpholine derrivatives (Figure 6) prepared by two synthetic routes, in which 
substituted acetophenones were reacted with carbon disulfide and methyl iodide in the 
presence of sodium hydride to give 4-phenoxyphenyl-2,2- bis(methylthio)vinyl ketones, 
followed by in situ cyclization of the resulting N,S-acetals with hydrazine hydrate. 
 
   82
Ph
OS
S XHN X=O
X= N-Boc
Ph
H
N
N
N X
Figure 6
N2H4•H2O
 
 
6. Scott R. Tweedie et al.12 synthesized a palladium-catalyzed couplings of 
heteroaryl amines with aryl halides using sodium phenolate as the stoichiometric base 
(Figure 7). 
N
N
NH2
CN
Br
CN
N
H
N
N
Pd2(dba)3, ligand
 
base, MW, Δ , 2 h
Figure 7  
 
7. HooSook Kim et al13 have reported on the regio-selective synthesis of 1,3,4,5-
tetrasubstituted pyrazole derivatives from the reaction of Baylis-Hillman adducts of alkyl 
vinyl ketone and hydrazine derivatives (Figure 8). During the continuous studies on the 
chemical transformations of Baylis-Hillman adducts including the synthesis of pyrazole. 
OPh
O COOMe
PhNHNH2•HCl
ClCH2CH2Cl
 reflux, 48 h
NN
Ph
Ph
COOMe
Figure 8  
 
8. Kewei Wang et al.14 synthesized of efficient and divergent one-pot synthesis of 
fully substituted 1H-pyrazoles (Figure 9) from cyclopropyl oximes based on reaction 
conditions selection is reported. Under Vilsmeier conditions (POCl3/DMF), substituted 
1H-pyrazoles were synthesized from 1-carbamoyl, 1-oximyl cyclopropanes via sequential 
ring-opening, chlorovinylation, and intramolecular aza-cyclization.  
   83
R NHAr
ON
HO
POCl3 /DMF
rt
N N
Cl
CH2CH2Cl
R
R = Me, PhFigure 9
Ar
 
 
9. Galal H. Elgemeie et al15 have reported novel ketene N,S-acetals  were readily 
prepared by the reaction of cyanoacetamide or cyanothioacetamide with 
phenylisothiocyanate in the presence of potassium hydroxide, followed by alkylation of 
the produced salts with methyl iodide. The reaction of ketene N,S-acetals with hydrazine 
afforded different substituted pyrazole (Figure 10). 
H2N
X
CN
H
N
SCH3
PH2
NH2-NHR
EtOH / Δ N
N
R
HN
Ph
H2N
X
H2N
R= Me, Ph
X= O, S
Figure 10
 
 
10. Wenli Ma et al.16 has been developed an efficient three-component, two-step 
“catch and release” solid-phase synthesis of 3,4,5-trisubstituted pyrazole (Figure 11). The 
first step involves a base-promoted condensation of a 2-sulfonyl or a 2-carbonyl-
acetonitrile derivative with an isothiocyanate and in situ immobilization of the resulting 
thiolate anion on Merrifield resin. Reaction of the resin-bound sulfonyl intermediate with 
hydrazine, followed by release from the resin and intramolecular cyclization, affords 3,5-
diamino-4-(arylsulfonyl)-1H-pyrazoles (Figure 11), respectively. Reaction of the resin-
bound carbonyl intermediate with hydrazine, on the other hand, leads to 3-(aryl amino)-5-
aryl-1H-pyrazole-4- carbonitriles. 
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S
OO
HN
R2
N
NH
NH2
R1= Ph, 4-ClPh
R2= Ph, 2-ClPh, 3-CNPh, 4-FPh
Figure 11
 
 
11.  Daniel G. Rivera et al17 have been synthesized steroidal heterocycles containing 
the pyrazole ring fused to the 16,17-position of the steroid nucleus is reported. 
Androstenolone acetate reacted with carbon disulfide, iodomethane and sodium hydride 
to furnish 3β-acetoxy-16-[bis(methylthio)methylene]-5-androst-5-en-17-one. The 
reactions of 3β-acetoxy-16-[bis(methylthio)methylene]-5-androst-5-en-17-one with 
hydrazine hydrate afforded the 5-methylthio-pyrazole[4, 3 :16, 17]androst-5-en-3β-ols  
respectively (Figure 12). 
O
SMe
SMe
OAc
NH2NH2
MeOH, reflux, 5h
NH
N
SMe
HO
Figure 12
 
 
12. Geoffroy L. Sommen et al18 synthesized variously substituted pyrroles in two 
steps by reacting a primary or secondary amine and a ketene dithioacetals in a basic 
medium in moderate to good yield. Ketene dithioacetals are readily prepared from 
acetylaceton or malononitrile, carbon disulfide, and methyl iodide (Figure 13). 
Me
O
MeS SMe
Me
O
HN
R2
R1
K2CO3 / DMF
RT / 4 h
N
MeAc
MeS R2
R1
R1= H, Me
R2= COOH, CO2Et
Figure 13
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13. Thomas Kurz et al19 synthesized novel fluorinated ketene N,S-acetals  were 
readily prepared by the reaction of fluorosubstituted cyanoacetamide derivatives with 
arylisothiocyanate in the presence of potassium hydroxide, followed by the alkylation of 
the produced salts with methyl iodide. The reaction of fluorinated ketene N,S-acetals with 
hydrazine afforded different fluorosubstituted pyrazole (Figure 14). 
N
H
O
NH
N
HN
H2N
NH2NH2
EtOH / Δ
H
N NH
SCH3O
CN
F
F
X
X
X= H, 2-F, 4-F, 4-Cl
Figure 14
 
 
14. Galal H. Elgemeie et al20 synthesized  variety of novel α-cyanoketene S,S-acetals, 
readily prepared by the reaction of cyanoacetanilides or cyanothioacetamide with carbon 
disulfide, followed by alkylation, react smoothly with nucleophile to afford variously 
substituted methylthio derivatives of pyrazole (Figure 15). 
CN
MeS
SMe
S NH2
RNHNH2, 
EtOH, PiP, heat
N
N
SMe
O
H2N
H2N
RR= H, Ph
Figure 15  
 
15. Maria T. Di Parsia et al.21 synthesized several monopyrazole series which was 
prepared by the ketones were treated with ethyl format in dry pyridine or benzene 
utilizing sodium methoxide as catalyst, to afford the corresponding hydroxymethylene 
ketones. These intermediates without further purification were treated with hydrazine 
hydrate in refluxing methanol or ethanol to afford the final monopyrazole (Figure 16).  
OH
O NH2NH2
N
H
N
H3COH3CO Figure 16  
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3.3 Mechanism 
 In ketene dithioacetals systems the carbonyl carbon and β-carbon atoms can also 
be regarded as hard and soft electrophilic centers, since the carbonyl is adjacent to the 
hard-base oxygen while the β-carbon is flanked by the soft-base thiomethyl groups22 
(Figure 17). Thus, the nucleophile of hydrazine hydrate attack on β-carbon of systems 
and formed heterocyclic product by removal of thiomethyl group as good leaving group.   
PhHN
O
SMeMeS
NH2NH2
PhHN
O−
SMeMeS
N+
H
H
NH2
PhHN
O
SMeMeS
N
H
NH2H
N
H
O+
SMeMeS
−N
H
H NH2
−H2O
PhHN
N
NH2
SMe
MeS
+N
N
SMe
PhHN H
-MeSH
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NH
N
S
PhHN
α
β
Soft electrophile
Hard electrophile
Figure 17
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3.4     Biological activity of 1H-pyrazole 
 As mentioned above, the 1H-pyrazole derivatives possessed diverse biological 
activities such as antihyperglycemic, analgesic, anti-inflammatory, antipyretic, 
antibacterial, and sedative-hypnotic activity, cyclooxygenase-2 (Cox-2) inhibitors, IL-1 
synthesis inhibitors, protein kinase inhibitors which are described briefly as follows. 
Similarly a few of the 1,5-diarylpyrazole derivatives have been shown to exhibit non-
nucleoside HIV-1 reverse transcriptase inhibitory activities4 along with Cox-2 inhibitor.2g-
h The corresponding 1,3,5-triaryl-4-alkylpyrazoles have been recently identified as 
efficient ligands for estrogen receptor, displaying high binding affinities and selective 
transcriptional efficacy for ERR subtype.5 
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3.4.1 Anti-inflammatory activity  
 Anti-inflammatory preparations are widely used in the modern clinic, as 
pathogenetic agents in the treatment of many illnesses and pathological processes, alone 
or more frequently in combination with other drugs. However many of the known anti-
inflammatory agents cause a range of side phenomena and complications in addition to 
the main effect. Consequently the search for and study of new more active anti-
inflammatory agents of low toxicity is one of the urgent problems of contemporary 
science (Figure 17).23 
CH2N2
N
N
H
RH2C CCCH2R
R= 4-chlorobenzoyloxy,
      3-iodobenzoyloxy
Figure 17
RH2CC CC CCH2R
 
Toxicity was studied in 150 white mice of both sexes of weigh t 18-23 g. 
preparations were administered at 1-10% in oil solutions subcutaneously. Preparations 
were tested in not less than six animals at each dose. The volume of introduced solution 
did not exceed 1 ml. The value of the mean lethal dose (LDso) was determined by the 
method of Litchfield and Wilcoxon at p = 0.05. It was established that the synthesized 
compounds were of low toxicity. Even at doses of 1500 mg/kg they did not cause death of 
animals. Experiments on the study of anti-inflammatory activity were carried out on 250 
white rats of both sexes of weight 120- 200 g. Inflammation was caused by formalin. 
Substances were administered subcutaneously as an oil solution 1 h before formalin. Tile 
activity of a preparation was compared with that of the widely known preparation 
amidopyrine. 
 
3.4.2 Cyclooxygenase-2 (COX-2) Inhibitors 
 Celecoxib and rofecoxib analogues (Figure 18), in which the respective SO2NH2 
and SO2Me hydrogen-bonding pharmacophores were replaced by dipolar azido 
bioisosteric substituents, were investigated. Molecular modeling (docking) studies 
showed that the azidosubstituent of these two analogues (Figure 18) was inserted deep 
into the secondary pocket of the human COX-2 binding site where it undergoes 
electrostatic interaction with Arg513. The azido analogue of rofecoxib (Figure 18), the 
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most potent and selective inhibitor of COX-2 (COX-1 IC50= 159.7 µM; COX-2 IC50= 
0.196 µM; COX-2 selectivity index = 812), exhibited good oral anti-inflammatory and 
analgesic activities.24 
N
N
CF3
Me
O
N3
O
Figure 18Celecoxib analogues Rofecoxib analogues  
 
3.4.3 Helicobacter pylori DHODase 
The identification of several potent pyrazole-based inhibitors of bacterial 
dihydroorotate dehydrogenase (DHODase) via a directed parallel synthetic approach is 
described below (Figure 19). The initial pyrazole-containing lead compounds were 
optimized for potency against Helicobacter pylori DHODase.25 Using three successive 
focused libraries, inhibitors were rapidly identified with the following characteristics: Ki 
<10 nM against H. pylori DHODase, sub-µg/mL H. pylori minimum inhibitory 
concentration activity, low molecular weight, and >10 000-fold selectivity over human 
DHODase.  
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 Helicobacter pylori is a Gram-negative microaerophilic bacterium that infects up 
to 50% of the world’s human population.26 H. pylori resides in the acidic surroundings of 
the stomach, utilizing a high urease enzyme activity to provide a locally alkaline 
environment. H. pylori has been implicated in numerous gastrointestinal disorders and is 
associated with gastric ulcers, gastritis, and gastric cancer.27 The current treatment of H. 
pylori infections typically utilizes a multiple drug therapy involving at least one broad 
spectrum antibiotic (antimicrobial therapy) and a proton pump inhibitor (antisecretory 
therapy). However, a H. pylori specific antimicrobial would be very desirable; a specific 
agent should avoid many of the negative gastrointestinal side effects associated with a 
broad spectrum antibacterial resulting from eradication of the normal gastrointestinal 
flora. 
A number of potent H. pylori DHODase inhibitors based upon a pyrazole core 
were identified. Directed parallel synthesis enabled the rapid optimization of lead 
compounds via three focused libraries. All of the libraries discussed above were 
developed, synthesized, and purified. The most potent DHODase inhibitors are very 
selective (>10000-fold) for H. pylori over human DHODase enzymes. The inhibitors 
display low µg/mL to sub-µg/mL antibacterial activity against H. pylori. However, no 
antibacterial activity is seen against a variety of other Gram-positive and Gram-negative 
organisms (Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, E. 
coli, Haemophilus influenzae, Moraxella catarrhalis, and Psuedomonas aeruginosa). 
 
3.4.4 Antibacterial activity 
 Akihiko Tanitame et al.28 have synthesized a pyrazole derivative (Figure 20) 
possesses antibacterial activity and inhibitory activity against DNA gyrase and 
topoisomerase IV. They have synthesized new pyrazole derivatives and found that 5-[(E)-
2-(5-chloroindol-3-yl)vinyl]pyrazole (Figure 21) possesses potent antibacterial activity 
and selective inhibitory activity against bacterial topoisomerases. Many of the 
synthesized pyrazole derivatives were potent against clinically isolated quinolone 
coumarin-resistant Gram-positive strains and had minimal inhibitory concentration values 
against these strains equivalent to those against susceptible strains. 
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Among them, the pyrazole derivative (Figure 21) was identified as an interesting 
lead candidate. Figure 21 showed the same minimal inhibitory concentration value (MIC) 
against clinically isolated multidrug resistant Gram-positive bacteria as against 
susceptible strains. However, the antibacterial activity of (Figure 21) was weak (MIC) 64 
µg/mL) because it only slightly inhibited DNA gyrase and topoisomerase IV (IC50) 128 
µg/mL). In this study was to optimize the lead compound (Figure 21) and to find new, 
potent DNA gyrase inhibitors with antibacterial activity against MRSA, PRSP, and VRE. 
They report herein the synthesis and structure-activity relationships of a series of pyrazole 
derivatives. In addition, pyrazole derivatives showed a more potent antibacterial activity 
against clinically isolated quinolone and coumarin-resistant Gram-positive bacteria than 
sparfloxacin and novobiocin, respectively. We are pursuing further modifications of this 
novel pyrazole scaffold that can potently inhibit DNA gyrase and topoisomerase IV. 
 
3.4.5 Antiproliferative activity 
 Chih Y. Ho et al29 have repoted a series of (6,7-dimethoxy-2,4-dihydroindeno[1,2-
c]pyrazol-3-yl)phenylamines (Figure 22) has been optimized to preserve both potent 
kinase inhibition activity against the angiogenesis target, the receptor tyrosine kinase of 
Platelet-Derived Growth Factor-BB (PDGF-BB), and to improve the broad tumor cell 
antiproliferative activity of these compounds. This series culminates in the discovery of 
(Figure 22) (JNJ-10198409), a compound with anti-PDGFR-α kinase activity (IC50 = 
0.0042 µM) and potent antiproliferative activity in six of eight human tumor cell lines 
(IC50 = 0.033 µM). 
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Chih Y. Ho has developed antiangiogenic compounds with an additional 
antiproliferative activity capable of inhibiting tumor progression by controlling both the 
vascularization and proliferation of the tumor mass. Tumors may be regarded as a two-
compartment system consisting of the vasculature supporting tumor growth composed of 
‘normal’ homogeneous vascular endothelial cells, smooth muscle cells, and pericytes that 
are surrounded by colonies of neoplastic cancer cells. To find molecules that would affect 
both the vascular and transformed compartments, we identified several compounds with 
the potential to inhibit the PDGFR-β kinase-mediated angiogenic effect and then assayed 
them for collateral antiproliferative activity against a panel of human tumor cell lines. 
 
3.4.6 Antiallergic activity 
 The synthesis and study of the oral antiallergic activity of a series of 
monopyrazole derivatives (Figure 23) considered as analogues of active bis pyrazole are 
described.30 None of the compounds showed significant inhibition of the rat passive 
cutaneous anaphylaxis (PCA), with the exception of the already known 5-aminoindazole 
(Figure 23).  
N
H
N
H3CO
Figure 23  
The biological assay was performed as reported previously for compound  (Figure 24).31 
All the compounds were given orally at a single dose of 200 mg/kg. Anti-PCA activity 
was measured 1 and 3 h after oral administration. When compared to the 77 and 55% 
inhibition produced by compound  (Figure 24), the monopyrazole synthesized showed no 
significant inhibition of the PCA reaction in rats either at 1 or 3 h after administration. 
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With the methoxy-substituted compounds, only the 6 and 8 isomers show some degree of 
activity against the PCA reaction 1 h after oral administration with inhibition values of 15 
and 32%, respectively. After 3 h, however, the activity of the 7-isomer begins to 
approximate that of the other isomers after 1 h (27%), but still the level of activity is 
rather low to allow any sort of correlation. Surprisingly, with the corresponding hydroxyl 
compounds the anti-PCA activity is even lower, and after 3 h one of the isomers (9) tends 
to become a weak potentiator of the PCA reaction. The rest of the compounds can 
likewise be regarded as inactive, with the exception of Figure 23 (54%, 3 h). Compound 
(Figure 23) shows the type of prolonged activity characteristic of Figure 24. It is 
interesting that it becomes a better inhibitor with time and thus represents a new “core” 
structure upon which one can design a potentially interesting structure-activity study. 
N
NH
N
HN
Figure 24  
 
 
3.4.7 Antimalarial activity 
 Pyrazole derivatives are known to possess various kinds of biological activity. For 
example, the pyrazole-[3,4-b]pyrimidine derivative, an isostere of caffeine, is 
indistinguishable from caffeine in its diuretic properties and is also a strong CNS32 
stimulant. 
 Robert G. Stein et al33 have combined the features of the pyrazole ring, a 
substituted quinoline, and an "antimalarial" side chain in one molecule for antimalarial 
testing. The key intermediate required was a 4-chloro-1H-pyrazolo [3,4-b]quinoline 
(Figure 25), in which the active C1 could be replaced with suitable amines expected to 
impart antimlalarial activity to the final products.  
N
N
N X
R
H3C
H3C
X= H, Cl,
R= Cl, OH,
Figure 25  
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3.5 Aim of current work 
 The pyrazole nucleus is present in a wide variety of biologically  interesting 
compounds, which exhibit antihyperglycemic, analgesic, anti-inflammatory, antipyretic, 
antibacterial, hypoglycemic, sedative-hypnotic activity.1-5 Thus, continuous efforts have 
been devoted to the development of more general and versatile synthetic methodologies 
to this class of compounds.1-5 
Ketene dithioacetals bearing the cyano, amide, thioamide, or alkoxycarbonyl 
group at the α-position are extremely interesting eletrophilic reagents for the introduction 
of three or two carbon units into the ring of heterocyclic compounds.34, 35   
N
NH
S CH3
HN
OR
Figure 26
R= aryl amine
 
We have recently developed different successful approaches for synthesis of new 
ketene S,S-acetals as starting from acetoacetanilides (2a-s). In an extension of this work, 
we are now reporting a synthesis of some novel ketene S,S-acetals and their use in the 
synthesis of functionalized pyrazole derivatives (4a-s) (Figure 26). 
 
3.6 Chemistry 
 α-Oxoketene dithioacetals (Figure 27, 28, 29) especially the dimethyl thioacetals  
have recently received considerable attention due to their synthetic importance for the 
construction of a variety of alicyclic, aromatic and heterocyclic compounds.36, 37 Ketene 
dithioacetals, in the presence of various regents, undergo different types of reactions to 
yield other heterocyclic compounds, e.g., pyrazole, thiophene, pyrimidines, pyridines, etc. 
Consequently we were interested in surveying the synthetic utility of ketene dithioacetals. 
   94
R1
R2 O
SMe
SMe
R1
R2 O
S
S
R1
R2 O
SBn
SBn
Ketene dithioacetals
Figure 27 Figure 28 Figure 29
 
 
The method for preparation of α-oxoketene dithioacetals is common, the 
combination of an active methylene/methyl substrate, CS2, RX, and a suitable base. 
Lawesson and Larsson,38-40 Junjappa and Ila41 have reported the synthesis of mixed 
dialkylketene dithioacetals from dithioesters which were prepared from ketone and 
dimethyl trithiocarbonate.42 
R
NHO
SMe O
MeS
R
NHO
HN N
MeS
Figure 30 Figure 31
R= aryl amine
 
In an extension to this work, we now report a novel synthesis of functionalized  3-
isopropyl-5-(methylthio)-N-aryl-1H-pyrazole-4-carboxamide derivatives by the reaction 
of ketene dithioacetals with acetoacetanilide derivatives. Thus, it has been found that 
reaction of substituted acetoacetanilide derivatives with carbon disulfide in the presence 
of potassium carbonate followed by the alkylation with methyl iodide gives the novel 
ketene dithioacetals (Figure 30), the structures of which have been established on the 
basis of their elemental analysis and spectral data. Ketene dithioacetals with hydrazine in 
refluxing isopropyl alcohols gave the pyrazole derivatives (Figure 31). 
 
3.7 Results and discussion 
 Various substituted 4-methyl-3-oxo-N-phenylpentanamide (2a-s) were prepared 
by reacting substituted amines and methyl-4-methyl-3-oxopentanoate in toluene with a 
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catalytic amount of NaOH or KOH (Scheme 1). The reaction mixture was reflux for 15-
20 h. Fifteen different acetoacetanilide were synthesized bearing various electron 
donating and electron withdrawing groups like 2,3-diCH3; 3,4-diCH3; 4-CH3; H; 2,5-
diCH3; 2,4-diCH3; 3-Cl-4-F; 4-F; 4-Cl; 2-Cl; 2-F; 4-OCH3; 2,5-diCl and 3-NO2 on the 
phenyl ring.  
Thus, it has been found that reaction of substituted acetoacetanilide (2a-s) 
derivatives (Scheme 1) with carbon disulfide in the presence of potassium carbonate 
followed by the alkylation with methyl iodide gives the novel ketene dithioacetals 3a-s, 
when 3a-s was reacted with hydrazine hydrate in refluxing isopropyl alcohol, the 
corresponding 3-isopropyl-5-(methylthio)-N-aryl-1H-pyrazole-4-carboxamide derivatives 
4a-s was obtained in 85 to 90% yield. 
The structures of 4a-s were established on the basis of their elemental analysis and 
spectral data (MS, IR, and 1H NMR). The analytical data for 3a revealed a molecular 
formula C16H21NO2S2 (m/z 323). The 1H NMR spectrum revealed a two singlet at δ = 
1.18-1.20 ppm assigned to isopropyl-CH3, a singlet at δ = 1.57 ppm assigned to the –CH3 
protons, a singlet at δ = 2.44 ppm assigned to (2 × SCH3), a multiplet at δ = 3.17-3.24 ppm 
assigned to the isopropyl-CH protons, a multiplet at δ = 6.99–7.54 ppm assigned to the 
aromatic protons, and one broad singlets at δ = 8.38 ppm assigned to -CONH groups. 
Reaction of compounds 3a-s with hydrazine in refluxing isopropyl alcohol gave the 
corresponding 3-isopropyl-5-(methylthio)-N-aryl-1H-pyrazole-4-carboxamide derivatives 
4a-s. The structures of 4q were established on the basis of their elemental analysis and 
spectral data (MS, IR, 1H NMR, and 13C NMR). Structure 4q was supported by its mass 
(m/z 327), which agrees with its molecular formula C14H15ClFN3OS; its 1H NMR 
spectrum had signals at δ= 1.29-1.31ppm (2 × CH3), δ= 2.53ppm (SCH3), a multiplet at δ 
= 3.84-3.87 ppm assigned to the isopropyl-CH protons, a signal at δ = 7.12–7.98 ppm (m, 
3H, Ar) related to the aromatic protons, 9.61 (br, s, -CONH) and 12.94 (br s,  pyrazole 
NH). 
 
3.8 Conclusion 
In summary, we have achieved a novel synthesis of interesting 4-methyl-3-oxo-N- 
phenylpentanamide (acetoacetanilide, 2a-s), ketene S,S-acetals and their conversions to 
several 3-isopropyl-5-(methylthio)-N-aryl-1H-pyrazole-4-carboxamide derivatives, 
compounds which have both chemical and biological potential. 
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3.9 Reaction scheme of 2-(bis (methylthio)methylene)-4-methyl-3-oxo-N- 
arylpentanamide (2a-s), dithioacetals(3a-s) and 3-isopropyl-5-(methylthio)-
N-aryl-1H-pyrazole-4-carboxamide derivatives (4a-s) 
NH2 MeO
O
NaOH / KOH
Toluene, reflux, 
 15-20 h
H
N
O OO
2a-s1a-s
R
R
1) K2CO3/DMF/RT
2) CS2
3) CH3INHO
O
R
NHO
OSMe
MeS
R
2a-s 3a-s
N2H4•H2O / iPrOH
NHO
HN N
MeS
R
4a-s
Scheme 1
Scheme 2
Δ / 3-5 h
R=H, CH3, OCH3, Cl, F, NO2
 
3.10 Experimental procedure 
Melting points were determined on an electro thermal apparatus using open 
capillaries and are uncorrected. Thin-layer chromatography was accomplished on 0.2-mm 
precoated plates of silica gel G60 F254 (Merck). Visualization was made with UV light 
(254 and 365nm) or with an iodine vapor. IR spectra were recorded on a FTIR-8400 
spectrophotometer using DRS prob. 1H NMR spectra were recorded on a Bruker 
AVANCE II (400 MHz) spectrometer in DMSO. Chemical shifts are expressed in δ ppm 
downfield from TMS as an internal standard. Mass spectra were determined using direct 
inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were 
evaporated with a BUCHI rotary evaporator.  
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3.10.1 General synthesis of 4-methyl-3-oxo-N-phenylpentanamide (2a-s) 
 A mixture containing the primary amine (10 mmol), methyl isobutyrylacetate (10 
mmol), and catalytic amount of sodium or potassium hydroxide lie (10 %) was reflux at 
110 oC for the approximately 15-20 h. The reaction was monitored by TLC. After 
completion of reaction, the solvent was removed under vaccuo when the reaction was 
completed. The solid or oil was crystallized from methanol to give pure product (2a-s). 
 
3.10.2 General synthesis of ketene dithioacetals (3a-s) 
 A 100mL conical flask equipped with magnetic stirrer and septum was charged 
with a solution of 4-methyl-3-oxo-N-phenylpentanamide (2a-o, 10 mmol) in DMF (10 
mL). Dried K2CO3 (10 mmol) was added and the mixture was stirred for 2 h at room 
temperature. CS2 (30 mmol) was added and the mixture was stirred for an additional 2 h 
at room temperature. Methyl iodide (20 mmol) was then added and the mixture was 
stirred for 4 h before being poured onto water (40 mL). The precipitated crude product 
was purified by filtration followed by crystallization from EtOH. When the product was 
oil, the organic phase was extracted with Et2O (3 × 10 mL). The combined organic 
extracts were washed with H2O (2 × 10 mL), dried (MgSO4), and concentrated in vaccuo 
to afford ketene dithioacetals directly used for the next step. 
 
3.10.3 General synthesis of 3-isopropyl-5-(methylthio)-N-aryl-1H-pyrazole-
4-carboxamide derivatives (4a-s) 
 A 100mL round-bottom flask equipped with condenser and septum was charged 
with a solution of ketene dithioacetals (3a-o, 10.0 mmol) in isopropyl alcohol (30 mL), 
followed by the hydrazine hydrate (10.0 mmol) was added and the mixture was reflux for 
4 h at 90 oC. The reaction was monitored by TLC, after complete the reaction mixture 
was then cooled down to room temperature, poured into crushed ice and stirred for 1 h 
before usual standard work-up. When the product was oil, the organic phase was 
extracted with diethyl ether (3 × 100 mL). The combined organic extracts were washed 
with H2O (2 × 100 mL), dried (MgSO4), concentrated in vaccuo, and purified on silica gel 
with ethyl acetate-hexane (9:1) as eluant. When precipitated, the product is filtered, 
washed with water, and purified by recrystallization from ethanol to give pure product 
(4a-s). 
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3.11 Spectral data of synthesized compounds (3a-s & 4a-s): 
 
2-(bis(methylthio) methylene)-4-methyl-3-oxo-N-p-tolylpentanamide 3a. yellow solid, 
yield 90%, mp 155-158°C; Anal. Calcd for C16H21NO2S2: C, 59.41; H, 6.54; N, 4.33; 
Found: C, 59.33; H, 6.45; N, 4.23; m/z:323 [M+]; 1H NMR (400 MHz, DMSO): δ ppm 
1.18-1.20 (m, 6H, 2 × iprCH3), 1.57 (s, 3H, CH3),  2.44 (s, 6H, 2 × SCH3), 3.17-3.24 (m, 
1H, iprCH), 6.99–7.54 (m, 4H, Ar), 8.38  (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 3373, 
3072, 2895, 2828, 1694, 1635, 1482, 1343, 1298.  
 
2-(bis(methylthio)methylene)-N-(4-methoxyphenyl)-4-methyl-3-oxopentanamide 3p. 
yellow solid, yield 92%, mp 169-171°C; Anal. Calcd for C16H21NO3S2: C, 56.61; H, 6.24; 
N, 4.13; Found: C, 56.53; H, 6.14; N, 4.06; m/z:339 [M+]; 1H NMR (400 MHz, DMSO): 
δ ppm 1.18-1.20 (m, 6H, 2 × iprCH3), 2.44 (s, 6H, 2 × SCH3), 3.17-3.24 (m, 1H, iprCH), 
3.75 (s, 3H, OCH3), 6.99–7.54 (m, 4H, Ar), 8.38  (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 
3439, 3007, 2928, 2808, 1599, 1462, 1327, 1255.   
 
3-isopropyl-5-(methylthio)-N-p-tolyl-1H-pyrazole-4-carboxamide 4a. yellow solid, 
yield 80%, mp 195–198°C; Anal. Calcd for C15H19N3OS: C, 62.25; H, 6.62; N, 14.52; 
Found: C, 62.10; H, 6.53; N, 14.43; m/z:289 [M+]; 1H NMR (400 MHz, DMSO): δ ppm 
1.29-1.31(d, J = 6.88 Hz, 6H, 2 × iprCH3) 2.32 (s, 3H, PhCH3), 2.45 (s, 3H, SCH3), 3.89-
3.96 (m, 1H, iprCH), 7.17–7.55 (m, 4H, Ar), 9.24 (br, s, 1H, -CONH) and 12.85 (br, s, 
1H,  pyrazole NH); IR (KBr), ν(cm-1): 3298, 3167, 2980, 2881, 2825, 1697, 1641, 1408, 
1307, 1213.    
 
N-(4-fluorophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4b. white 
solid, yield 88%, mp 185–188°C; Anal. Calcd for C14H16FN3OS: C, 57.32; H, 5.50; N, 
14.32; Found: C, 57.25; H, 5.43; N, 14.22; m/z:293 [M+];  IR (KBr), ν(cm-1): 3292, 3167, 
3019, 2859, 2882, 1698, 1630, 1481, 1343, 1298.    
 
3-isopropyl-N-(2,3-dimethylphenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 4c. 
off white  solid, yield 85%, mp 201–202°C; Anal. Calcd for C16H21N3OS: C, 63.33; H, 
6.98; N, 13.85; Found: C, 63.22; H, 6.88; N, 13.73; m/z:303 [M+]; IR (KBr), ν(cm-1): 
3292, 3167, 3074, 2894, 2829, 1694, 1638, 1482, 1343, 1298.    
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3-isopropyl-N-(2,4-dimethylphenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 4d.  
white  solid, yield 83%, mp 211–212°C; Anal. Calcd for C16H21N3OS: C, 63.33; H, 6.98; 
N, 13.85; Found: C, 63.22; H, 6.88; N, 13.73; m/z:303 [M+]; IR (KBr), ν(cm-1): 3292, 
3167, 3072, 2895, 2828, 1690, 1635, 1482, 1343, 1298.   
 
3-isopropyl-N-(2,5-dimethylphenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 4e.  
white  solid, yield 84%, mp 218–220°C; Anal. Calcd for C16H21N3OS: C, 63.33; H, 6.98; 
N, 13.85; Found: C, 63.22; H, 6.88; N, 13.73; m/z:303 [M+]; 1H NMR (400 MHz, 
DMSO): δ ppm 1.33 (d, J = 7.08 Hz, 6H, 2 × iprCH3), 2.16-2.32 (s, 6H, ArCH3), 2.53 (s, 
3H, SCH3), 3.84-3.87 (m, 1H, iprCH), 6.84–7.86 (m, 3H, Ar), 9.61 (br, s, -CONH) and 
12.94 (br, s,  pyrazole NH); IR (KBr), ν(cm-1): 3292, 3167, 3072, 2895, 2828, 1694, 
1635, 1482, 1343, 1298.   
 
N-(2-chlorophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4f. white 
solid, yield 80%, mp 175–178°C; Anal. Calcd for C14H16ClN3OS: C, 54.27; H, 5.21; N, 
13.56; Found: C, 54.15; H, 5.12; N, 13.46; m/z:309 [M+]; IR (KBr), ν(cm-1): 3292, 3167, 
3072, 2895, 2828, 1694, 1635, 1482, 1343, 1298.    
 
N-(3-chlorophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4g. white 
solid, yield 82%, mp 185–188°C; Anal. Calcd for C14H16ClN3OS: C, 54.27; H, 5.21; N, 
13.56; Found: C, 54.15; H, 5.12; N, 13.46; m/z:309 [M+]; IR (KBr), ν(cm-1): 3292, 3167, 
3071, 2894, 2828, 1694, 1635, 1482, 1343, 1298.    
 
N-(4-chlorophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4h. 
white solid, yield 85%, mp 198–200°C; Anal. Calcd for C14H16ClN3OS: C, 54.27; H, 
5.21; N, 13.56; Found: C, 54.15; H, 5.12; N, 13.46; m/z:309 [M+]; 1H NMR (400 MHz, 
CDCl3): δ ppm 1.21-1.22 (d, J = 6.92 Hz, 6H, 2 × iprCH3), 2.43 (s, 3H, SCH3), 4.05-4.31 
(m, 1H, iprCH), 7.23–7.67 (m, 4H, Ar), 9.78 (br, s, 1H, -CONH) and 12.99 (br, s, 1H,  
pyrazole NH); IR (KBr), ν(cm-1): 3292, 3167, 3078, 2896, 2829, 1694, 1637, 1482, 1343, 
1298.    
 
N-(2,6-dichlorophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4i. 
white solid, yield 74%, mp 245–248°C; Anal. Calcd for C14H15Cl2N3OS: C, 48.84; H, 
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4.39; N, 12.21; Found: C, 48.78; H, 4.31; N, 12.11;  m/z:344 [M+];  IR (KBr), ν(cm-1): 
3292, 3167, 3071, 2895, 2828, 1694, 1635, 1481, 1343, 1298.   
 
N-(2-bromophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4j. Off-
white solid, yield 85%, mp 222-223°C; Anal. Calcd for C14H16BrN3OS: C, 47.46; H, 4.55; 
N, 11.56; Found: C, 47.35; H, 4.46; N, 11.76; m/z:353 [M+]; IR (KBr), ν(cm-1): 3292, 
3167, 3077, 2895, 2824, 1694, 1635, 1482, 1343, 1298.   
 
N-(3-bromophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4k. Off-
white solid, yield 87%, mp 232-233°C; Anal. Calcd for C14H16BrN3OS: C, 47.46; H, 4.55; 
N, 11.56; Found: C, 47.35; H, 4.46; N, 11.76; m/z:353 [M+]; IR (KBr), ν(cm-1): 3292, 
3167, 3073, 2895, 2828, 1694, 1635, 1482, 1343, 1298.   
 
N-(4-bromophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4l. Off-
white solid, yield 85%, mp 240-241°C; Anal. Calcd for C14H16BrN3OS: C, 47.46; H, 4.55; 
N, 11.56; Found: C, 47.35; H, 4.46; N, 11.76; m/z:353 [M+]; IR (KBr), ν(cm-1): 3292, 
3167, 3071, 2894, 2828, 1694, 1635, 1482, 1343, 1298.   
 
N-(2-nitrophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4m. Off-
white solid, yield 71%, mp 217-219°C; Anal. Calcd for C14H16N4O3S: C, 52.49; H, 5.03; 
N, 17.49; Found: C, 52.36; H, 4.96; N, 17.38; m/z:320 [M+]; IR (KBr), ν(cm-1): 3292, 
3167, 3072, 2899, 2828, 1694, 1635, 1482, 1343, 1298.   
 
N-(3-nitrophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4n. Off-
white solid, yield 75%, mp 227-230°C; Anal. Calcd for C14H16N4O3S: C, 52.49; H, 5.03; 
N, 17.49; Found: C, 52.36; H, 4.96; N, 17.38; m/z:320 [M+]; IR (KBr), ν(cm-1): 3292, 
3167, 3071, 2895, 2827, 1693, 1635, 1482, 1343, 1298.   
 
N-(4-nitrophenyl)-3-isopropyl-5-(methylthio)-1H-pyrazole-4-carboxamide 4o. Off-
white solid, yield 78%, mp 237-239°C; Anal. Calcd for C14H16N4O3S: C, 52.49; H, 5.03; 
N, 17.49; Found: C, 52.36; H, 4.96; N, 17.38; m/z:320 [M+]; IR (KBr), ν(cm-1): 3292, 
3167, 3071, 2894, 2828, 1694, 1635, 1482, 1343, 1298.   
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3-isopropyl-N-(4-methoxyphenyl)-5-(methylthio)-1H-pyrazole-4-carboxamide 4p. 
white solid, yield 80%, mp 217-220°C; Anal. Calcd for C15H19N3O2S: C, 58.99; H, 6.27; 
N, 13.76; Found: C, 58.86; H, 6.17; N, 13.68; m/z:305 [M+]; 1H NMR (400 MHz, 
CDCl3): δ ppm 1.23-1.25 (d, J = 8 Hz, 6H, 2 × iprCH3), 2.47 (s, 3H, SCH3), 3.77 (s, 3H, 
OCH3), 4.10-4.35 (m, 1H, iprCH), 7.30–7.68 (m, 4H, Ar), 9.85 (br, s, 1H, -CONH) and 
13.10 (br, s, 1H,  pyrazole NH); IR (KBr), ν(cm-1): 3292, 3167, 3072, 2895, 2828, 1694, 
1635, 1482, 1343, 1298.   
 
N-(3-chloro-4-fluorophenyl)-3-isopropyl-5(methylthio)-1H-pyrazole-4-carboxamide 
4q. white solid, yield 82%, mp 207-209°C; Anal. Calcd for C14H15ClFN3OS: C, 51.30; H, 
4.61; N, 12.82; Found: C, 51.16; H, 4.51; N, 12.71; m/z:327 [M+]; 1H NMR (400 MHz, 
DMSO): δ ppm 1.29-1.31 (d, 6H, 2 × iprCH3), 2.53 (s, 3H, SCH3), 3.84-3.87 (m, 1H, 
iprCH), 7.12–7.98 (m, 3H, Ar), 9.61 (br, s, -CONH) and 12.94 (br s,  pyrazole NH); IR 
(KBr), ν(cm-1): 3292, 3167, 3065, 2894, 2828, 1694, 1635, 1482, 1343, 1298.   
 
N-(3,4-difluorophenyl)-3-isopropyl-5(methylthio)-1H-pyrazole-4-carboxamide  4r. 
Off-white solid, yield 81%, mp 205-207°C; Anal. Calcd for C14H15F2N3OS: C, 54.01; H, 
4.86; N, 13.50; Found: C, 53.91; H, 4.73; N, 13.43; m/z:311 [M+]; IR (KBr), ν(cm-1): 
3292, 3167, 3072, 2895, 2828, 1694, 1635, 1481, 1343, 1298.  
  
N-(4-ethylphenyl)-3-isopropyl-5(methylthio)-1H-pyrazole-4-carboxamide 4s. White 
solid, yield 90%, mp 135-137°C; Anal. Calcd for C16H21N3OS: C, 63.33; H, 6.98; N, 
13.85; Found: C, 63.23; H, 6.87; N, 13.73; m/z:303 [M+]; 1H NMR (400 MHz, CDCl3): δ 
ppm 1.18 (t, 3H, PhCH2CH3), 1.34-1.36 (d, J = 7.08 Hz, 6H, 2 × iprCH3), 2.56 (s, 3H, 
SCH3), 3.89-3.96 (m, 1H, iprCH), 7.17–7.55 (m, 4H, Ar), 9.22 (br, s, 1H, -CONH) and 
10.85 (s, 1H,  pyrazole NH); IR (KBr), ν(cm-1): 3292, 3167, 2964, 1633, 1591, 1518, 
1411, 1311, 1259; 13C NMR (400 MHz, CDCl3): 15.69, 18.08, 21.43, 25.83, 28.33, 
112.60, 120.17, 128.32, 135.76, 140.25, 155.80, 160.93.   
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3.12 Spectral representation of synthesized compounds 
3.12.1 1H NMR spectrums compound of 3a 
 
3.12. 2 1H NMR spectrums compound of 3p 
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3.12. 3 1H NMR spectrums compound of 4s 
 
3.12. 4 13C NMR spectrums compound of 4s 
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3.12. 5 1H NMR spectrums compound of 4q  
 
3.12. 6 Mass spectrum of compound 4b 
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3.12. 7 Mass spectrum of compound 4e 
 
3.12. 8 Mass spectrum of compound 4p 
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3.12. 9 Mass spectrum of compound 4q 
 
3.12. 10 Mass spectrum of compound 4s 
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3.12. 11 IR spectrum of coumpound 4a 
 
3.12. 12 IR spectrum of coumpound 4s 
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Chapter 4 
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4.1 Introduction  
 
The pyrimidine fragment is present of a series of biologically active compounds, 
many of which have found use in medical practice (soporific, anti-inflammatory, antitumor, 
and other products).1,2 In this connection, great attention has recently been paid to derivatives 
of pyrimidine, including their hydrogenation products. The first investigations into the 
synthesis of such compounds appeared more than a hundred years ago (e.g., the Biginelli 
reaction),3  and for a long time they remained unused. Only in the last decade have methods 
been developed specifically for the production of hydrogenated pyrimidine systems and their 
physicochemical properties been studied. This is explained by the high reactivity and by the 
wide range of biological activity in these derivatives. Thus, for example, 2-substituted 5-
alkoxycarbonyl-4-aryl-l,4-dihydropyrimidines, which are structural analogs of hantsch esters, 
are modulators of the transport of calcium through membranes.4-7  Recently, non-nucleoside 
inhibitors of reverse transcriptase, which have high activity against HIV-1, have been found 
among hydrogenated quinazolines.8-10 Many hydrogenated pyrimidines exhibit 
antimicrobial,11 hypoglemic,12  herbicidal,13 and pesticidal14 activity. Publications devoted to 
these problems have been summarized in a number of reviews.12-17  
Of great interest among the investigated compounds are the nitro-substituted 
dihydropyrimidines. They readily undergo various chemical transformations, among which 
the unique ability to undergo recyclization to heterocyclic and carbocyclic compounds should 
be noted in particular. The interest in the nitrodihydropyrimidines is also due to the fact that 
these compounds represent the active principle or act as metabolites responsible for the 
physiological action of nitropyrimidines. Recently, products having antimicrobial18 and 
antiviral19-21 activity and also products suitable for the treatment of cardiovascular diseases22-
25 have been found among them.  
5-Nitrodihydropyrimidines can be described by five structures, having one (1,4-, 1,6-, 
and 1,2-) or two (2,5- and 4,5-dihydropyrimidine systems) geminal centers, the carbon atoms 
of which are characterized by sp3 hybridization (Figure 1). 
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 The 5-nitro-l,2-, 5-nitro-l,4-, and 5-nitro-l,6-dihydropyrimidines are cyclic enamines, 
in which the electron pair of the sp3-hybridized nitrogen atom is in conjugation with the four 
π electrons of the C = C and C = N double bonds. On account of the mobility of the hydrogen 
atom of the NH group, the 5-nitro-1,4- and 5-nitro-1,6-dihydropyrimidines can be in 
tautomeric equilibrium. At the same time the 5-nitro-2,5- and 5-nitro-4,5-dihydropyrimidines 
are cyclic imines, in which there is no conjugation.26  
 
4.2 Methods for the preparation of nitrodihydropyrimidines 
 The methods for the production of dihydropyrimidines described in the literature can 
be divided into two main groups such as: synthesis from acyclic compounds and 
transformations based on pyrimidine derivatives (Figure 2). Analysis of the published data 
makes it possible to conclude that the first methods have advantages over the other. 
However, the second methods are used more widely if an electron withdrawing group, and 
particularly a nitro group, is introduced into the pyrimidine molecule. (One of the acyclic 
compounds contains a nitro group.)  
Figure 2  
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4.2.1 Synthesis from acyclic compounds  
 Only derivatives of 5-nitro-l,4-dihydropyrimidine have been obtained from acyclic 
compounds (Figure 3). Three-component (A) and two-component (B, C) versions of 
cyclocondensation, based on the Biginelli reaction,17, 27-29 and also intramolecular cyclization 
of the already prepared six-membered chain (version D) have been used for this. Nitro 
ketones (versions A, C) and 1-arylidene-l-nitropropan-2-ones (version B) are used as nitro 
components in these reactions and derivatives of urea, arninopyrazole, and amidines are used 
as N-C-N fragments. 
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Methods for the synthesis of 5-nitro-l,4-dihydropyrimidines from acyclic compounds
Figure 3
 
 The proposed methods of cyclocondensation are interrelated. As a rule, realization of 
the reactions by one of the methods leads not to the final product but to an intermediate 
compound, which is in turn the starting compound for another method of cyclization. 
 The formation of 5-nitro-4,6-diphenyl-l,4-dihydropyrimidin-2(1H)-one (Figure 4) 
from benzylidenebisurea and α-nitroacetophenone  was first described in 1972.30 According 
to the mechanism of the Biginelli reaction,28 at the first stage the urea fragment is clearly 
substituted by the nitroketone residue, and this is followed by cyclization of the six-
membered intermediate in the acidic medium. 
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 In the reaction of aromatic aldehydes with nitro acetone and a two-fold excess of urea 
or N-methyl urea in boiling ethanol in the presence of HCI  4-aryl-6-methyl- or 4-aryl-l,6-
dimethyl-5-nitro-l,4-dihydropyrimidin-2(1H)-ones (Figure 5).25, 31 The latter are also formed 
as a result of the two-component cyclization  of the respective 1-arylidene-l-nitropropan-2-
ones with urea or N-methyl urea. 
ArCHO MeCOCH2NO2
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H COMe
NO2
NH2CONHR
EtOH,
conc. HCl
R = H, Me
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N
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R
 
 By analysis of the spectral characteristics it is possible to assign compounds (Figure 
5) the 1,2,3,4-tetrahydropyrimidine structure. It should be noted that almost any aromatic 
aldehydes enter into the described transformations. This is important during comparison of 
the pharmacological activity of compounds of this series with the corresponding derivatives 
of 4-aryl-l,4-dihydropyridines. 
 
4.2.2 Synthesis based on nitropyrimidines 
 Owing to their reactivity, nitropyrimidines, which contain accepting nitro groups and 
"pyrimidines" nitrogen atoms, have been found to be a useful synthon for the production of 
various derivatives of pyrimidine and also various other types of organic compounds whose 
synthesis by other methods is difficult or practically impossible.32-34  
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4.2.3 Alternative synthetic routes for better yield, shorter reaction time to 
 synthesize new analogs 
 Various modifications have been applied to Biginelli reaction to get better yield and 
to synthesize biologically active analogs. Different catalysts have been reported to increase 
the yield of the reaction. Microwave synthesis strategies have also been applied to shorten 
the reaction time. Solid phase synthesis and combinatorial chemistry has made possible to 
generate library of DHPM analogs. The various modifications are discussed in the following 
section. 
 
Catalysts 
 Min Yang and coworkers35 have synthesized the different DHPMs by using different 
inorganic salts as a catalyst (Figure 6). They found that the yields of the one-pot Biginelli 
reaction can be increased from 20-50 % to 81-99 %, while the reaction time shorted for 18-
24 hr to 20-30 min. This report a new and simple modification of the Biginelli type reaction 
by using Yb(OTf)3 and YbCl3 as a catalyst under solvent free conditions. One additional 
important feature of this protocol is the catalyst can be easily recovered and reused.  
R1
R2
R
CHO
NH2
OH2N
Yb(OTf)3
100 o C
N
H
NH
R
O
R1
R2
O
Figure 6  
 
 Indium(III)chloride was emerged as a powerful Lewis catalyst imparting high region 
and chemo selectivity in various chemical transformations. B. C. Ranu and co-workers36 
reported indium(III) chloride (InCl3) as an efficient catalyst for synthesis of 3,4-
dihydropyrimidn-2(1H)-ones (Figure 7). A variety of substituted aromatic, aliphatic and 
heterocyclic aldehydes have been subjected to this condensation very efficiently.  Thiourea 
has been used with similar success to provide the corresponding dihydropyrimidin-2(1H)-
thiones. 
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 Majid M. Heravi et al. have reported a simple, efficient and cost-effective method for 
the synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thiones by one pot three-component 
cyclocondensation reaction of a 1,3-dicarbonyl compound, an aldehyde and urea or thiourea 
using 12-tungstophosphoric acid37 and 12-molybdophosphoric acid38 as a recyclable catalyst 
(Figure 8). 
H3C
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N
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X
R2COO
H3C
Figure 8
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 A novel covalently anchored sulfonic acid onto the surface of silica was prepared and 
investigated for the Biginelli reaction by Satya Paul and co-workers (Figure 9).39 The 
catalyst is highly stable, completely heterogeneous and recyclable for several times. The 
workup procedure is very simple and Biginelli compounds were obtained in good to 
excellent yields (Figure 10). 
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 An efficient three-component synthesis of 3,4-dihydropyrimidinones using 
trichloroisocyanuric acid (TCCA) as mild, homogeneous and neutral catalyst for Biginelli 
reaction in ethanol or DMF under reflux condition.40 Many researchers41-47 have investigated 
an efficient Biginelli reaction under solvent-free conditions for one-pot synthesis of 3,4-
dihydropyrimidi-2-(1H)ones/thiones using various catalyst as described under.  
 
Solid phase synthesis 
 The generation of combinatorial libraries of heterocyclic compounds by solid phase 
synthesis is of great interest for accelerating lead discovery and lead optimization in 
pharmaceutical research. Multi-component reactions (MCRs)29, 48-53 leading to heterocycles 
are particularly useful for the creation of diverse chemical libraries, since the combination of 
any 3 small molecular weight building blocks in a single operation leads to high 
combinatorial efficiency. Therefore, solid phase modifications of MCRs are rapidly become 
the cornerstone of combinatorial synthesis of small-molecule libraries.  
 The first solid-phase modification of the Biginelli condensation was reported by Wipf 
and Cunningham54 in 1995 (Figure11). In this sequence, γ-aminobutyric acid derived urea 
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was attached to Wang resin using standard procedures. The resulting polymer-bound urea 
was condensed with excess β-ketoester and aromatic aldehydes in THF at 55 °C in the 
presence of a catalytic amount of HCl to afford the corresponding immobilized DHPMs. 
Subsequent cleavage of product from the resin by 50 % trifluoroacetic acid (TFA) provided 
DHPMs in high yields and excellent purity. 
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Weiwei Li and Yulin Lam55 described the synthesis of 3,4-dihydropyrimidin-2- 
(1H)ones/thiones using sodium benzenesulfinate as a traceless linker (Figure 12). The key 
steps involved in the solid-phase synthetic procedure include sulfinate acidification, 
condensation of urea or thiourea with aldehydes and sulfinic acid and traceless product 
release by a one-pot cyclization-dehydration process. Since a variety of reagents can be used, 
the overall strategy appears to be applicable to library generation. 
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Gross et al.56 developed a protocol for based on immobilized α-ketoamides to increase 
the diversity of DHPM (Figure 13). The resulting synthetic protocol proved to be suitable for 
the preparation of a small library using different building blocks. They found that the 
expected DHPM derivatives were formed in high purity and yield, if aromatic aldehyde and 
α-ketoamide building blocks were used. The usage of an aliphatic aldehyde leads to an 
isomeric DHPM mixture. Purities and yields were not affected if thiourea was used instead of 
urea. 
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Liquid phase synthesis 
 In the solid phase synthesis there are some disadvantages of this methodology 
compared to standard solution-phase synthesis, such as difficulties to monitor reaction 
progress, the large excess of reagents typically used in solid-phase supported synthesis, low 
loading capacity and limited solubility during the reaction progress and the heterogeneous 
reaction condition with solid phase.57 Recently, organic synthesis of small molecular 
compounds on soluble polymers, i.e. liquid phase chemistry has increasingly become 
attractive field.58 It couples the advantages of homogeneous solution chemistry with those of 
solid phase chemistry. 
 Moreover owing to the homogeneity of liquid-phase reactions, the reaction conditions 
can be readily shifted from solution-phase systems without large changes and the amount of 
excessive reagents is less than that in solid-phase reactions. In the recent years, Task Specific 
room temperature Ionic Liquids (TSILs) has emerged as a powerful alternative to 
conventional molecular organic solvents or catalysts. Liu Zuliang et al.59 reported cheap and 
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reusable TSILs for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones via one-pot three 
component Biginelli reaction. 
 Ionic liquid-phase bound acetoacetate reacts with thiourea and various aldehydes with 
a cheap catalyst to afford ionic liquid-phase supported 3,4-dihydropyrimidin-2(1H)-thiones 
by Jean Pierre Bazureau and co-workers (Figure 14).60 3,4-Dihydropyrimidinones was 
synthesized in one-pot of aldehydes, β-dicarbonyl compounds and urea, catalyzed by non-
toxic room temperature ionic liquid 1-n-butyl-3-methylimidazolium saccharinate 
(BMImSac).61 
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Microwave assisted synthesis 
 In general, the standard procedure for the Biginelli condensation involves one pot 
condensation of the three building blocks in a solvent such as ethanol using a strongly acidic 
catalyst that is hydrochloric acid.58 One major drawback of this procedure, apart from the 
long reaction times involving reflux temperatures, are the moderate yields frequently 
observed when using more complex building blocks. Microwave irradiation (MWI) has 
become recognized tool in organic synthesis, because the rate enhancement, higher yields 
and often, improved selectivity with respect to conventional reaction conditions.62 The 
publication by Anshu Dandia et al.63 described microwave-enhanced solution-phase Biginelli 
reactions employing ethyl acetoacetate, thiourea and a wide variety of aromatic aldehydes as 
building blocks (Figure 15). Upon irradiation of the individual reaction mixtures (ethanol, 
catalytic HCl) in an open glass beaker inside the cavity of a domestic microwave oven the 
reaction times were reduced from 2–24 hours of conventional heating 80 °C, reflux to 3–11 
minutes under microwave activation (ca. 200 –300 W). At the same time the yields of 
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DHPMs obtained were markedly improved compared to those reported earlier using 
conventional conditions. 
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 In recent years, solvent free reactions using either organic or inorganic solid supports 
have received increasing attention.64 There are several advantages to performing synthesis in 
dry media: (i) short reaction times, (ii) increased safety, (iii) economic advantages due to the 
absence of solvent. In addition, solvent free MWI processes are also clean and efficient. M. 
Gopalakrishnan and co-workers have reported Biginelli reaction under microwave irradiation 
in solvent-free conditions using activated fly ash as a catalyst, activated fly ash, an industrial 
waste (pollutant) is an efficient and novel catalyst for some selected organic reactions in 
solvent free conditions under microwave irradiation.65 
 
Ultrasound assisted synthesis 
 Ultrasound as a green synthetic approach has gradually been used in organic synthesis 
over the last three decades. Compared with the traditional methods, it is more convenient, 
easier to be controlled, and consumes less power. With the use of ultrasound irradiation, a 
large number of organic reactions can be carried out in milder conditions with shorter 
reaction time and higher product yields.66 Ultrasound irradiated and amidosulfonicacid 
(NH2SO3H) catalyzed synthesis of 3,4-dihydropyrimidi-2-(1H)ones have reported by Ji-Taai 
Li and co-workers67 using aldehydes, β-ketoester and urea. 
 Chenjiang Liu et al.68 have synthesized a novel series of 4-substituted pyrazolyl- 3,4-
dihydropyrimidin-2(1H)-thiones under ultrasound irradiation using magnesium perchlorate 
[Mg(ClO4)2] as catalyst (Figure 16), by the condensation of 5-chloro/phenoxyl-3-methyl-1-
phenyl-4-formylpyrazole, 1,3-dicarbonyl compound and urea or thiourea in moderate yields. 
The catalyst exhibited remarkable reactivity and can be recycled. 
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 Sonication of aromatic aldehydes, urea and ethyl acetoacetate in presence of solvent 
(ethanol) or solvent-less dry media (bentonite clay) by supporting-zirconium chloride (ZrCl4)  
as catalys at 35 kHz gives 6-methyl-4-substitutedphenyl-2-oxo-1,2,3,4- 
tetrahydropyrimidine-5-carboxylic acid ethyl esters proficiently in high yields reported by 
Harish Kumar et al. (Figure 17).69 
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4.3 Mechanistic studies 
 Since the 1930s several mechanistic pathways have been proposed for the Biginelli 
reaction. In 1933, Folkers and Johnson reported that one of three intermediates (Figure 18, 
19, 20) was likely to be present in this reaction.70 
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 Forty years after the initial proposal, Sweet and Fissekis proposed a more detailed 
pathway involving a carbonium ion species.29 After 25 years of second proposed mechanism 
by Sweet and Fissekis, Kappe71 reexamined the same mechanism in 1997 using 1H and 13C 
NMR spectroscopy to support the argument that the key step in this sequence involves the 
acid-catalyzed formation of an N-acyliminium ion intermediate of type (Figure 22) from the 
aldehyde (Figure 21) and urea (Figure 27) precursors. Interception of the iminium ion 
(Figure 24) by α-nitroacetophenone, presumably through its active methelene produces an 
open chain ureide which subsequently cyclizes to hexahydropyrimidine(Figure 25). Acid-
catalyzed elimination of water from (Figure 25) ultimately leads to the final DHPM product 
(Figure 26). 
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4.4 Biological activity of 4-aryl-1,4-dihydropyridines and  5-nitro DHPM  
4.4.1 Calcium channel modulators 
 4-Aryl-1,4-dihydropyridines (DHPs, e.g. nifedipine, ) are the most studied class of 
organic calcium channel modulators. More than 30 years after the introduction of nifedipine 
many DHP analogs have now been synthesized and numerous second-generation commercial 
products have appeared on the market.72,73 
 In recent years interest has also focused on aza-analogs such as dihydropyrimidines 
(DHPMs) which show a very similar pharmacological profile to classical dihydropyridine 
calcium channel modulators.5-7, 74-78 Over the past few years several lead-compounds were 
developed (i.e. SQ 32,926) that are superior in potency and duration of antihypertensive 
activity to classical DHP drugs, and compare favorable with second-generation analogs such 
as amlodipine and nicardipine (Figure 28).79 
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4.4.2 Potent and selective r1A receptor antagonists 
 Barrow et al reported in vitro and in vivo evaluation of dihydropyrimidinone C-5 
amides as potent and selective r1A receptor antagonists for the treatment of benign prostatic 
hyperplasia (Figure 29). R1 Adrenergic receptors mediate both vascular and lower urinary 
tract tone, and R1 receptor antagonists such as terazosin are used to treat both hypertension 
and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor 
have been identified, with the R1A receptor being most prevalent in lower urinary tract 
tissue. Barrow et al reported 4-aryldihydropyrimidinones attached to an aminopropyl-4-
arylpiperidine via a C-5 amide as selective R1A receptor subtype antagonists. In receptor 
binding assays, these types of compounds generally display Ki values for the R1a receptor 
subtype <1 nM while being greater than 100-fold selective versus the R1b and R1d receptor 
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subtypes. Many of these compounds were also evaluated in vivo and found to be more potent 
than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure 
without significantly affecting blood pressure. While many of the compounds tested 
displayed poor pharmacokinetics, one compound was found to have adequate bioavailability 
(>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the R1a over the 
R1b and R1d receptors as well as its favorable pharmacokinetic profile, it has the potential to 
relieve the symptoms of BPH without eliciting effects on the cardiovascular system.80-84 
The 4-aryldihydropyrimidinone heterocycles attached to an aminopropyl-4-
arylpiperidine via a C-5 amide has proved to be an excellent template for selective R1A 
receptor subtype antagonists. These types of compounds are exceptionally potent in both 
cloned receptor binding studies as well as in vivo pharmacodynamic models of prostatic tone. 
 Compounds exhibited high binding affinity and subtype selectivity for the cloned 
human R1a receptor. Systematic modifications led to identification of highly potent and 
subtype-selective compounds with high binding affinity (Ki) 0.2 nM) for R1a receptor and 
greater than 1500- fold selectivity over R1b and R1d adrenoceptors. The compounds were 
found to be functional antagonists in human, rat, and dog prostate tissues. They exhibited 
excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic 
blood pressure (DBP) in mongrel dogs (Kb(DBP)/Kb(IUP))suggesting uroselectivity for R1a-
selective compounds (Figure 30).85 
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 Cho et. al. reported 3-N-substituted-3,4-dihydropyrimidine and 3-N-substituted-
dihydropyrimidin-2(1H)-ones as calcium channel antagonist (Figure 31). Compounds 
[especially  [R1=(CH2)2N(benzyl)(2-naphthylmethyl) R2= i-Pr, X=o-N02] and [R'= 
(CH2)2N(benzyl)(3,4-dichlorobenzyl) R2= i-Pr, X=o-NO2]] exhibited not only more potent 
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and longer lasting vasodilative action but also a hypertensive activity with slow onset as 
compared with dihydropyridines. Moreover, some dihydropyrimidines [R' 
=(CH2)2N(benzyl)(3-phenylpropyl), R2 = CH2(cyclopropyl), X = o-NO2] were weaker in 
blocking atrioventricular conduction in anesthetized open-chest dogs and less toxic than the 
dihydropyridines.5 
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 Atwal et al examined a series of novel dihydropyrimidine calcium channel blockers 
that contain a basic group attached to either C5 or N3 of the heterocyclic ring (Figure 32). 
Structure-activity studies show that l-(phenylmethyl)-4-piperidinyl carbamate moiety at N3 
and sulfur at C2 are optimal for vasorelaxant activity in vitro and impart potent and long-
acting antihypertensive activity in vivo. One of these compounds was identified as a lead, 
and the individual enantiomers were synthesized. Two key steps of the synthesis were (1) the 
efficient separation of the diastereomeric ureido derivatives and (2) the high-yield 
transformation of 2-methoxy intermediate to the (p-methoxybenzyl)thio intermediates. 
Chirality’s was demonstrated to be a significant determinant of biological activity, with the 
dihydropyridine receptor recognizing the enamines ester moiety but not the carbamate 
moiety. Dihydropyrimidine is equipotent to nifidepine and amlodipine in vitro. In the 
spontaneously hypertensive rat, dihydropyrimidine is both more potent and longer acting 
than nifidepine and compares most favorably with the long-acting dihydropyridine derivative 
amlodipine. Dihydropyrimidine has the potential advantage of being a single enantiomer.76 
N
H
N
i-PrO2C
S
O2
C
N
R
F3C
N
H
N
i-PrO2C
S
O2
C
N
F
F3C
HCl
Figure 32  
 129
In order to explain the potent antihypertensive activity of the modestly active (ICw = 
3.2 pM) dihydropyrimidine calcium channel blocker, Atwal et al carried out drug metabolism 
studies in the rat and found it is metabolized. Two of the metabolites (ICw = 16 nM) and 
(ICw = 12 nM), were found to be responsible for the antihypertensive activity of compound. 
Potential metabolism in vivo precluded interest in pursuing compounds related to it. 
Structure-activity studies aimed at identifying additional aryl-substituted analogues led to 
comparable potential in vivo, though these compounds were less potent in vitro. To 
investigate the effects of absolute stereochemistry on potency, authors resolved via 
diastereomeric ureas, prepared by treatment with (R)-α-methylbenzylamine. The results 
demonstrate that the active R-(-)-enantiomer is both more potent and longer acting than 
nifedipine as an antihypertensive agent in the SHR. The in vivo potency and duration is 
comparable to the long-acting dihydropyridine amlodipine. The superior oral 
antihypertensive activity compared to that of previously described carbamates (R2=COOEt) 
could be explained by its improved oral bioavailability, possibly resulting from increased 
stability of the urea functionality (Figure 33).6 
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 Authors modified the structure of previously described dihydropyrimidine i.e. 3-
substituted 1,4-dihydropyrimidines. Structure-activity studies using potassium-depolarized 
rabbit aorta show that ortho, meta-disubstituted aryl derivatives are more potent than either 
ortho or meta-monosubstituted compounds. While vasorelaxant activity was critically 
dependent on the size of the C5 ester group, isopropyl ester being the best, a variety of 
substituents (carbamate, acyl, sulfonyl, and alkyl) were tolerated at N3. The results show 
dihydropyrimidines are significantly more potent than corresponding 2- heteroalkyl-l,4-
dihydropyrimidines and only slightly less potent than similarly substituted 2-heteroalkyl-1-4-
dihydropyridines (Figure 34). Where as dihydropyridine enantiomer usually show 10-15-
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fold difference in activity, the enantiomer of dihydropyrimidine show more than a 1000-fold 
difference in activity. These results strengthen the requirement of an enaminoester for 
binding to the dihydropyridine receptor and indicate a nonspecific role for the N3-
substituent. 
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2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylicesters 
(Figure 35), which lack the potential symmetry of dihydropyridine calcium channel 
blockers, were prepared and evaluated for biological activity. Biological assays using 
potassium-depolarized rabbit aorta and radio ligand binding techniques showed that some of 
these compounds are potent mimics of dihydropyridine calcium channel blockers.75 
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4.4.3 Antiarrhythmic activity  
 Arkadiy O. Bryzgalov et. al. reported the antiarrhythmic activity of 4,6-di(het)aryl-5-
nitro-3,4-dihydropyrimidin-(1H)-2-ones toward two types of experimental rat arrhythmia has 
been studied (Figure 36). With CaCl2 induced arrhythmia model, several agents have 
demonstrated high Antiarrhythmic activity and the lack of influence on arterial pressure of 
rats.86 
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4.5 Aim of current work 
 Much interest has been focused around 5-nitro dihydropyrimidine derivatives because 
of their wide variety of pharmacological properties and industrial applications. In view of 
these findings we were interested to prepare some new 3,4-dihydro-6-(2-hydroxy-3,5-
dimethylphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one (Figure 37) by using 1-(2-hydroxy-
4,6-dimethylphenyl)-2-nitroethanone instead of β-dicarbonyl compound in the Biginelli 
reaction with substituted benzaldehydes and urea under standard conditions (EtOH, HCl). 
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 In extension of work, the same molecules when synthesized through green chemistry 
approach by utilizing Etidronic acid through microwave irradiation technique resulted in 
formation of all newly synthesized compounds with higher yields and also reaction hours are 
reduced to a great extent in comparison with conventional synthetic methods as mentioned in 
literature.  
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 Etidronic acid [(1-hydroxyethylidene)bisphosphonic acid] (Figure 38) is a 
phosphonic acid and is also known as a bisphosphonate having a molecular formula 
C2H8O7P2. The two PO3 (phosphonate) groups are covalently linked to a single carbon atom.87 
It is different from PPE and polyphosphoric acid (PPA). As a result we found increased yield 
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about 20-25% more than conventional method. All newly synthesized compounds were 
characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. The 
antiviral screening of the compounds synthesized with this modification to DHPM skeleton is 
under investigation. 
 
4.6 Chemistry 
 The synthesis of 4-Hydroxy-6,8-dimethyl-3-nitro-2H-chromen-2-one is outline in 
(Scheme 1). The requisite 4-Hydroxy-6,8-dimethyl-2H-chromen-2-one  were prepared by 
Pechmann condensation of polyphenols (resorcinol)88  and equimolar malonic acid with 2 
moles of POCl3 and 3 moles of ZnCl2. The nitration of 4-Hydroxy-6,8-dimethyl-2H-
chromen-2-one in concentrated nitric acid in glacial acetic acid on steam bath yielded the 4-
Hydroxy-6,8-dimethyl-3-nitro-2H-chromen-2-one. The above 4-Hydroxy-6,8-dimethy-3-
nitro-2H-chromen-2-one was dissolved in 5% sodium hydroxide solution and the reaction 
mixture was kept at room temperature for 24 hr then acidified with hydrochloric acid to give 
1-(2-hydroxy-4,6-dimethylphenyl)-2-nitroethanone (3) (Scheme 1). Thus obtained 
compound 3 was subjected to Biginelli reaction with substituted benzaldehydes and urea 
under standard conditions (EtOH, HCl) to furnish the desired 3,4-dihydro-6-(2-hydroxy-3,5-
dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one (Figure 37). 
 With a view to elucidate whether analogous modifications could be applied to the 
synthesis of 5-nitrodihydropyrimidine (Figure 37) to raise their yields, we examined three-
component condensation of 1-(2-hydroxy-4,6-dimethylphenyl)-2-nitroethanone (3) with 
aromatic aldehydes (4a-v) and urea in the presence of  etidronic acid as a catalyst (Scheme 
3), in boiling ethanol and isolated desired product of 3,4-dihydro-6-(2-hydroxy-3,5-
dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one (5a-v). 
 
4.7  Results and discussion 
 3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one  
have been synthesized in excellent yields in short reaction time at ambient temperature in the 
presence of etidronic acid catalyst by the reaction of aromatic or aliphatic aldehydes with 1-
(2-hydroxy-4,6-dimethylphenyl)-2-nitroethanone (3)  and urea  in ethanol under microwave 
irradiation. The overall synthetic strategy for the preparation of compounds (5a-v) is based 
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on the modification of classical three component Biginelli condensation. The process 
involves (includes) the one-pot cyclocondensation of a 1-(2-hydroxy-4,6-dimethylphenyl)-2-
nitroethanone (1.0 equiv) with an aryl  aldehyde (1.5 equiv) and urea (1.5 equiv) in ethanol in 
the presence of etidronic acid. That is outlined in (Scheme 3).  
 The structures of the resulting 5-nitro DHPM were confirmed by quantitative 
elemental analysis and PMR spectroscopy. The spectra of compounds (5a-v) contain two 
signals for a two methyl at 2.24-2.26 ppm and signals characteristic for 1-(2-hydroxy-4,6-
dimethylphenyl)-2-nitroethanone.The pyrimidine ring system –CH proton appear at 5.15-
5.76 ppm and both –NH signals at 7.77 and 8.29 ppm. The aryl ring and 1-(2-hydroxy-4,6-
dimethylphenyl)-2-nitroethanone proton was overlapped shows at 7.0-7.60 ppm. The 
hydroxyl protons of -OH resonate at weak field 9.0-12.0 ppm. The IR spectrum of 5a–v 
displayed bands at 3369–3336 and 1699-1681 cm–1 due to -NH and cyclic ketone stretching 
frequencies, respectively. On the other hand, the absorption bands were observed in the 
region 1641–1627cm−1 for (C-N). The aromatic stretching bending vibrations were observed 
as a sharp medium to strong band at 3097-3069 cm−1 in compounds (5a–v). The mass 
spectrum of 5a exhibited a molecular ion peak at m/z 339 (5%) in accordance with its 
molecular formula C18H17N3O4. Other prominent peaks appeared at m/z 293, 276, 250, 199, 
160, 106, 91 and 77. 
 
4.8 Conclusion 
 In summary, we have established a rapid and economical procedure for constructing a 
novel 3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one (5a-
v) by combining microwave irradiation with a catalytically amount of etidronic acid. 
Comparison of the proposed method with conventional syntheses of the same compound 
showed that the microwave-assisted syntheses were characterized by much shorter reaction 
times and higher product yields. The specific advantages offered by the use of etidronic acid  
as new catalyst in microwave irradiation in organic synthesis are the following: (1) the 
routine product isolation is very simple because the side product is removed by washings 
from the appropriate solvent/eluent, (2) the product was obtained with high purity after 
column chromatography, we are  reported of the rapid synthesis of 3,4-dihydro-6-(2-
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hydroxy-3,5-dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one (5a-v) using a catalytically 
amount of etidronic acid one-pot three-component strategy under microwave irradiation. 
4.9 Reaction scheme of 3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-
nitro-4-arylpyrimidin-2(1H)-one 
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4.10  Experimental procedure 
 Melting points were determined on an electro thermal apparatus using open 
capillaries and are uncorrected. Thin-layer chromatography was accomplished on 0.2-mm 
precoated plates of silica gel G60 F254 (Merck). Visualization was made with UV light (254 
and 365nm) or with an iodine vapor. IR spectra were recorded on a FTIR-8400 
spectrophotometer using DRS prob. 1H NMR spectra were recorded on a Bruker AVANCE 
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II (400 MHz) spectrometer in DMSO. Chemical shifts are expressed in δ ppm downfield 
from TMS as an internal standard. Mass spectra were determined using direct inlet probe on 
a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI 
rotary evaporator.  
4.10.1 General procedure for conventional synthesis of 3,4-dihydro-6-(2-
hydroxy-3,5-dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one (5a-v) 
 This title compound is prepared following the method as describe by P. Biginelli3 
 
4.10.2 General procedure for microwave-assisted synthesis of 3,4-dihydro-6-    
(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one (5a-v) 
 A well stirred mixture of 1-(2-hydroxy-4,6-dimethylphenyl)-2-nitroethanone (3) (0.01 
mol) in 10-20ml ethanol, appropriate aldehyde (4a-v) (0.01 mol), and urea (0.01 mol) in the 
presence of etidronic acid (100 mg/0.01 mol) was irradiated under microwave oven for 5.0 to 
10.0 min at 300W. The reaction was monitored by TLC. After completion of reaction, the 
reaction mixture was taken up in chloroform and extracted with water. The organic layer was 
washed with 5% aq. sodium bisulphite (100 mL), followed by water (200 mL) and brine (100 
mL) and dried over anhy.sodium sulphate. The solvent was removed under reduced pressure 
and the residue was purified by column chromatography (SiO2) using hexane–ethyl acetate 
(8:2) as an eluent. The fraction containing the main products were combined and evaporated 
to dryness under reduce pressure. The crude product thus obtained was crystallized from 
ethanol to afford the targeted 5-nitroDHPM. 
 Similarly, other 3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-
arylpyrimidin-2(1H)-one (5a-v) were prepared. 
4.11 Spectral data of synthesized compounds (3, and 5a-v) 
  
1-(2-hydroxy-4,6-dimethylphenyl)-2-nitroethanone (3) Pale yellow solid, yield 92%, mp 
135–137°C; Anal. Calcd for C10H11NO4: C, 57.41; H, 5.30; N, 6.70; Found: C, 57.32; H, 
5.15; N, 6.56; m/z:209 [M+]; 1H NMR (400 MHz, DMSO): δ ppm 2.10-2.30 (s, 6H, 2CH3), 
6.45 (s, 2H, CH2NO2), 7.30-7.50 (s, 2H, Ar), 10.95 (s, 1H, OH). 
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3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-arylpyrimidin-2(1H)-one 5a. 
Pale yellow solid, yield 88%, mp 235–237°C; Anal. Calcd for C18H17N3O4: C, 63.71; H, 5.05; 
N, 12.98; Found: C, 63.65; H, 4.99; N, 12.92; m/z:339 [M+]; 1H NMR (400 MHz, DMSO): δ 
ppm 2.24 (s, 3H CH3), 2.26 (s, 3H, CH3), 5.75 (s, 1H, Pyrm-CH), 6.90-7.00 (s, 2H, 2-OH-
phenyl ring), 7.38-7.57 (m, 5H, Ar), 7.44 (s, 1H, Pyrm-NH), 8.16 (s, 1H, Pyrm-NH), 8.46 (s, 
1H, OH); IR (KBr), ν(cm-1): 3485, 3369, 3068, 2895, 2818, 1699, 1627, 1491, 1319, 1286.   
 
4-(4-fluorophenyl)-3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitropyrimidin-
2(1H)-one 5b. yellow solid, yield 90%, mp 245–247°C; Anal. Calcd for C18H16FN3O4: C, 
60.50; H, 4.51; N, 11.76; Found: C, 60.45; H, 4.46; N, 11.70; m/z:357 [M+]; 1H NMR (400 
MHz, DMSO): δ ppm 2.16 (s, 3H CH3), 2.20 (s, 3H, CH3), 5.60 (s, 1H, Pyrm-CH), 6.85-6.98 
(s, 2H, 2-OH-phenyl ring), 7.02-7.54 (m, 4H, Ar), 8.27 (s, 1H, Pyrm-NH), 8.75 (s, 1H, Pyrm-
NH), 9.83 (s, 1H, OH); IR (KBr), ν(cm-1): 3483, 3372, 3066, 2890, 2822, 1695, 1630, 1488, 
1325, 1280.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(2,5-dimethoxyphenyl)-5- 
nitropyrimidin-2(1H)-one 5c. yellow solid, yield 85%, mp 252–254°C; Anal. Calcd for 
C20H21N3O6: C, 60.14; H, 5.30; N, 10.52; Found: C, 60.10; H, 5.20; N, 10.46; m/z:399 [M+]; 
1H NMR (400 MHz, DMSO): δ ppm 2.26 (s, 3H CH3), 2.28 (s, 3H, CH3), 5.96 (s, 1H, Pyrm-
CH), 6.80-6.83 (s, 2H, 2-OH-phenyl ring), 6.89-6.91 (m, 3H, Ar), 8.54 (s, 1H, Pyrm-NH), 
9.39 (s, 1H, Pyrm-NH), 10.40 (s, 1H, OH); IR (KBr), ν(cm-1): 3485, 3375, 3060, 2892, 2824, 
1690, 1633, 1485, 1327, 1283.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(3,4-dimethoxyphenyl)-5-
nitropyrimidin-2(1H)-one 5d. yellow solid, yield 80%, mp 242–244°C; Anal. Calcd for 
C20H21N3O6: C, 60.14; H, 5.30; N, 10.52; Found: C, 60.10; H, 5.20; N, 10.46; m/z:399 [M+];  
IR (KBr), ν(cm-1): 3484, 3374, 3062, 2893, 2825, 1691, 1634, 1486, 1328, 1284.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(2-hydoxyphenyl)-5-nitropyrimidin-
2(1H)-one 5e. yellow solid, yield 75%, mp 192–194°C; Anal. Calcd for C18H17N3O5: C, 
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60.84; H, 4.82; N, 11.83; Found: C, 60.80; H, 4.80; N, 11.78; m/z:355 [M+]; IR (KBr), ν(cm-
1): 3483, 3372, 3063, 2890, 2828, 1691, 1630, 1480, 1326, 1285.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(3-hydoxyphenyl)-5-nitropyrimidin-
2(1H)-one 5f. yellow solid, yield 78%, mp 202–204°C; Anal. Calcd for C18H17N3O5: C, 
60.84; H, 4.82; N, 11.83; Found: C, 60.82; H, 4.81; N, 11.79; m/z:355 [M+]; IR (KBr), ν(cm-
1): 3482, 3373, 3064, 2891, 2827, 1690, 1631, 1481, 1327, 1286.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(4-hydoxyphenyl)-5-nitropyrimidin-
2(1H)-one 5g. yellow solid, yield 80%, mp 212–214°C; Anal. Calcd for C18H17N3O5: C, 
60.84; H, 4.82; N, 11.83; Found: C, 60.79; H, 4.78; N, 11.77; m/z:355 [M+]; IR (KBr), ν(cm-
1): 3484, 3375, 3066, 2893, 2829, 1692, 1633, 1482, 1329, 1288.   
 
4-(2-chlorophenyl)-3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitropyrimidin-
2(1H)-one 5h. yellow solid, yield 82%, mp 188–190°C; Anal. Calcd for C18H16ClN3O4: C, 
57.84; H, 4.31; N, 11.24; Found: C, 57.79; H, 4.28; N, 11.19. m/z:373 [M+]; IR (KBr), ν(cm-
1): 3488, 3379, 3076, 2898, 2833, 1697, 1638, 1487, 1333, 1293.   
 
4-(3-chlorophenyl)-3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitropyrimidin-
2(1H)-one 5i. yellow solid, yield 84%, mp 208–210°C; Anal. Calcd for C18H16ClN3O4: C, 
57.84; H, 4.31; N, 11.24; Found: C, 57.78; H, 4.29; N, 11.18; m/z:373 [M+]; IR (KBr), ν(cm-
1): 3486, 3377, 3077, 2896, 2831, 1695, 1635, 1482, 1330, 1290.   
 
4-(4-chlorophenyl)-3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitropyrimidin-
2(1H)-one 5j. yellow solid, yield 85%, mp 222–225°C; Anal. Calcd for C18H16ClN3O4: C, 
57.84; H, 4.31; N, 11.24; Found: C, 57.79; H, 4.27; N, 11.20; m/z:373 [M+]; 1H NMR (400 
MHz, DMSO): δ ppm 2.30 (s, 3H CH3), 2.35 (s, 3H, CH3), 5.66 (s, 1H, Pyrm-CH), 6.85-6.94 
(s, 2H, 2-OH-phenyl ring), 7.02-7.20 (m, 4H, Ar), 8.60 (s, 1H, Pyrm-NH), 8.65 (s, 1H, Pyrm-
NH), 10.40 (s, 1H, OH); IR (KBr), ν(cm-1): 3480, 3370, 3070, 2890, 2825, 1690, 1630, 1480, 
1333, 1295.   
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4-(2,4-dichlorophenyl)-3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-
nitropyrimidin-2(1H)-one 5k. yellow solid, yield 80%, mp 242–245°C; Anal. Calcd for 
C18H15Cl2N3O4: C, 52.96; H, 3.70; N, 10.29; Found: C, 52.90; H, 3.67; N, 10.20; m/z:373 
[M+]; IR (KBr), ν(cm-1): 3482, 3373, 3072, 2895, 2828, 1694, 1635, 1482, 1343, 1298.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-(2-nitrophenyl)pyrimidin-
2(1H)-one 5l. pale yellow solid, yield 75%, mp 178–180°C; Anal. Calcd for C18H16N4O6: C, 
56.25; H, 4.20; N, 14.58; Found: C, 56.20; H, 4.12; N, 14.54; m/z:384 [M+]; IR (KBr), ν(cm-
1): 3488, 3379, 3076, 2898, 2833, 1697, 1638, 1487, 1333, 1293.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-(3-nitrophenyl)pyrimidin-
2(1H)-one 5m. pale yellow solid, yield 77%, mp 198–200°C; Anal. Calcd for C18H16N4O6: C, 
56.25; H, 4.20; N, 14.58; Found: C, 56.22; H, 4.11; N, 14.50; m/z:384 [M+]; IR (KBr), ν(cm-
1): 3490, 3389, 3070, 2899, 2832, 1692, 1640, 1485, 1335, 1291.  
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-(4-nitrophenyl)pyrimidin-
2(1H)-one 5n. pale yellow solid, yield 77%, mp 198–200°C; Anal. Calcd for C18H16N4O6: C, 
56.25; H, 4.20; N, 14.58; Found: C, 56.20; H, 4.15; N, 14.49; m/z:384 [M+]; 1H NMR (400 
MHz, DMSO): δ ppm 2.36 (s, 3H CH3), 2.38 (s, 3H, CH3), 5.70 (s, 1H, Pyrm-CH), 6.88-6.98 
(s, 2H, 2-OH-phenyl ring), 7.35-8.10 (m, 4H, Ar), 8.75 (s, 1H, Pyrm-NH), 8.88 (s, 1H, Pyrm-
NH), 12.52 (s, 1H, OH); IR (KBr), ν(cm-1): 3490, 3389, 3070, 2899, 2832, 1692, 1640, 1485, 
1335, 1291.  
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(2-methoxyphenyl)-5-nitropyrimidin-
2(1H)-one 5o. light yellow solid, yield 87%, mp 215–218°C; Anal. Calcd for C19H19N3O5: C, 
61.78; H, 5.18; N, 11.38; Found: C, 61.70; H, 5.09; N, 11.31; m/z:369 [M+];  IR (KBr), ν(cm-
1): 3491, 3379, 3079, 2890, 2831, 1690, 1645, 1480, 1330, 1292.  
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(4-methoxyphenyl)-5-nitropyrimidin-
2(1H)-one 5p.  yellow solid, yield 90%, mp 225–228°C; Anal. Calcd for C19H19N3O5: C, 
61.78; H, 5.18; N, 11.38; Found: C, 61.71; H, 5.10; N, 11.30; m/z:369 [M+]; 1H NMR (400 
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MHz, DMSO): δ ppm 2.34 (s, 3H CH3), 2.38 (s, 3H, CH3), 3.75 (s, 3H, OCH3) 5.98 (s, 1H, 
Pyrm-CH), 6.60-6.75 (s, 2H, 2-OH-phenyl ring), 6.84-6.95 (m, 4H, Ar), 8.72 (s, 1H, Pyrm-
NH), 8.81 (s, 1H, Pyrm-NH), 12.42 (s, 1H, OH); IR (KBr), ν(cm-1): 3490, 3389, 3069, 2880, 
2835, 1680, 1640, 1470, 1320, 1282; 13C NMR (400 MHz, CDCl3): 15.43, 20.38, 50.86, 
80.64, 91.79, 114.48, 118.22, 125.02, 126.02, 127.45, 128.77, 132.01, 139.87, 182.42.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(4-hydroxy-3-methoxyphenyl)-5-
nitropyrimidin-2(1H)-one 5q.  yellow solid, yield 71%, mp 251–254°C; Anal. Calcd for 
C19H19N3O6: C, 59.22; H, 4.97; N, 10.90; Found: C, 59.17; H, 4.90; N, 10.87; m/z:385 [M+]; 
IR (KBr), ν(cm-1): 3491, 3382, 3066, 2889, 2845, 1682, 1643, 1473, 1324, 1286.  
 
4-(3,5-difluorophenyl)-3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitropyrimidin-
2(1H)-one 5r. yellow solid, yield 75%, mp 251–252°C; Anal. Calcd for C18H15F2N3O4: C, 
57.60; H, 4.03; N, 11.20; Found: C, 57.55; H, 3.96; N, 11.11; m/z:375 [M+]; IR (KBr), ν(cm-
1): 3483, 3372, 3066, 2890, 2822, 1695, 1630, 1488, 1325, 1280.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitro-4-p-tolylpyrimidin-2(1H)-one 5s. 
yellow solid, yield 85%, mp 195–198°C; Anal. Calcd for C19H19N3O4: C, 64.58; H, 5.42; N, 
11.89; Found: C, 64.50; H, 5.38; N, 11.81; m/z:369 [M+]; IR (KBr), ν(cm-1): 3491, 3379, 
3079, 2890, 2831, 1690, 1645, 1480, 1330, 1292.  
 
4-(furan-2-yl)-3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-5-nitropyrimidin-2(1H)-
one 5t. yellow solid, yield 75%, mp 251–252°C; Anal. Calcd for C16H15N3O5: C, 58.36; H, 
4.59; N, 12.76; Found: C, 58.30; H, 4.52; N, 12.71; m/z:375 [M+]; IR (KBr), ν(cm-1): 3481, 
3371, 3065, 2892, 2824, 1693, 1632, 1480, 1320, 1288.   
 
3,4-dihydro-6-(2-hydroxy-3,5-dimethylphenyl)-4-(3-hydroxy-4-methoxyphenyl-5-
nitrophenyl)-5-nitropyrimidin-2(1H)-one 5u.  yellow solid, yield 73%, mp 261–263°C; 
Anal. Calcd for C19H19N4O8: C, 53.03; H, 4.22; N, 13.02; Found: C, 52.97; H, 4.17; N, 
12.97; m/z:430 [M+]; IR (KBr), ν(cm-1): 3490, 3388, 3064, 2887, 2848, 1681, 1644, 1478, 
1327, 1287. 
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4.12 Spectral representation of synthesized compounds 
4.12.1 1H NMR spectrums of 1-(2-hydroxy-4,6-dimethylphenyl)-2-nitroethanone 
(3)  
 
4.12.2 1H NMR spectrums of compound 5a 
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4.12.3 1H NMR spectrums of compound 5b 
 
4.12.4 1H NMR spectrums of compound 5c 
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4.12.5 mass spectra of compound 5a 
 
4.12.6 mass spectra of compound 5b 
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4.12.7 mass spectra of compound 5c 
 
4.12.8 mass spectra of compound 5u 
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4.12.9 IR spectra of compound 5a 
 
4.12.10 IR spectra of compound 5p 
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4.12.11 13C NMR spectrums of compound 5p 
 
4.12.12 13C NMR spectrums of compound 5b 
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5.1 INTRODUCTION 
 
Isoxazole is a five member heterocyclic compound having two hetero atoms oxygen 
at position 1 and nitrogen at position 2. In 1888, Claisen have been first reported an isoxazole 
(Figure 1) for a product from the reaction of 1,3-diketone with hydroxylamine.1 
Subsequently a solid foundation for the chemistry of isoxazole was laid down by Claisen and 
his students. It was shown to possess typical properties of an aromatic system but under 
certain reaction conditions. Particularly in reducing or basic media, it becomes very highly 
labile. 
N
O
Figure 1  
The next important contribution to the chemistry of isoxazoles was made by Quelico.2 
in 1945, when he began to study the formation of isoxazoles from nitrile N-oxide and 
unsaturated compounds. 
 
5.2 Synthetic methods for isoxazoles 
 Isoxazoles can be synthesized by various methods, which are described as under. 
 
1. Sabine Kuettel et al.3 have been synthesized 4-(3-phenylisoxazol-5-yl)morpholine 
derivatives (Figure 2) by two synthetic routes, in which substituted acetophenones were 
reacted with carbon disulfide and methyl iodide in the presence of sodium hydride to give 4-
phenoxyphenyl-2,2-bis(methylthio)vinylketones, followed by in situ cyclization of the 
resulting N,S-acetals with hydroxylamine. 
Ph
O
S
S
XHN
X=O
X= N-Boc
NH2OH•HCl / KOH
Ph
ON
N X
Figure 2  
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2. Pranab K. Mahata et al4 have been synthesized 3-dimethoxymethyl-5-(methylthio) 
isoxazole derivative (Figure 3) shown to be useful three carbon synthon for efficient 
regiospecfic synthesis of a varity of five (isoxazole) with mask or unmask aldehyde 
functionality by cyclocondensation with bifunctional heteronucleophiles such as 
hydroxylamine. 
OMe
MeO
HC
O
SMe
SMe
H2NOH•HCl / KOH
EtOH / pH=7 / Δ N
O
SMe
OMe
MeO
Figure 3
 
 
3. Scott R. Tweedie et al.5 synthesized a palladium-catalyzed couplings of heteroaryl 
amines with aryl halides using sodium phenolate as the stoichiometric base. (Figure 4) 
O
N
NH2
CN
Br
CN
N
H
O
N
Pd2(dba)3, ligand
 
 MW, Δ , 2 h
base
Figure 4  
     
4. Issa Yavari et al.6 synthesized of isoxazoles (Figure 5) through the reaction of 
activated acetylenes and alkyl 2-nitroethanoates in the presence of triphenylphosphine. 
PPh3
COMe
COMe EtO
O
NO2
P(Ph)3
reflux
O
N
MeOC CO2Et
MeOC
Figure 5  
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5. Jesse P. Waldo et al.7 have been synthesized of isoxazoles (Figure 6) via electrophilic 
cyclization under mild reaction conditions by the reaction of 2-alkyn-1-one O-methyl oximes 
with ICl, I2, Br2, or PhSeBr. 
Ph O
Ph
NH2OMe•HCl
Ph
N
Ph2
OMe E-X
O
N
Ph
Ph E
E-X = I2, ICl, Br2Figure 6  
 
6. David J. Burkhart et al.8 synthesized ethyl 4-acetyl-5-methyl-3-isoxazoyl carboxylate 
was smoothly lithiated at the 5-methyl position. The anion was quenched with a varity of 
electrophiles such as alkyl halides, aldehyde, TMSCl and Me3SnCl in good to excellent 
yields. 
NEtO2C
Cl
OH
O
O
NaOEt / EtOH
NO
O
CO2Et
Figure 7  
 
7. Keisuke Suzuki et al.9 have synthesized functionalized isoxazole derivatives (Figure 
8) by cyclocondensation of C-chlorooximes with cyclic 1,3-diketones. 
O
Cl
N
OH
O O
PrOH
Nao/Pr
O N O
O
Figure 8  
 
8. Solid phase synthesis of isoxazole derivatives based on amino acids was reported by 
Lidia De Luca and co-workers10 in the presence of basic catalyst and dichloromethane used 
as a solvent. One-pot syntheses of polyfunctionalized isoxazoles11 have been reported by the 
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reaction of dipyrrolidinium 3, 3-dimethylpentanedinitrile- 2, 4-dinitronate and acetyl chloride 
in benzene.  
 
9. Mark Lauten et al.12 have been prepared highly functionalized isoxazoles (Figure 9) 
by the reaction of N-acetoacetyl derivatives and hydroxyl amine hydrochloride in              
methanol. 
R
O
H
O
X
R
O
N
X
R R
NH2OH•HCl
NaOAc , MeOH
R=Me,Et
X=N(CH3)2
Figure 9
 
  
10. V. P. Kislyi et al.13 were prepared 4-amino-5-benzoyl (acetyl) isoxazole-3-
carboxamides (Figure 10) by cyclization of α-hydroxyimino nitriles O-alkylated with 
bromoaceto-phenones (bromoacetone). The purity of the target 4-aminoisoxazoles can be 
substantially increased by treating O-alkylated oximes with LiClO4 before cyclization. 
COOEtNC
N
OCH2COC6H4Br
LiOH, LiClO4 , 5%
EtOH
N
O
EtOOC NH2
C6H4Br
O
Figure 10  
 
11. Wolfgang Holzer et al.14 have synthesized 1,3-disubstituted 4-benzoyl-5-
hydroxypyrazoles with phosphorusoxytrichloride affords the corresponding 4-benzoyl-5-
chloropyrazoles. Reaction of the latter with hydroxylamine leads to oximes, which can be 
cyclized to novel 3-phenyl-6H-pyrazolo [4, 3-d] isoxazoles (Figure 11) by treatment with 
sodium hydride in dimethylformamide. 
OH
NOH
H
Cl3CCONCO
 
K2CO3, THF
O
NR
R
R= H, Me, PhFigure 11  
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12. Matthew P. Bourbeau et al.15 have been synthesized series of 4-alkyl-5-
aminoisoxazoles (Figure 12) in high yield by nucleophilic addition of lithiated alkyl nitriles 
to α-chlorooximes. The scope and limitations of this reaction were examined by varying the 
nature of the nitrile and chloride oxime. 
R Cl
N
HO
R' CN
tBuLi
-78 oC
15 min
N
O
NH2
R'
R
R= aryl, heteroaryl, alkyl
R' = alky, aryl, benzyl
Figure 12
 
 
13. Kewei Wang et al.16 synthesized of efficient and divergent one-pot synthesis of fully 
substituted isoxazoles in the presence of POCl3/CH2Cl2, (Figure 13) were obtained from the 
cyclopropyl oximes via ring-opening and intramolecular nucleophilic vinylic substitution 
(SNV) reactions. 
R NHAr
ON
HO
POCl3 /CH2Cl2
rt
N O
NHAr
CH2CH2Cl
R
R = Me, Ph
Figure 13
 
 
14. Haifeng Duan et al.17 synthesized of a catalytic cascade synthesis of isoxazoline-N-
oxide (Figure 14) was developed through proline-catalyzed nitroalkene activation. A large 
substrate scope was obtained with good to excellent yields. Mechanistic studies revealed 
intramolecular cyclization as the rate-determining step, giving only trans isomers in all cases. 
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NO2
Ph
OAc
20% Proline, NaOAc
DMSO, rt, 10 h
N+ O
--O
Ph Ph
Figure 14
 
 
15. Giuseppe Daidone et al.18 have synthesized several new 3-(isoxazol-3-yl)-quinazolin-
4(3H)-one derivatives (Figure 15). Thus, synthesized starting from the 2-nitroaroyl chlorides 
and 3-amino-5-methylisoxazole in anhydrous chloroform. When compounds were treated 
with stannous chloride in aqueous hydrochloric acid the corresponding N-(5-methylisoxazol-
3-yl)-2-aminobenzamide derivatives (Figure 15) were obtained. 
COCl
NO2
N
O
H2N
SnCl2 in con.HCl
NO2
O
N
H
ON
Figure 15  
 
16. Okram Mukherjee Singh et al.19 have synthesized the regioselective synthesis of 
isomeric isoxazoles 3-(2-arylcyclopropyl)-5-methylthio and 5-(2-arylcyclopropyl)-3-
methylthio-isoxazoles is described (Figure 16). 
H
R1
H
R
O
SMe
SMe
H
H
R
N
O
MeS R1
H
H
R
N
O
R1
SMe
R= Ph, 4-MeOC6H4, 4-ClC6H4
R1= H
NH2OH•HCl-NaOMe -MeOH
NH2OH•HCl-NaOAc -AcOH
H2O /C6H6
Figure 16
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5.3 Mechanism 
In dioxoketene dithioacetals systems the carbonyl carbon and β-carbon atoms can 
also be regarded as hard and soft electrophilic centers, since the carbonyl is adjacent to the 
hard-base oxygen while the β-carbon is flanked by the soft-base thiomethyl groups20 (Figure 
17). Thus, the nucleophile of hydroxylamine hydrochloride attack on β-carbon of systems 
and formed heterocyclic product by removal of thiomethyl group as good leaving group.   
PhHN
O
SMeMeS
NH2OH
PhHN
O−
SMeMeS
N+
H
H
OH
PhHN
O
SMeMeS
N
H
OHH
N
H
O+
SMeMeS
−N
H
H OH
−H2O
PhHN
N
OH
SMe
MeS
O
N
SMe
PhHN H
-MeSH
Ph
O
N
S
PhHN
α
β
Soft electrophile
Hard electrophile
Figure 17  
 
5.4 Biological activity of isoxazole 
 The biological activity of substituted isoxazoles21 has made them a focus of medicinal 
chemistry over the years. Isoxazoles are potent, selective agonists at human cloned dopamine 
D4 receptors22 and  exhibit GABAA antagonist,23 analgesic,24 antiinflammatory,24 
ulcerogenic,24 antimicrobial,25 antifungal,25 COX-2 inhibitory,26 antinociceptive,27 and 
anticancer28 activity. 
 
5.4.1 Cyclooxygenase-2 (COX-2) inhibitors 
 Some N-phenyl and N-benzyl-substituted (Figure 18) amido analogs of 
cyclooxygenase (COX-2) selective tricyclic non-steroidal anti-inflammatory drugs have been 
synthesized with the aim to obtain information on the structural requirements for the COX-
inhibitory activity29. Compounds were tested in vitro for their inhibitory properties only 
towards COX-2 enzyme by measuring prostaglandin E2 (PGE2) production on activated 
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J774.2 macrophages. Some of the new compounds showed a modest activity, with 
percentage inhibition values near 30% at a concentration of 10 μM. These data have been 
tentatively explained by a conformational study which indicates that at least the N-phenyl-
substituted amides present steric hindrances which may prevent a good interaction with 
COX-2 active site. 
O
N
O
N
H
Ph
SO2Me
O
N
O
N
H
SO2Me
Ph
Figure 18  
 For the new compounds (Figure 18) the inhibitory activity towards COX-2, which 
constitutes the ideal target of an anti-inflammatory drug, was evaluated in vitro by measuring 
the PGE2 production on activated J774.2 macrophages. The results were reported in Table 1 
together with those obtained in the same type of test with Celecoxib and with the previously 
studied cyclopentenyl and thienyl oxime-ethers. As it can be seen, only compounds (Figure 
18) at a concentration of 10 μM showed a modest activity, with percentage inhibition values 
close to 30%, while the other analogs resulted practically inactive. In the same experimental 
conditions, the benzyloxyimino-ethers showed IC50 values in the μM range. These data 
indicate that in the field of the analogs of the tricyclic anti-inflammatory drugs, an amidic 
group, either N-phenyl or N-benzyl-substituted, as the ones present in (Figure 18) is less 
effective than MAOMM in replacing the aryl lacking of sulfurated moiety of compounds. 
 Aldo Balsamo et al30 have repotted several heteroaromatic analogues of (2-aryl-1-
cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors (Figure 19), in which 
the cyclopentene moiety was replaced by pyrazole, thiophene or isoxazole ring, were 
synthesized, in order to verify the influence of the different nature of the central core on the 
COX inhibitory properties of these kinds of molecules. Among the compounds tested, only 
the 3-(p-methylsulfonylphenyl) substituted thiophene derivatives, showed a certain COX-2 
inhibitory activity, accompanied by an appreciable COX-2 versus COX-1 selectivity. Only 
one of the 1-(p-methylsulfonylphenyl)pyrazole compounds displayed a modest inhibitory 
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activity towards both type of isoenzymes, while the pyrazole 1-(p-aminosulfonylphenyl) 
substituted 12 proved to be significantly active only towards COX-1. All the isoxazole 
derivatives were inactive on both COX isoforms. 
O
N
S
O
O
Me
H
N
OR
Figure 19  
 Amgad G. Habeeb et al31 also repotted a 4,5-diphenyl-4-isoxazolines (Figure 20) 
possessing a variety of substituents (H, F, MeS, MeSO2) at the para position of one of the 
phenyl rings were synthesized for evaluation as analgesic and selective cyclooxygenase-2 
(COX-2) inhibitory anti-inflammatory (AI) agents. Although the 4,5-phenyl-4-isoxazolines 
(Figure 20), which do not have a C-3 Me substituent, exhibited potent analgesic and AI 
activities, those compounds evaluated  were not selective inhibitors of COX-2. In contrast, 
2,3-dimethyl-5-(4-methylsulfonylphenyl)-4-phenyl-4-isoxazoline exhibited excellent 
analgesic and AI activities, and it was a potent and selective COX-2 inhibitor (COX-1, IC50) 
258 μM; COX-2, IC50) 0.004 μM).  
O
N Me
R1
R2
R3
R1= H, Me
R2, R3=H, F, SMe, SO2Me
Figure 20  
 A related compound (Figure 20) having a F substituent at the para position of the 4-
phenyl ring was also a selective (SI =3162) but less potent (IC50 =0.0316 μM) inhibitor of 
COX-2 than 2,3-dihydro-2,3-dimethyl-5-(4-(methylsulfonyl)phenyl)-4-phenylisoxazole. A 
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molecular modeling (docking study) for 4-(4-fluorophenyl)-2,3-dihydro-2,3-dimethyl-5-(4-
(methylsulfonyl)phenyl)-4-phenylisoxazole showed that the S atom of the MeSO2 substituent 
is positioned about 6.46 Å  inside the entrance to the COX-2 secondary pocket (Val523) and 
that a C-3 Me (2,3-dihydro-2,3-dimethyl-5-(4-(methylsulfonyl)phenyl)-4-phenylisoxazole, 4-
(4-fluorophenyl)-2,3-dihydro-2,3dimethyl-5-(4-(methylsulfonyl)phenyl)-4-phenylisoxazole) 
central isoxazoline ring substituent is crucial to selective inhibition of COX-2 for this class of 
compounds. 
 John J. Talley et al32 have repotted N-[[(5-Methyl-3-phenylisoxazol-4-yl)- 
phenyl]sulfonyl]propanamide, sodium Salt, parecoxib sodium: A potent and selective 
inhibitor of COX-2 for parenteral administration. 
O
N
S
CH3NR
O
OO
−
Na
R= CH3, CH2CH3, CH2CH2CH3
Figure 21  
 
 Among the most potent and selective COX-2 inhibitors that have been identified is 
the isoxazole sulfonamide valdecoxib (Figure 21). Against recombinant human 
cyclooxygenase isoforms, showed the following activity: hCOX-1 IC50= 140 μM and hCOX-
2 IC50= 0.005 μM. In addition, sulfonamide valdecoxib possesses exceptional anti-
inflammatory activity in vivo.33 our strategy to develop an injectable COX-2 inhibitor 
commenced with the idea of identifying a water-soluble prodrug of sulfonamide valdecoxib 
that would undergo biotransformation in vivo. To test whether an acylated sulfonamide34,35 
would serve as a prodrug for sulfonamide valdecoxib. Against the recombinant isoforms of 
human cyclooxygenase, sodium salt of isoxazole was found to show very weak inhibitory 
activity, hCOX-1 IC50 →100 μM and hCOX-2 IC50 → 20 μM. However, in the carrageen an 
air pouch model of inflammation,36  showed potent anti-inflammatory activity after 
intravenous, intramuscular, or oral administration, ED50 = 0.5 mg/kg. 
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5.4.2 Antitumor and chemosensitizing activities 
 Curcumin (CUR) can be considered as a good lead compound for the design of new 
anticancer drugs. Further, structure–activity relationship studies may clarify the importance 
of the redox activities in the antitumor effects of the drug. We have elaborated the α,β-
unsaturated 1,3-diketone moiety of CUR into the isoxazole (ISO) derivatives (Figure 22).37 
These derivatives should be much less prone to nucleophilic addition than CUR and benzyl 
mercaptan addition analyses showed that indeed they do not form isolable conjugated 
products. When compared with CUR, ISO exhibited increased cell growth inhibitory and 
pro-apoptotic effects in liver cancer HA22T/VGH cells as well as in other tumor cell types; 
in contrast to CUR, the antitumor effects of ISO were not influenced by concomitant 
administration of N-acetylcysteine, as a source of -SH groups, or buthionine sulfoximine, as 
an inhibitor of glutathione synthesis. Further, treatment with CUR, but not with ISO, 
significantly decreased the content of reduced glutathione in the HA22T/VGH cells. Finally, 
ISO lacked the ability of the parent compound to sensitize the HA22T/VGH cells to cisplatin 
(CIS), an effect which appeared to occur through an interaction of CUR and CIS at the level 
of the –SH groups. Thus, the ability of interacting with cell thiols might not be requested for 
the more potent antitumor activities of new diketone modified CUR derivatives, which might 
rely on other mechanisms, though possibly devoid of chemosensitization capabilities. 
O N
HO OH
O O
CH3 CH3
Figure 22  
 Curcumin (diferuloylmethane) (CUR), a polyphenoliccompound extracted from 
Curcuma longa L. and present in curry spice, has a long story of use in Indian medicine for 
anti-inflammatory and other therapeutic purposes; it has exhibited definite tumor preventive 
and suppressive activities inmany in vitro or in vivo models.38 CUR is endowed with a 
diketone function, which appears to be important for its antitumor activity:39-41 also 
depending on the dose, the compound may show complex either pro-oxidant or anti-oxidant 
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effects, which both may, at least in part, be linked to this structural moiety.42-43 In the lower 
concentration, ‘chemo preventive’, range, CUR behaves mainly as an anti-oxidant, although 
this activity may possibly provide negative interactions with other chemotherapeutic 
agents.44-45 At higher concentrations, the α,β-unsaturated 1,3-diketone, as a Michael acceptor, 
can form adducts with the –SH groups and generate reactive oxygen species.46 This may lead 
to induction of apoptosis through different possible mechanisms involving loss of 
mitochondrial membrane potential, endoplasmic reticulum stress, activation of terminal 
caspases or also other mitochondria- and caspase-independent pathways.47-50 
 
5.4.3 Anti-HIV activity 
 As a continuation of efforts to replace the metabolically labile methyl esters of lead 
alkenyldiarylmethanes(ADAMs) with stable bioisosteres, compounds bearing 
benzo[d]isoxazole and oxazolidine-2- one rings were designed and evaluated as a new series 
of potent HIV-1 non-nucleoside reverse transcriptase inhibitors with anti-HIV activity. All of 
the resulting ADAMs were found to inhibit HIV-1 RT with poly (rC) oligo(dG) as the 
template primer. The most promising compound in this series was ADAM (Figure 23), with 
EC50 values of 40 nM (vs HIV-1RF) and 20 nM (vs HIV-1IIIB).51 Methyl 5-((Z)-5-
(methoxycarbonyl)-1-(3-methoxy-7-methylbenzo[d]isoxazole-5-yl)pent-1-enyl-2-methoxy-3-
methylbenzoate also inhibited HIV-1 reverse transcriptase with an IC50 of 0.91 μM. ADAM 4 
has an antiviral EC50 of 0.6 μM in CEM-SS cells and a plasma half-life of 51.4 min.  
N
O
H3CO
O
H3C
OCH3
CH3
OCH3H3COOC
Figure 23  
 Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of acquired 
immunodeficiency syndrome (AIDS), one of the world’s most serious health problems with 
about 33 million people infected worldwide in 2007. The reverse transcriptase (RT) of HIV-1 
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is an essential enzyme in HIV replication and has been a key target in anti-AIDS drug 
discovery. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine, 
delavirdine, and efavirenz have been approved by the Food and Drug Administration (FDA) 
for the treatment of AIDS.52 They are very useful drugs in combination therapy with 
nucleoside analogues (NRTIs) and protease inhibitors (PIs)53-54 for the treatment of AIDS. 
However, a number of problems still remain with these agents. In particular, significant 
resistance has developed against these drugs. Therefore, considerable effort has been 
expended to develop new NNRTIs that would overcome the current drug resistance. More 
than 30 structurally different classes of molecules have been reported as NNRTIs.52-54 
Recently, the NNRTI etravirine was approved by the FDA for treatment of antiretroviral 
drug-resistant HIV infections. The cytotoxicities of the newly synthesized ADAMs were 
determined along with their abilities to inhibit the cytopathic effect of HIV-1 in cell culture. 
The inhibition of HIV-1 RT by the ADAMs, and their metabolic stabilities in rat plasma were 
also investigated. 
 
5.4.4 GABAA  antagonists 
 A series of 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists have been 
synthesized and pharmacologically characterized.55 The meta-phenyl-substituted compounds 
and the para-phenoxy-substituted compound (Figure 24) all display high affinities (Ki = 10-
70 nM) and antagonist potencies in the low nanomolar range (Ki = 9-10 nM). These 
potencies are significantly higher than those of previously reported 4-PIOL antagonists and 
considerably higher than that of the standard GABAA antagonist SR 95531. 
 
HN O
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O
S
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O
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Figure 24  
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 4-Aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central 
nervous system, exerts its effect in the central nervous system through two different classes 
of receptors, the ion tropic GABAA and GABAC receptors and the metabotropic GABAB 
receptors. Especially the GABAA receptors have attracted much attention as therapeutic 
targets for the treatment of conditions such as anxiety, epilepsy, and sleep disorders.56  
 The GABAA receptor is a member of a super family of ligandgated ion channels, 
which also comprises the nicotinic acetylcholine, the glycine, and the serotonin (5-HT3) 
receptors. The GABAA receptor is a heteropentameric transmembrane allosteric protein 
complex, and in addition to the GABA recognition site, it contains a considerable number of 
separate but allosterically interacting binding sites. This is reflected in the structural diversity 
of compounds acting at the GABAA receptors, including important drugs such as 
benzodiazepines, neurosteroids, and barbiturates. 
 In contrast to the allosteric modulatory sites, the GABA binding site has very distinct 
and specific structural requirements for recognition and activation. Thus, very few different 
classes of structures have been reported. Within the series of compounds showing agonist 
activity at the GABAA receptor site are the selective GABAA agonists muscimol57 and 
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol,57-58 which have been used for the 
characterization of the GABAA receptors (Figure 24).59 Recently, 4,5,6,7-
tetrahydroisoxazolo[5,4-c]pyridin-3-ol has been shown to be functionally selective for a 
subpopulation of GABAA receptors and is currently in clinical trials as a therapeutic for the 
regulation of sleep. 
 
5.4.5 Antibacterial activity 
 The synthesis of 2,3,5-substituted perhydropyrrolo[3,4-d]isoxazole-4,6-diones  has 
been accomplished by the cycloaddition reaction of N-methyl-C-arylnitrones with N-
substituted maleimides.60 The compounds were screened for their antibacterial activities and 
most of them exhibited activity against Enterococcus faecalis (ATCC 29212) and 
Staphylococcus aureus (ATCC 25923). Figure 25 were found fairly effective against 
Enterococcus faecalis (ATCC 29212) and Staphylococcus aureus (ATCC 25923) with MIC 
values of 25 and 50 μg/ml. With the changes of cis isomers of the compounds to trans, their 
antibacterial activities also changed against the bacteria studied. First, pharmacophoric 
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fragments had been calculated in accordance with the rules of the electronictopological 
method (ETM). Next, both active compounds and pharmacophores had been projected to the 
nodes of Kohonen’s self-organizing maps (SOM) to obtain the weights of pharmacophore 
fragments as numerical descriptors, that were used after this for the associative neural 
networks (ASNN) training. A model for the activity prediction was developed as the result of 
training the ASNNs. 
N
O
N
O
O
R
N
O
N
O
O
R
H3C H3C CH3CH3
R= p-Et2NC6H4 R= 4-BzO-3-MeOC6H3
Figure 25  
 
5.4.6 Anticonvulsant activity 
 Due to the exceptional anticonvulsant activity displayed by substituted aniline 
enaminones, related pyridine derivatives61 and phenothiazines synthesized, the further 
investigation of various aromatic heterocycles was undertaken. Condensation of cyclic 1,3-
diketo esters with 3 and 5 aminoisoxazole derivatives led to a series of potent anti-maximal 
electroshock (MES) analogues, three of which occurred in the 3-amino series: ethyl ester, 
orally (po) active in rats [ED50 68.9 mg kg−1, TD50 > 500 mg kg−1, protective index 
(PI=TD50/ED50) > 49.6]; methyl ester, ED50 68.9 mg kg−1 intraperitoneally (ip) in mice, TD50 
>500 mg kg−1, PI >7.3, and tert-butyl ester, ED50 28.1 mg kg−1 po in rats, TD50 > 500 mg 
kg−1, PI > 17.8. Sodium channel binding studies, as well as evaluations against 
pentylenetetrazol, bicuculline, and picrotoxin on isoxazole were all negative, leading to an 
unknown mechanism of action. X-ray diffraction patterns of a representative of the 3-amino 
series (Figure 26) unequivocally display the existence of intramolecular hydrogen bonding 
of the nitrogen to the vinylic proton in the cyclohexene ring, providing a pseudo three ring 
structure which was also shown previously with the vinylic benzamides. Physicochemical-
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permeability across the BBB suggested an efflux mechanism for the previously synthesized 
aniline enaminones, but not with isoxazole. 
HN N
O
OH3C
CO2R
R1
R = CH3, C2H5
R1= H, CH3
Figure 26  
 
5.4.7 Antithrombotic activity 
 The 3-substituted phenyl-5-isoxazolecarboxaldehydes62 has been identified as 
activated aldehydes for the generation of isoxazole-based combinatorial libraries on solid 
phase through automation. Three highly functionalized isoxazole-based libraries comprising 
of (Figure 27) compounds each have been synthesized in parallel format using Baylis 
Hillman reaction, Michael addition, reductive amination and alkylation reactions. With an 
objective of lead generation all the three libraries were evaluated for their antithrombin 
activity in vivo. 
N
O
N
R
H2N O
R1
R2
R= CH2Ph, (CH2)4NH2
R1=H, - 4CH3, -2Cl
R2=H, - 4CN, - 4Br
Figure 27  
 Some of the biological activities ascribed to isoxazole derivatives includes 
antithrombotic, PAF antagonist, hypolipidemic, nootropic, immunomodulator, antiviral, 
antiobesity and CNS modulation.63 The substituted isoxazoles, are also considered to be 
important synthons due to their versatility towards chemical transformations to useful 
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synthetic intermediates such as 1,3-dicarbonyl, 1,3-iminocarbonyl and γ-amino alcohols. The 
significance of this class of molecules gets further impetus due to their involvement as 
intermediates in the synthesis of various natural products.64 All the compounds obtained were 
evaluated for their antithrombotic activity in vivo.  Swiss mice (20–25 g, from CDRI animal 
colony) were used in a group of at least 10 animals each. Thrombosis was induced by 
infusion of a mixture of 15 mg collagen and 5 mg adrenaline in a volume of 100 mL into the 
tail vein of each mouse. This resulted either death or hind limb paralysis of 100% animals. 
The compounds were administered at 30 μmol/kg by oral route 1 h prior to the thrombotic 
challenge. The antithrombotic effects of these compounds were assessed by the percentage 
protection offered by these agents to mice from death or paralysis following thrombotic 
challenge using aspirin as a standard. 
 
5.4.8 Antinociceptive activity 
 A number of arylpiperazinylalkylpyridazinones65 structurally related to the previously 
described lead A (Figure 28) (5-{[4-(3-chlorophenyl)piperazin-1-yl]-propyl}-3-methyl-7-
phenylisossazolo[4,5-d]pyridazin-4-(5H)-one) were synthesized and tested for their analgesic 
activity. Many of the tested molecules, at the dose of 20 mg kg-1 p.o., showed high 
antinociceptive activity, in particular, substituted lead a compound which was able to reduce 
the number of abdominal constrictions by more than 50% in writhing test. The 
pharmacological investigation of lead (Figure 28) led us to clarify the mechanism of action 
of this compound, showing that it carries out its analgesic action through the inhibition of 
reuptake of noradrenaline. The antinociception of some of the most interesting new 
molecules was completely prevented by pretreatment with α2-antagonist yohimbine, 
suggesting the involvement of α2-adrenoceptors, as with prototype (Figure 28). 
NN
N
O
O
H3C
(H2C)3 N N
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Figure 28  
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 The present results indicate the involvement of α2-adrenoceptor and, in particular, of 
the subtype α2A. (Figure 28) increases the pain threshold, and this effect is imputable to an 
amplification of adrenergic neurotransmission due to an inhibition of noradrenaline uptake. 
 
5.4.9 Potent dual inhibitor of p38α 
 Christian Peifer et al66 reported on the discovery of isoxazole (Figure 29) as a potent 
dual inhibitor of p38α (IC50= 0.45 μM) and CK1δ (IC50= 0.23 μM). Because only a few 
effective small molecule inhibitors of CK1 have been described so far, we aimed to develop 
this structural class toward specific agents. Molecular modeling studies comparing 
p38α/CK1δ suggested an optimization strategy leading to design, synthesis, biological 
characterization, and SAR of highly potent compounds including possessing differentiated 
specificity. Selected compounds were profiled over 76 kinases and evaluation of their 
cellular efficacy showed 18 (CKP138) to be a highly potent and dual-specific inhibitor of 
CK1δ and p38α. 
O
N
N
F
Figure 29  
 Small molecule inhibitors of various protein kinases are utilized extensively in 
research and drug development. The human kinome consists of more than 500 protein 
kinases, and kinase inhibitors typically bind in the highly conserved ATP pocket of these 
enzymes.67 Thus the specificity of ATP competitive kinase inhibitors is of significant interest 
and represents a crucial factor for their use in, e.g., signal transduction research or therapeutic 
applications. 
  
5.5 Aim of current work 
 The biological activity of substituted isoxazoles21 has made them a focus of medicinal 
chemistry over the years. Isoxazole are potent, selective agonists at human cloned dopamine 
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D4 receptors22 and  exhibit GABAA antagonist,23 analgesic,24 antiinflammatory,24 
ulcerogenic,24 antimicrobial,25 antifungal,25 COX-2 inhibitory,26 antinociceptive,27 and 
anticancer28 activity. 
 Many synthetic methods have been employed in the synthesis of isoxazoles,68 
including reactions of hydroxylamine with 1,3-dicarbonyl compounds,69 α,β-unsaturated 
carbonyl compounds,70 and α,β-unsaturated nitriles.71 The reaction of an oxime-derived 
dianion and an ester72 or amide73 also provides isoxazoles. [3 + 2] Cycloaddition reactions 
between alkynes and nitrile oxides have also been developed.74 Ketene dithioacetals bearing 
the cyano, amide, thioamide, or alkoxycarbonyl group at the α-position are extremely 
interesting electrophilic reagents for the introduction of three or two carbon units into the 
ring of heterocyclic compounds.75, 76 
Figure 30
R= aryl
R
HN O
O N
MeS
 
 We have recently developed different successful approaches for synthesis of new 
ketene S,S-acetals as starting from acetoacetanilides (2a-s).  In an extension of this work, we 
are now reporting a synthesis of some novel ketene S,S-acetals and their use in the synthesis 
of functionalized isoxazole derivatives (4a-s) (Figure 30). 
 
5.6 Chemistry 
 α-Oxoketene dithioacetals (Figure 31, 32, 33) especially the dimethylthioacetals  
have recently received considerable attention due to their synthetic importance for the 
construction of a variety of alicyclic, aromatic and heterocyclic compounds.77, 78 Ketene 
dithioacetals, in the presence of various regents, undergo different types of reactions to yield 
other heterocyclic compounds, e.g., isoxazole, pyrazole, thiophenes, pyrimidines, pyridines, 
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etc. Consequently we were interested in surveying the synthetic utility of ketene 
dithioacetals. 
R1
R2 O
SMe
SMe
R1
R2 O
S
S
R1
R2 O
SBn
SBn
Ketene dithioacetals
Figure 31 Figure 32 Figure 33
 
 The method for preparation of α-oxoketene dithioacetals is common, the combination 
of an active methylene/methyl substrate, CS2, RX, and a suitable base. Lawesson and 
Larsson,79-81 Junjappa and Ila82 have reported the synthesis of mixed dialkylketene 
dithioacetals from dithioesters which were prepared from ketone and dimethyl 
trithiocarbonate.83 
R
NHO
SMe O
MeS
R
NHO
O N
MeS
Figure 34 Figure 35
R= aryl amine
 
 
5.7 Result and discussion 
  Various substituted 4-methyl-3-oxo-N-phenylpentanamide (2a-s) were 
prepared by reacting substituted amines and methyl-4-methyl-3-oxopentanoate in toluene 
with a catalytic amount of NaOH or KOH (Scheme 1). The reaction mixture was reflux for 
15-20 h. Fifteen different acetoacetanilide were synthesized bearing various electron 
donating and electron withdrawing groups like 2,3-diCH3; 3,4-diCH3; 4-CH3; H; 2,5-diCH3; 
2,4-diCH3; 3-Cl-4-F; 4-F; 4-Cl; 2-Cl; 2-F; 4-OCH3; 2,5-diCl and 3-NO2 on the phenyl ring.  
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Thus, it has been found that reaction of substituted acetoacetanilide (2a-s) derivatives 
(Scheme 1) with carbon disulfide in the presence of potassium carbonate followed by the 
alkylation with methyl iodide gives the novel ketene dithioacetals (Figure 34, 3a-s), when 
3a-s was reacted with hydroxylamine hydrochloride in refluxing ethanol, the corresponding 
3-isopropyl-5-(methylthio)-N-arylisoxazole-4-carboxamide derivatives (Figure 35, 4a-s) was 
obtained in 85 to 90% yield. 
The structures of 4a-s were established on the basis of their elemental analysis and 
spectral data (MS, IR, and 1H NMR). The analytical data for 3a revealed a molecular formula 
C16H21NO2S2 (m/z 323). The 1HNMR spectrum revealed a doublet at δ = 1.18-1.20 ppm 
assigned to isopropyl-CH3, a singlet at δ = 1.57 ppm assigned to the –CH3 protons, a two 
singlet at δ = 2.44 ppm assigned to (2 × SCH3), a multiplet at δ = 3.17-3.24 ppm assigned to 
the isopropyl-CH protons, a multiplet at δ = 6.99–7.54 ppm assigned to the aromatic protons, 
and one broad singlet at δ = 8.38 ppm assigned to -CONH groups. Reaction of compounds 
3a-s with hydroxylamine hydrochloride in refluxing ethanol gave the corresponding 3-
isopropyl-5-(methylthio)-N-arylisoxazole-4-carboxamide derivatives 4a-s. The structures of 
4b were established on the basis of their elemental analysis and spectral data (MS, IR, 1H 
NMR, and 13C NMR). Structure 4a was supported by its mass (m/z 294), which agrees with 
its molecular formula C14H15FN2O2S; its 1H NMR spectrum had signals at δ= 1.22-1.23 ppm 
(2 × CH3), δ= 2.62 ppm (SCH3), a multiplet at δ = 4.04-4.08 ppm assigned to the isopropyl-
CH protons, a signal at δ = 7.14–7.64 ppm (m, 4H, Ar) related to the aromatic protons, 10.21 
(br, s, -CONH). 
 
5.8 Conclusion 
 In summary, we have achieved a novel synthesis of interesting 4-methyl-3-oxo-N- 
phenylpentanamide (acetoacetanilide, 2a-s), ketene S,S-acetals and their conversions to 
several 3-isopropyl-5-(methylthio)-N-arylisoxazole-4-carboxamide derivatives (4a-s) which 
have both chemical and biological potential. 
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5.9 Reaction scheme of 2-(bis (methylthio)methylene)-4-methyl-3-oxo-N- 
arylpentanamide(2a-s), dithioacetals(3a-s) and 3-isopropyl-5-(methylthio)-N-
arylisoxazole-4-carboxamide derivatives (4a-s). 
NH2 MeO
O
NaOH / KOH
Toluene, reflux, 
 15-20 h
H
N
O OO
2a-s1a-s
R
R
1) K2CO3/DMF/RT
2) CS2
3) CH3INHO
O
R
NHO
OSMe
MeS
R
2a-s 3a-s
H2NOH•HCl / EtOH
NHO
O N
MeS
R
4a-s
Scheme 1
Scheme 2
Δ / 3-5 h
R=H, CH3, OCH3, Cl, F, NO2
 
5.10 Experimental procedure 
 Melting points were determined on an electro thermal apparatus using open 
capillaries and are uncorrected. Thin-layer chromatography was accomplished on 0.2-mm 
precoated plates of silica gel G60 F254 (Merck). Visualization was made with UV light (254 
and 365nm) or with an iodine vapor. IR spectra were recorded on a FTIR-8400 
spectrophotometer using DRS prob. 1H NMR spectra were recorded on a Bruker AVANCE 
II (400 MHz) spectrometer in DMSO. Chemical shifts are expressed in δ ppm downfield 
from TMS as an internal standard. Mass spectra were determined using direct inlet probe on 
a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were evaporated with a BUCHI 
rotary evaporator.  
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5.10.1 General synthesis of 4-methyl-3-oxo-N-phenylpentanamide (2a-s) 
 A mixture containing the primary amine (10 mmol), methyl isobutyrylacetate (10 
mmol), and catalytic amount of sodium or potassium hydroxide lie (10 %) was reflux at 110 
oC for the approximately 15-20 h. The reaction was monitored by TLC. After completion of 
reaction, the solvent was removed under vaccuo when the reaction was completed. The solid 
or oil was crystallized from methanol to give pure product (2a-s). 
 
5.10.2 General Synthesis of ketene dithioacetals (3a-s) 
 A 100mL conical flask equipped with magnetic stirrer and septum was charged with a 
solution of 4-methyl-3-oxo-N-phenylpentanamide (2a-s, 10 mmol) in DMF (10 mL). Dried 
K2CO3 (10 mmol) was added and the mixture was stirred for 2 h at room temperature. CS2 
(30 mmol) was added and the mixture was stirred for an additional 2 h at room temperature. 
Methyl iodide (20 mmol) was then added and the mixture was stirred for 4 h before being 
poured onto water (40 mL). The precipitated crude product was purified by filtration 
followed by crystallization from EtOH. When the product was oil, the organic phase was 
extracted with Et2O (3 × 10 mL). The combined organic extracts were washed with H2O (2 × 
10 mL), dried (MgSO4), and concentrated in vaccuo to afford ketene dithioacetals directly 
used for the next step. 
 
5.10.3 General synthesis of 3-isopropyl-5-(methylthio)-N-arylisoxazole-4-
carboxamide derivatives (4a-s) 
 A 100mL round-bottom flask equipped with condenser and septum was charged with 
a solution of ketene dithioacetals (3a-s, 10.0 mmol) in isopropyl alcohol (30 mL), followed 
by the hydroxylamine hydrochloride (10.0 mmol) was added and the mixture was reflux for 4 
h at 90 oC. The reaction was monitored by TLC, after completion the reaction mixture was 
then cooled down to room temperature, poured into crushed ice and stirred for 1 h before 
usual standard work-up. When the product was oil, the organic phase was extracted with 
diethyl ether (3 × 100 mL). The combined organic extracts were washed with H2O (2 × 100 
mL), dried (MgSO4), concentrated in vaccuo, and purified on silica gel with ethyl acetate-
hexane (9:1) as eluant. When precipitated, the product was filtered, washed with water, and 
purified by recrystallization from ethanol to give pure product (4a-s). 
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5.11 Spectral data of synthesized compounds (3a-s & 4a-s) 
2-(bis(methylthio) methylene)-4-methyl-3-oxo-N-p-tolylpentanamide 3a. yellow solid, 
yield 90%, mp 155-158°C; Anal. Calcd for C16H21NO2S2: C, 59.41; H, 6.54; N, 4.33; Found: 
C, 59.33; H, 6.45; N, 4.23; m/z:323 [M+]; 1H NMR (400 MHz, DMSO): δ ppm 1.18-1.20 (m, 
6H, 2 × iprCH3), 1.57 (s, 3H, CH3),  2.44 (s, 6H, 2 × SCH3), 3.17-3.24 (m, 1H, iprCH), 6.99–
7.54 (m, 4H, Ar), 8.38  (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 3370, 3071, 2895, 2820, 1693 
1635, 1480, 1340, 1298.  
 
2-(bis(methylthio)methylene)-N-(4-methoxyphenyl)-4-methyl-3-oxopentanamide 3p. 
yellow solid, yield 92%, mp 169-171°C; Anal. Calcd for C16H21NO3S2: C, 56.61; H, 6.24; N, 
4.13; Found: C, 56.53; H, 6.14; N, 4.06; m/z:339 [M+]; 1H NMR (400 MHz, DMSO): δ ppm 
1.18-1.20 (m, 6H, 2 × iprCH3), 2.44 (s, 6H, 2 × SCH3), 3.17-3.24 (m, 1H, iprCH), 3.75 (s, 
3H, OCH3), 6.99–7.54 (m, 4H, Ar), 8.38  (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 3373, 3072, 
2895, 2828, 1694, 1635, 1482, 1343, 1298.  
 
3-isopropyl-5-(methylthio)-N-p-tolylisoxazole-4-carboxamide 4a. white solid, yield 82%, 
mp 178–180°C; Anal. Calcd for C15H18N2O2S: C, 62.04; H, 6.25; N, 9.65; Found: C, 61.93; 
H, 6.14; N, 9.53; m/z:290 [M+]; 1H NMR (400 MHz, CDCl3): δ ppm 1.21-1.22 (d, J = 6.92 
Hz, 6H, 2 × iprCH3), 2.34 (s, 3H, CH3), 2.73 (s, 3H, SCH3), 3.80-3.90 (m, 1H, iprCH), 7.10–
7.80 (m, 4H, Ar), and 8.0 (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 3439, 3007, 2928, 2808, 
1599, 1462, 1327, 1255, 13C NMR (400 MHz, CDCl3): 15.00, 20.16, 20.88, 20.98, 26.83, 
27.57, 50.86, 109.62, 111.20, 120.18, 129.60, 134.82, 156.49, 158.93, 165.97, 169.45, 
182.80.   
 
N-(4-fluorophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4b. Off-white 
solid, yield 85%, mp 188–190°C; Anal. Calcd for C14H15FN2O2S: C, 57.13; H, 5.14; N, 9.52; 
Found: C, 57.01; H, 5.00; N, 9.45; m/z:294 [M+]; 1H NMR (400 MHz, DMSO): δ ppm 1.22-
1.23 (d, J = 6.92 Hz, 6H, 2 × iprCH3), 2.62 (s, 3H, SCH3), 4.04-4.08 (m, 1H, iprCH), 7.15–
7.64 (m, 4H, Ar), and 10.21 (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 3373, 3072, 2895, 2828, 
1694, 1635, 1482, 1343, 1298.  
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3-isopropyl-N-(2,3-dimethylphenyl)-5-(methylthio)isoxazole-4-carboxamide 4c. off white  
solid, yield 84%, mp 191–192°C; Anal. Calcd for C16H20N2O2S: C, 63.13; H, 6.62; N, 9.20; 
Found: C, 63.05; H, 6.54; N, 9.13; m/z:304 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3072, 2895, 
2828, 1694, 1635, 1482, 1343, 1298.   
 
3-isopropyl-N-(2,4-dimethylphenyl)-5-(methylthio)isoxazole-4-carboxamide 4d. Off- 
white solid, yield 81%, mp 201–202°C; Anal. Calcd for C16H20N2O2S: C, 63.13; H, 6.62; N, 
9.20; Found: C, 63.05; H, 6.54; N, 9.13; m/z:304 [M+]; IR (KBr), ν(cm-1): 3382, 3070, 2897, 
2827, 1698, 1638, 1480, 1342, 1291.   
 
3-isopropyl-N-(2,5-dimethylphenyl)-5-(methylthio)isoxazole-4-carboxamide 4e. Off- 
white  solid, yield 79%, mp 213–215°C; Anal. Calcd for C16H20N2O2S: C, 63.13; H, 6.62; N, 
9.20; Found: C, 63.05; H, 6.54; N, 9.13; m/z:304 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3072, 
2895, 2828, 1694, 1635, 1482, 1343, 1298.   
 
N-(2-chlorophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4f. white solid, 
yield 80%, mp 187–188°C; Anal. Calcd for C14H15ClN2O2S: C, 54.10; H, 4.86; N, 9.01; 
Found: C, 54.01; H, 4.72; N, 8.91; m/z:310 [M+]; IR (KBr), ν(cm-1): 3480, 3373, 3071, 2895, 
2828, 1694, 1638, 1481, 1343, 1298.   
 
N-(3-chlorophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4g. white solid, 
yield 74%, mp 202–204°C; Anal. Calcd for C14H15ClN2O2S: C, 54.10; H, 4.86; N, 9.01; 
Found: C, 54.01; H, 4.72; N, 8.91; m/z:310 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3072, 2895, 
2828, 1694, 1635, 1482, 1343, 1298. 
    
N-(4-chlorophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4h. white solid, 
yield 75%, mp 212–214°C; Anal. Calcd for C14H15ClN2O2S: C, 54.10; H, 4.86; N, 9.01; 
Found: C, 54.01; H, 4.72; N, 8.91; m/z:310 [M+]; 1H NMR (400 MHz, DMSO): δ ppm 1.21-
1.22 (d, J = 6.92 Hz, 6H, 2 × iprCH3), 2.63 (s, 3H, SCH3), 4.04-4.11 (m, 1H, iprCH), 7.16–
7.64 (m, 4H, Ar), and 10.20 (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 3488, 3371, 3078, 2896, 
2827, 1694, 1637, 1481, 1342, 1298.    
     
  178 
 
 
N-(2,6-dichlorophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4i. white 
solid, yield 71%, mp 228–230°C; Anal. Calcd for C14H14Cl2N2O2S: C, 48.70; H, 4.09; N, 
8.11; Found: C, 48.58; H, 4.0; N, 8.01; m/z:344 [M+]; IR (KBr), ν(cm-1): 3382, 3373, 3172, 
2995, 2928, 1694, 1635, 1482, 1343, 1298.   
 
N-(2-bromophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4j. Off-white 
solid, yield 80%, mp 202-204°C; Anal. Calcd for C14H15BrN2O2S: C, 47.33; H, 4.26; N, 7.89; 
Found: C, 47.23; H, 4.18; N, 7.79; m/z:355 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3018, 2895, 
2829, 1694, 1635, 1482, 1343, 1298.   
 
N-(3-bromophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4k. Off-white 
solid, yield 77%, mp 212-213°C; Anal. Calcd for C14H15BrN2O2S: C, 47.33; H, 4.26; N, 7.89; 
Found: C, 47.23; H, 4.18; N, 7.79; m/z:355 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3020, 2895, 
2828, 1694, 1635, 1482, 1343, 1298.   
 
N-(4-bromophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4l. Off-white 
solid, yield 74%, mp 230-232°C; Anal. Calcd for C14H15BrN2O2S: C, 47.33; H, 4.26; N, 7.89; 
Found: C, 47.23; H, 4.18; N, 7.79; m/z:355 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3072, 2895, 
2828, 1698, 1635, 1482, 1343, 1298.   
 
N-(2-nitrophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4m. Off-white 
solid, yield 71%, mp 205-207°C; Anal. Calcd for C14H15N3O4S: C, 52.33; H, 4.70; N, 13.08; 
Found: C, 52.26; H, 4.61; N, 13.00; m/z:321 [M+]; IR (KBr), ν(cm-1): 3374, 3072, 2895, 
2830, 1694, 1631, 1486, 1348, 1298.   
 
N-(3-nitrophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4n. Off-white 
solid, yield 72%, mp 220-221°C; Anal. Calcd for C14H15N3O4S: C, 52.33; H, 4.70; N, 13.08; 
Found: C, 52.26; H, 4.61; N, 13.00; m/z:321 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3072, 
2895, 2828, 1694, 1635, 1482, 1343, 1298.   
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N-(4-nitrophenyl)-3-isopropyl-5-(methylthio)isoxazole-4-carboxamide 4o. Off-white 
solid, yield 72%, mp 225-227°C; Anal. Calcd for C14H15N3O4S: C, 52.33; H, 4.70; N, 13.08; 
Found: C, 52.26; H, 4.61; N, 13.00; m/z:321 [M+]; IR (KBr), ν(cm-1): 3381, 3072, 2865, 
2828, 1694, 1635, 1482, 1343, 1298.   
 
3-isopropyl-N-(4-methoxyphenyl)-5-(methylthio)isoxazole-4-carboxamide 4p. white 
solid, yield 80%, mp 213-216°C; Anal. Calcd for C15H18N2O3S: C, 58.80; H, 5.92; N, 9.14; 
Found: C, 58.79; H, 5.83; N, 9.03; m/z:306 [M+]; IR (KBr), ν(cm-1): 3482, 3073, 2895, 2828, 
1694, 1635, 1482, 1343, 1298.   
 
N-(3-chloro-4-fluorophenyl)-3-isopropyl-5(methylthio)isoxazole-4-carboxamide 4q. 
white solid, yield 76%, mp 227-228°C; Anal. Calcd for C14H14ClFN2O2S: C, 51.14; H, 4.29; 
N, 8.52; Found: C, 51.01; H, 4.19; N, 8.43; m/z:305 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 
3072, 2895, 2828, 1694, 1635, 1482, 1343, 1298.   
 
N-(3,4-difluorophenyl)-3-isopropyl-5(methylthio)isoxazole-4-carboxamide 4r. Off-white 
solid, yield 78%, mp 222-224°C; Anal. Calcd for C14H14F2N2OS: C, 53.84; H, 4.52; N, 8.97; 
Found: C, 53.75; H, 4.43; N, 8.90; m/z:312 [M+]; IR (KBr), ν(cm-1): 3482, 3373, 3072, 2898, 
2842, 1694, 1635, 1481, 1343, 1298.   
 
N-(4-ethylphenyl)-3-isopropyl-5(methylthio)isoxazole-4-carboxamide 4s. White solid, 
yield 82%, mp 209-211°C; Anal. Calcd for C16H20N2O2S: C, 63.13; H, 6.62; N, 9.20; Found: 
C, 63.03; H, 6.53; N, 9.13; m/z:304 [M+]; 1H NMR (400 MHz, CDCl3): δ ppm 1.22 (t, 3H, 
PhCH2CH3), 1.36-1.38 (d, J = 7.08 Hz, 6H, 2 × iprCH3), 2.62 (s, 3H, SCH3), 3.99-4.06 (m, 
1H, iprCH), 7.27–7.65 (m, 4H, Ar), and 10.65 (br, s, 1H, -CONH); IR (KBr), ν(cm-1): 3482, 
3373, 3072, 2894, 2827, 1694, 1634, 1482, 1343, 1298. 
 
 
5.12 Spectral representation of synthesized compounds 
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5.12.1 1H NMR spectrums compound of 3a 
 
5.12.2 1H NMR spectrums compound of 3p 
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5.12.3 1H NMR spectrums compound of 4a 
 
5.12.4 1H NMR spectrums compound of 4b 
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5.12.5 Mass spectra of compounds 4a 
 
5.12.6 Mass spectra of compounds 4b 
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5.12.7 Mass spectra of compounds 4j 
 
5.12.8  13C NMR spectrums compound of 4a 
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5.12.9  IR spectrums compound of 4a 
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Summary of the present work 
 
The work to be presented in the thesis entitled “DESIGN, SYNTHESIS, 
CHARACTERIZATION & BIOLOGICAL ACTIVITIES OF FEW HETEROCYCLIC 
COMPOUNDS” is divided into five chapters.  
 
In Chapter-1, Synthesis and characterization of novel 2-aryl-3-(3,3-
diphenylpropyl)thiazolidin-4-ones derivatives is reported. This chapter deals with the 
thiazolidinones and its derivatives are an important class of heterocyclic compounds 
because of their broad spectrum of biological activities, such as COX-1 inhibition, anti-
inflammatory, antiproliferative, antihistaminic, and anti-HIV activities. 
In the present chapter, efforts have been made for the synthesis of novel 2-aryl-3-
(3,3-diphenylpropyl)thiazolidin-4-ones derivatives. The targeted compounds were 
prepared by three component one pot reaction of 3,3-diphenyl propylamine, 
mercaptoacetic acid and appropriate aldehyde under conventional methods. We also 
found that the targeted compound can be synthesized in excellent yields through green 
chemistry approach by utilizing Fuller’s earth as solid support through microwave 
irradiation technique. The newly prepared compounds were characterized by Mass, IR, 
1H NMR, and 13C NMR spectroscopy. 
 
Chapter-2, Etidronic acid-catalyzed Synthesis of novel Mannich Base derivatives 
of 7-hydroxy-4-isopropyl-2H-chromen-2-one. The Mannich reaction is a fundamentally 
important carbon–carbon bond forming reaction in organic synthesis, and it has been 
widely utilized in the synthesis of nitrogen-containing drugs, natural products and 
biologically active compounds. Following our interest in benzopyrans, this chapter 
devoted to exploring the activity of some Mannich bases of 7-hydroxy-4-isopropyl-2H-
chromen-2-one. 
 A convenient synthesis of Mannich base has been achieved through a one-pot 
multicomponent reaction involving etidronic acid as catalyst. Thus, 7-hydroxy-4-
isopropyl-2H-chromen-2-one was reacted with formaldehyde and appropriate amines in 
presence of etidronic acid. The targeted compounds were isolated in moderate to good 
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yields. The newly synthesized compounds were characterized by Mass, IR, 1H NMR, and 
13C NMR spectroscopy. 
 
Chapter-3, Synthesis and characterization of novel 3-isopropyl-5-(methylthio)-N-
aryl-1H-pyrazole-4-carboxamide derivatives. The pyrazole moiety is present in a wide 
variety of biologically  interesting compounds, which exhibit antihyperglycemic, 
analgesic, anti-inflammatory, antipyretic, antibacterial, hypoglycemic, sedative-hypnotic 
activity. Thus, continuous efforts have been devoted to the development of more general 
and versatile synthetic methodologies to this class of compounds. 
The synthesis of novel functionalized pyrazole derivatives has been achieved 
from the reaction of dithioacetals and hydrazine hydrate. The requisite dithioacetals were 
prepared from various acetoacetanilide by reacting with carbon disulfide in the presence 
of potassium carbonate followed by the alkylation with methyl iodide. Thus obtained, 
ketene dithioacetals were further reacted with hydrazine in isopropyl alcohols under 
reflux to generated corresponding pyrazole derivatives. All newly synthesized 
compounds were characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy and 
elemental analysis. 
 
Chapter-4, Etidronic acid-catalyzed Synthesis of novel 3,4-dihydro-6-(2-
hydroxy-3,5-dimethylphenyl)-5-nitro-4-arylpyrimid in-2(1H)- one derivatives. Recently, 
much interest has been focused around 5-nitro dihydropyrimidine derivatives because of 
their wide variety of pharmacological properties and industrial applications. In view of 
these, we were interested to prepare some new 3,4-dihydro-6-(2-hydroxy-3,5-
dimethylphenyl)-5-nitro-4-phenylpyrimidin-2(1H)-one. To achieve the targeted 
compounds, 1-(2-hydroxy-4,6-dimethylphenyl)-2-nitroethanone was reacted with 
substituted benzaldehydes and urea in presence of etidronic acid  as catalyst under 
microwave irradiation.  
We found that the reaction proceeded smoothly under this protocol leading to the 
formation of pyrimidin-2(1H)-one in excellent yields. The chemical structure of newly 
synthesized compounds were established by IR, Mass, 1H NMR, 13C NMR spectroscopy 
and elemental analysis.  
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Chapter-5, Synthesis and characterization of novel 3-isopropyl-5-(methylthio)-N- 
arylisoxazole-4-carboxamide derivatives. Isoxazoles are potent, selective agonists at 
human cloned dopamine D4 receptors and exhibit GABAA antagonist, analgesic, anti-
inflammatory, ulcerogenic, antimicrobial, antifungal, COX-2 inhibitory, antinociceptive, 
and anticancer activity. Many synthetic methods have been employed in the synthesis of 
isoxazoles, including reactions of hydroxylamine with 1,3-dicarbonyl compounds, α,β-
unsaturated carbonyl compounds, and α,β-unsaturated nitriles.  
In this chapter a new synthetic approach for the novel isoxazoles utilizing ketene 
S,S-acetals as synthon is described. Various dithioacetals prepared from various 
acetoacetanilide, were reacted with hydroxylamine hydrochloride in ethanolic KOH 
under reflux condition to afford 3-isopropyl-5-(methylthio)-N-arylisoxazole-4-
carboxamide in good yields. All newly synthesized compounds were characterized by IR, 
Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. 
 
All the newly synthesized compounds are under investigation for antiviral and 
antimicrobial screening. 
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